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Tuberculosis (TB), caused by Mycobacterium tuberculosis, is one of the top 10 causes of death 
worldwide, with more than 95% of deaths occurring in low- and middle-income countries. 
Eradication of TB disease within these countries requires the development of more effective 
diagnostic tools, anti-TB drugs and vaccines. The host immune response against M. 
tuberculosis is largely governed by CD4+ T-cells, making M. tuberculosis-specific antigens 
that induce strong CD4+ T-cell responses of interest for vaccine studies. The induction of an 
effective cell-mediated immune response requires activation of CD4+ T-cells following antigen 
presentation via MHC-II molecules. The human leukocyte antigen (HLA) alleles that encode 
MHC-II molecules are polymorphic, resulting in thousands of these alleles within a population. 
The distribution of HLA alleles differs between individuals from different geographical 
populations; thus, an effective vaccine candidate should include a variety of epitopes that bind 
numerous HLA alleles. The PPE_MPTR proteins are a sub-family of the PE/PPE proteins, 
which are encoded by the pe/ppe genes. This family occupies approximately 10% of the M. 
tuberculosis H37Rv genome, however the precise role of PE/PPE proteins in M. tuberculosis 
pathogenicity is unclear. Numerous PE/PPE proteins have shown to be highly immunogenic, 
however little is known regarding the immunogenicity of PPE_MPTR proteins. Previous work 
in our laboratory made use of a reverse vaccinology workflow which identified 35 PPE_MPTR 
epitopes predicted to have strong binding affinity for HLA alleles found in African populations. 
Nineteen epitopes from six PPE_MPTR proteins (PPE_MPTR12, -13, -28, -40, -42 and -62) 
showed high population coverage in four African populations.  
Here we present functional assays performed to assess the immunogenicity of the nineteen 
epitopes in African populations. We also investigated the potential of these epitopes to 
distinguish between infected vs uninfected and active TB vs LTBI individuals, as determined 
by cytokine release assays following peptide stimulation. This was complemented by analysing 
the distribution of functional and activation markers following PPE_MPTR stimulation. The 
remaining red blood cells were lysed and the distribution of functional states of CD4+ and CD8+ 
T-cells and B-cells in peripheral blood were analysed using specific antibody staining in 
conjunction with flow cytometry.  
PPE_MPTR peptides induced a pro-inflammatory cell-mediated response characterized by 
detectable concentrations of IL-6, TNF-α and IL-17A. In response to PPE_MPTR peptides, 
significant differences in cytokine production were observed between individuals of different 
disease states. The PPE_MPTR peptides were shown to induce the expansion and activation of 
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memory CD4+ and CD8+ T-cells, with CD4+ T-cell populations being the predominant 
responding population.  
The results of this study highlight the heterogeneity of the host immune response against M. 
tuberculosis. The pro-inflammatory cell-mediated immune response and the emergence of 
circulating memory populations in response to stimulation with selected PPE_MPTR peptides, 
make these promising vaccine candidates. Future work in which further immunological 
characterization of these peptides is performed, either alone or in combination, would greatly 





Tuberkulose (TB) word veroorsaak deur Mycobacterium tuberculosis en is een van die top tien 
wêreldwye oorsake van sterftes, met meer as 95% van dié sterftes in lande met ‘n lae tot 
middelinkomste. Die uitwissing van TB binne dié lande vereis die ontwikkeling van meer 
effektiewe diagnostiese hulpmiddels, anti-TB behandeling en entstowwe. Die immunrespons 
teen M. tuberculosis word grotendeels beheer deur CD4+ T-sel reaksies. M. tuberculosis-
specific antigens that induce strong CD4+ T-cell responses of interest for vaccine studies. Dus 
is M. tuberculosis-spesifieke antigene wat ‘n sterk CD4+ T-sel reaksie kan induseer van belang 
vir entstof verwante studies. ‘n Effektiewe sel-bemiddelde immuunrespons vereis die 
aktivering van CD4+ T-selle na die oordra van antigene deur middel van MHC-II molekules. 
MHC-II molekules word geënkodeer deur die polimorfiese menslike leukosiet antigeen (HLA) 
allele en duisende van hierdie allele kom voor binne ‘n bevolking. Die HLA allele tussen 
bevolkings verskil, daarom moet ‘n effektiewe entstof ‘n verskeidenheid epitope insluit wat 
verskeie HLA allele kan bind. Die PPE_MPTR proteïne is ‘n sub-familie van die PE/PPE 
proteïne en word gëenkodeer deur pe/ppe gene. Die pe/ppe gene beslaan ongeveer 10% van die 
M. tuberculosis H37Rv genoom, maar die funksie van die proteïne in M. tuberculosis
patogenisiteit is nie bekend nie. Daar is bewys dat verskeie van die PE/PPE proteïne immuun
stimulerende eienskappe het, maar min is bekend oor die immunogenesiteit van PPE_MPTR
proteïne. Vorige werk in ons laboratorium het 35 PPE_MPTR epitope deur ‘n omgekeerde
inenting werkstroom geïdentifiseer wat voorspel wat HLA allele met hoë affiniteit bind in
Afrika bevolkings. Negentien epitope van ses PPE_MPTR proteïne (PPE_MPTR12, -13, -28,
-40, -42 and -62) het hoë bevolkingsdekking getoon in vier Afrika bevolkings.
In die studie het ons funksionele toetse gedoen wat die immunogenesiteit van die negentien 
epitope geëvalueer het in Afrika bevolkings. Ons het ook ondersoek ingestel na die potensiaal 
van hierdie epitope om tussen geïnfekteerde en nie- geïnfekteerde pasïente en mense met 
aktiewe TB of LTBI te onderskei. Dit was gedoen deur ontleding van sitokien produksie en die 
funksionele en aktiveringsmerkers na pepteidstimulasie te ondersoek. Die oorblywende rooi 
bloed selle was gelys en die verspreiding van funksionele toestande van CD4+ end CD8+ T-
selle en B-selle in die perifêre bloed is ondersoek deur vloei sitometrie.  
PPE_MPTR proteïne het ‘n pro-inflammatoriese respons veroorsaak wat gekenmerk word deur 
‘n waarneembaar konsentrasies van IL-6, TNF-α en IL-17A. Na peptiedstimulasie is 
buduidende verskille in sitokien produksie waargeneem in mense met verkillende 




gelei. Daar is gevind dat die CD4+ T-selle die oorheersende T-sel bevolking was wat met 
PPE_MPTR peptiede reageer het. 
Die uitkoms van hierdie studie bekleemtoon die heterogenesiteit van die immunrespons teen 
M. tuberculosis. Die gevolglike pro-inflammatoriese response en die produksie van geheue T-
sel bevolkings na PPE_MPTR stimulasie verwys na die potensiaal van die geselekteerde 
peptiede as entstof kandidate. Verdere immunologiese karakterisering van peptiede, alleen of 
in kombinasies, sal ons begrip oor die funksie van PPE_MPTR proteïne in die sel-bemiddelde 
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Chapter 1  
Introduction  
1.1 Background  
1.1.1 The immune response to tuberculosis  
Tuberculosis (TB), caused by Mycobacterium tuberculosis remains one of the world’s greatest 
health problems to date, especially in low- and middle-income countries such as South Africa 
(WHO, 2018). The host immune response to TB infection is extremely complex and is not yet 
fully understood. The innate immune response to M. tuberculosis is largely governed by 
alveolar macrophages that trigger numerous signalling cascades after phagocytosing M. 
tuberculosis. These signalling cascades initiate an inflammatory response from the host and 
the adaptive immune response is initiated.  
A critical link between the innate and adaptive immune response to M. tuberculosis is antigen 
presentation to CD4+ T-cells via major histocompatibility complex (MHC) class II molecules 
on antigen presenting cells (APCs) such as macrophages. Following phagocytosis of M. 
tuberculosis, M. tuberculosis proteins get degraded into peptides which are then presented to 
CD4+ T-cells by MHC-II molecules. MHC molecules, encoded by human leukocyte antigen 
(HLA) genes, and CD4+ T-cells have indispensable roles during TB infection. As such, mice 
deficient for CD4+ T-cells and MHC-II molecules were shown to be more susceptible to M. 
tuberculosis infection compared to wild type mice (Ladel et al., 1995; Caruso et al., 1999). The 
crucial role of CD4+ T-cells was exemplified by the increased susceptibility of M. tuberculosis 
infection in HIV-positive individuals who are known to have an extremely reduced CD4+ T-
cell count (Hazenberg et al., 2000; Geldmacher et al., 2012). Adaptive immunity to TB 
infection is primarily mediated by CD4+ T-lymphocytes (CD4+ T-cells), although important 
roles for B-cells (Maglione and Chan, 2009; Kozakiewics et al., 2013) and CD8+ T-cells 
(Joosten et al., 2010; Rozot et al., 2013) have also been indicated. MHC-I molecules recognise 
peptides derived from intracellular proteins and present these to CD8+ T-cells. MHC 
distribution within a population is heterogenous as there are thousands of HLA alleles present 
in a population, however an individual only carries a limited number in their genome 




promiscuous epitopes that can bind to a wide range of HLA alleles (Longmate et al., 2001; 
Tshabalala et al., 2015). 
In healthy individuals, M. tuberculosis infection may be eradicated by the co-ordinated action 
of innate and adaptive immunity. However in many cases the infection is merely contained 
within a granulomatous structure within the lungs (Pagan et al., 2015). Containment of M. 
tuberculosis within the granuloma requires constant immune regulation and therefore can fail 
in some individuals such as HIV-positive patients or those with diabetes or malnutrition 
(Diedrich et al., 2016). When the immune system fails to contain the infection, M. tuberculosis 
may escape the restricted environment of the granuloma resulting in active TB disease (Pagán 
et al., 2015). 
1.1.2 Tuberculosis and the desperate need for new vaccines and 
diagnostic tools 
In 2017, The World Health Organisation estimated ten million people worldwide to have 
developed active TB disease, with an estimated 1.6 million people dying as a result of the 
illness (WHO, 2018). The severity of the disease differs widely among countries, with fewer 
than 10 new cases per 100 000 people in most high-income countries to 150-500 new cases per 
100 000 people in high TB burden countries. Worldwide, South Africa is ranked among the 30 
high TB burden countries, along with other African countries including, Ethiopia, Congo and 
Zimbabwe, to name a few (WHO, 2018). 
The only available vaccine for protection against TB is the Bacillus Calmette-Guérin (BCG) 
vaccine. The BCG vaccine was developed in 1931 and is a live attenuated vaccine derived from 
a closely related mycobacterial species, Mycobacterium bovis. BCG is administered to infants 
and has been shown to be effective in preventing TB disease in children, which presents as 
pulmonary TB or TB meningitis (Abubakar et al., 2013; WHO, 2018). BCG has been shown 
to have varying levels of efficacy in the adult population, ranging from 0% to 80% (Rodrigues 
et al., 1993; Colditz et al., 1994; Fine, 1995; Trunz et al., 2006; Abubakar et al., 2013). The 
protective capability of BCG been shown to last no longer than 10 years, thus rendering the 
adolescent and adult population unprotected against TB infection (Sterne et al., 1998; Ozeki et 
al., 2011). The failure of BCG to prevent TB disease and the use of sub-optimal antibiotic 
treatment regimens to treat TB disease has increased the emergence of drug-resistant TB 
strains, thus further emphasizing the need for the development of more effective TB vaccines 




Currently there are eleven new TB vaccine candidates in clinical trials; five in Phase I and six 
in Phase II (Table 1.1) (WHO, 2018). These vaccines include prophylactic vaccines, such as 
BCG, which aim to prevent the development of TB infection and disease. Other approaches to 
vaccine development include, post-exposure vaccines that help prevent reactivation or relapse 
of TB disease and therapeutic vaccines that can be used as an adjunct to existing TB drug 
regimens to improve the outcome of TB treatment (Loxton et al., 2015). Vaccines can be 
broadly characterised into two different groups, live attenuated vaccines and subunit vaccines. 
Live attenuated vaccines are usually developed from an organism closely related to the disease-
causing agent, which is less virulent and unable to cause disease but still capable of providing 
protective immunity. Subunit vaccines consist of selected antigens delivered by an adjuvant or 
a viral vector while other vaccines can be comprised entirely of mycobacterial lysate (Loxton 
et al., 2015). 
Two of the vaccine candidates in Table 1.1 contain antigens from the PE/PPE protein family. 
PPE_MPTR42 has been included in the ID93 vaccine candidate (Bertholet et al., 2010) and 
PPE18 in the M72A vaccine candidate (Day et al., 2013). These proteins are not the only 
members of the PE/PPE protein family shown to have immunomodulatory effects, as several 
PE/PPE proteins have been shown to elicit an immune response and could be potential 
candidates for M. tuberculosis vaccine development (Vordermeier et al., 2012). These include 
PPE37 (Daim et al., 2011), PPE57 (Xu et al., 2015), PPE26 (Su et al., 2015), PE13 (Li et al., 
2016) and heterodimers PE32/PPE65 (Khubaib et al., 2016) and PE35/PPE68 (Tiwari et al., 
2014) . The effect of these, and other M. tuberculosis proteins, on the innate and adaptive 










Table 1.1: TB Vaccine candidates currently in clinical trails  
Vaccine type Vaccine name Phase Description  Reference 
Live attenuated  
MTBVAC I Two independent mutations for phoP (transcription factor 
coding for regulation of M. tb virulence) and fadD26 
(essential for synthesis of virulence factor phthiocerol 
dimycocerosates (DIM; surface lipid)) 
(Arbues et al., 2013) 
(Spertini et al., 2015) 
Recombinant 
BCG30 (rBCG30) 
I M. bovis BCG overexpressing fnpB (Ag85B), esxA (ESAT-6 
virulence factor) and ppe42 
(Lu et al., 2012) 
VPM1002 (∆ureC 
hly+ BCG) 
IIa M. bovis BCG overexpressing the gene for listeriolysin (hly) 
Listeria monocytogenes  
M. bovis urease-C (ureC) gene deleted  
(Grode et al., 2005) 
Adjuvanted subunit 
ID93/GLA-SE I Recombinant fusion protein of Rv2608 (PPE42), Rv3619 
(EsxV), Rv3620 (EsxW), Rv1813 (latency associated 
protein) adjuvanted to GLA-SE 
(Bertholet et al., 
2010)  




Recombinant fusion protein of Ag85B & ESAT-6 adjuvanted 
with IC31 or CAF01 
(van Dissel et al., 
2010, 2014) 
M72A/AS01 II Fusion protein MTB32A (serine protease PepA) & MTB39A 
(PPE18) adjuvanted to AS01 
(Day et al., 2013) 
Viral vector 
subunit  




II Recombinant replication-deficient adenovirus expressing M. 
tb antigens TB10.4, Ag85A and Ag85B 
(Abel et al., 2010) 
Therapeutic  
RUTI II Detoxified fragments M.tb cells delivered in liposomes (Cardona, 2006) 




1.1.3 The PE/PPE protein family  
An important knowledge gap in mycobacterial research is our incomplete understanding of the 
PE/PPE proteins. These PE/PPE proteins are encoded by a large multi-gene family known as 
the pe/ppe genes, which make-up approximately 10% of the coding capacity of the M. 
tuberculosis H37Rv genome (Cole et al., 1998). The 99 pe and 69 ppe genes are characterised 
by encoded conserved N-terminal proline-glutamate (PE) and proline-proline-glutamate (PPE) 
motifs, respectively (Figure 1.1). The N-terminal sequence is relatively conserved between the 
two groups and consists of approximately 110 and 180 amino acids in the PE and PPE families, 
respectively (Cole et al., 1998). The corresponding PE/PPE proteins are further classified into 
subfamilies according to the amino acid characteristics of their C-terminal domain, which are 
highly polymorphic and vary in size and composition. A subset of the proteins belonging to the 
PE family contain multiple copies of polymorphic GC-rich repetitive sequences and are thus 
referred to as PE_PGRS proteins. Similarly, a subset of PPE family proteins are rich in repeats 
that contain an Asn-X-Gly-X-Gly-Asn-X-Gly (NXGXGNXG)n signature and are referred to as 
major polymorphic tandem repeat proteins (PPE_MPTR) (Cole et al., 1998). 
  
Figure 1.1: The PE/PPE Protein family. The N-terminal, or PE/PPE region is highly 
conserved between families with approximately 110 and 180 amino acids, respectively. The 
C-terminal is highly polymorphic, varying in size and composition and based on these 
characteristics the PE/PPE proteins can be divided into subfamilies. The subfamilies known 
as the polymorphic GC-rich sequence (PGRS) and major polymorphic tandem repeat (MPTR) 
represent some of the most variable regions in the M. tuberculosis genome. (Image adapted 




PE_PGRS and PPE_MPTR proteins are restricted to pathogenic mycobacteria (Gey van Pittius 
et al., 2006) and due to their abundance in the genome of M. tuberculosis, it is speculated that 
they contribute to pathogenesis during TB infection. Large knowledge gaps exist regarding the 
function of PE and PPE proteins; however, they have been shown to be highly immunogenic 
(Sampson, 2011; Sayes et al., 2012; Vordermeier et al., 2012; Brennan, 2017). Microarray data 
demonstrated that 128/169 tested pe/ppe genes are differentially expressed during TB disease 
(Voskuil et al., 2004). These results were supported by the transcriptional profiles of M. 
tuberculosis isolated from pulmonary tissue, which demonstrated the upregulation of selected 
pe/ppe genes at the site of infection (Rachman et al., 2006). The presence of these proteins at 
the site of infection, along with evidence showing the secretion of some PE/PPE proteins (Ates 
et al., 2016), suggests that they could be involved in host-pathogen interactions that modulate 
the immune system. If this is so, they could show promise in vaccine development. 
The PE_PGRS proteins have been more widely studied than the analogous PPE_MPTRs. 
PE_PGRS62 and PE_PGRS30 have been shown to be required for replication inside the 
macrophage and persistence in granulomas in Mycobacterium marinum (Ramakrishnan et al., 
2000). Localisation studies have suggested that PE_PGRS33 is located on the cell wall of M. 
bovis BCG and the non-virulent, M. tuberculosis H37Ra (Brennan et al., 2001), allowing 
PE_PGRS33 to easily interact with the host. Research supports host-pathogen interactions 
facilitated by PE_PGRS33. Expression of PE_PGRS33 in Mycobacterium smegmatis 
suggested PE_PGRS33 to play a role in macrophage necrosis and stimulate the secretion of 
tumour necrosis factor (TNF)-alpha (α) (Dheenadhayalan, et al, 2006) through interactions 
with toll-like receptor (TLR)-2 (Basu et al., 2007). In another study investigating the 
expression of a recombinant M. bovis PE_PGRS62 protein in M. smegmatis, it was suggested 
that PE_PGRS62 reduces phagolysosome formation and stimulates the production of IL-1β 
(Huang et al., 2012). Furthermore, certain PE_PGRS proteins have been deemed essential for 
the full virulence of M. tuberculosis during TB infection (Iantomasi et al., 2012).  
1.1.4 PPE_MPTR proteins 
Akin to PE_PGRS proteins, PPE_MPTR proteins are highly variable and are prone to 
recombination events and mutations (Cole et al., 1998). PPE_MPTR proteins are also 
speculated to be a source of antigenic variation, however there is no experimental evidence for 




shown to localise at the cell wall (Sampson et al., 2001), which suggests that they may also 
interact with the host, however, little is known about PPE_MPTR-host interactions.  
There is evidence to suggest PPE_MPTR proteins can elicit immune responses (Choudhary et 
al., 2003; Chakhaiyar et al., 2004; Bertholet et al., 2008). Consequently, certain members of 
the PPE_MPTR family have been suggested to be viable candidates for TB vaccine 
development. For example, PPE_MPTR42 has been implicated in eliciting T-cell responses in 
TB positive patients (Chakhaiyar et al., 2004; Bertholet et al., 2008) and inducing high humoral 
responses in patients re-infected with TB (Chakhaiyar et al., 2004). PPE_MPTR42 has also 
been included in the ID93 vaccine candidate along with Rv1813 and Rv3620 (Table 1.1) 
(Baldwin et al., 2009; Bertholet et al., 2010). Of the three antigens included in the ID93 vaccine 
candidate, only PPE_MPTR42 demonstrated protective efficacy by reducing lung CFU in mice 
challenged with M. tuberculosis and immunized with PPE_MPTR42-CpG. PPE_MPTR42 was 
also shown to be the most immunogenic, by being the only antigen to induce IFN-γ and TNF-
α production (Bertholet et al., 2008). Furthermore, when PPE_MPTR42 was included in a 
recombinant BCG vaccine (rBCG) as a fusion protein with antigen 85B (Ag85B) and ESAT-6 
(Table 1.1), the cell-mediated immune response elicited to rBCG was much stronger than that 
to BCG alone (Lu et al., 2012).  
Members of the PPE_MPTR protein family are clearly involved in the host-immune response 
to M. tuberculosis and show potential in the vaccine development pipeline. There are many 
unanswered questions regarding the PPE_MPTR-mediated immune response and the cellular 
populations responsible for governing this response. This includes the cytokine and chemokine 
profiles elicited by stimulation with these proteins and identifying which immune cell 
populations are responsible for producing these molecules. More research needs to be 
conducted to understand the role and pathophysiological effects of the PPE_MPTR protein 
family during M. tuberculosis disease, and to realise their full potential, in immunodiagnostic 
and vaccine development. 
1.2 Problem Statement  
As outlined above, TB remains a serious health problem. Eradication of TB disease desperately 
requires the development of more effective anti-tuberculosis (anti-TB) drugs, diagnostic tools 
and vaccines. The M. tuberculosis-specific T-cell response is dominated by CD4+ T-cells 
(Orme et al., 1993) and thus many of the current approaches to developing new vaccines and 




Antigen-specific T-cells stimulate an immune response by recognising bacterial peptides 
(antigens) presented on human leukocyte antigen (HLA) molecules. The genes encoding HLA 
molecules are highly polymorphic and therefore thousands of HLA, and related alleles, can be 
found in a population. Each individual only encodes a certain number of these alleles, therefore 
a good vaccine candidate should include a range of epitopes that are able to bind to a wide 
range of HLA alleles, providing sufficient population coverage (Robinson et al., 2015). 
Furthermore, there are certain HLA alleles that are differentially prevalent in groups of 
different ancestry, suggesting that different populations will respond differently to the same 
peptide due to variability in their HLA alleles (Longmate et al., 2001).  
Currently, the live attenuated Mycobacterium bovis Bacillus Calmette-Guerin (BCG) vaccine 
is used for immunisation against M. tuberculosis. The protective immunity elicited by M. bovis 
BCG has varying levels of efficacy, which have been attributed to strain variation between M. 
bovis BCG preparations, the genetic and nutritional differences between populations and 
various environmental influences such as the exposure to non-tuberculosis mycobacteria (Fine, 
1995; Valadas, 2004). In addition to vaccination, the prompt and accurate diagnosis of TB 
disease could potentially aid in reducing M. tuberculosis transmission by enabling those who 
are infected to get effectively treated in the shortest time period. 
Previous work in our laboratory has made use of a reverse vaccinology workflow which 
identified thirty-five PPE_MPTR epitopes that are tailored to HLA alleles common in African 
populations (Colic, Manuscript in Progress). Nineteen epitopes from six PPE_MPTR proteins 
(PPE_MPTR12, -13, -28, -40, -42 and -62) showed high population coverage across four 
different African populations, however functional studies need to be performed to confirm the 
potential of these peptides as possible vaccine candidates. In this study, we investigate the 
immune response to these computationally identified PPE_MPTR epitopes predicted to 
provide high population coverage in black South African, Zimbabwean, Ethiopian and 
Congolese populations.  
1.3 Hypothesis  
The PPE_MPTR epitopes in this study will elicit an immune response in an African cohort, as 
predicted by the reverse vaccinology approach (Colic, Manuscript in Progress).  





To characterise the immune responses elicited by population-tailored PPE_MPTR epitopes in 
an African cohort. 
Objectives: 
I. Assess the immunogenicity of selected population-tailored PPE_MPTR peptides by 
measuring the resultant cytokine response in stimulated whole blood using cytokine 
release assays. 
II. Determine the diagnostic potential of population-tailored PPE_MPTR epitopes by 
comparing T-cell responses elicited in individuals with active and latent 
Mycobacterium tuberculosis infection. 
III. Investigate the PPE_MPTR-specific functional marker frequencies of lymphocyte 
populations in the whole blood of TB, LTBI and healthy individuals. 
1.5 Thesis Overview  
Chapter 2 Literature review: “Mycobacterium tuberculosis interacts with and 
manipulates the host immune response.” 
This review chapter provides an overview of current knowledge of the 
mechanisms M. tuberculosis uses to disrupt the host’s immunoregulatory 
pathways.  
Contribution: Developed outline, surveyed and synthesised literature, wrote 
and edited all drafts with input from supervisors. 
Chapter 3 Methods and Materials  
This chapter outlines the methodologies used to fulfil the above-mentioned 
objectives. 
Contribution: Wrote and edited all drafts with input from supervisors. 
Chapter 4 Results  
This chapter presents the results of evaluation of the immunogenic potential 
of computationally identified population-tailored PPE_MPTR epitopes in an 
African cohort. The diagnostic potential of these epitopes is also evaluated. 
The immunophenotype/s of immune cells governing the PPE_MPTR-




Contribution: Contributed to experimental design, participant recruitment, 
whole blood stimulation assays, antibody panel design and staining, flow 
cytometry, data analysis, interpretation and presentation. Wrote and edited 
all drafts with input from supervisors. 
Chapter 5 Discussion 
This chapter uses the results from Chapter 4 to gain a better understanding 
about the immunogenicity of PPE_MPTR proteins during TB disease. The 
potential of the computationally identified PPE_MPTR epitopes to elicit a 
population-tailored immune response is discussed, and their potential in TB 
diagnostics is evaluated.  
Contribution: Interpretation and contextualisation of results. Wrote and 
edited all drafts with input from supervisors. 
Chapter 6 Reference List 
Chapter 7  Appendices 
This chapter contains the Ethics Approval Letter and an example of the 
Signed Informed Consent Form used during recruitment. The activation 
states of CD4+ and CD8+ T-cells identified using flow cytometry are also 





Chapter 2  
Mycobacterium tuberculosis interacts with and 
manipulates the host immune response  
2.1 Introduction 
Each year, infection with Mycobacterium tuberculosis claims the lives of millions of people 
worldwide (WHO, 2018).The M. tuberculosis infection burden is further increased by the high 
prevalence of drug-resistant M. tuberculosis, where approximately 558 000 new multidrug 
resistant tuberculosis (TB) cases were reported in 2018 (WHO, 2018). Approximately one 
quarter of the global population is infected with TB, but show no signs or symptoms of the 
disease, a state of infection referred to as latent TB infection (LTBI) (WHO, 2018). People 
living with LTBI have a 5-15% chance of developing active disease within their lifetime 
(WHO, 2018). However, people who are immunocompromised, such as those co-infected with 
HIV, who have diabetes or are malnourished, have a higher risk of progressing from LTBI to 
active TB disease (WHO, 2018). 
During TB infection, M. tuberculosis interacts with the hosts innate immune cells, such as 
alveolar macrophages (AMs), which express pathogen recognition receptors (PRRs). These 
proteins interact with pathogen-associated molecular patterns (PAMPs) and initiate a signalling 
cascade that determines the type of immune response elicited (Rajaram et al., 2014). PAMPs 
are molecules shared by various pathogens and may include bacterial endotoxin 
lipopolysaccharide (LPS), terminal mannose residues, unmethylated GC-rich oligonucleotides 
and proteins such as the PE/PPE proteins, among others (Abbas et al., 2001). Recognition of 
PAMPs by a specific repertoire of PRRs will stimulate the host innate immune response to 
release pro-inflammatory cytokines, such as tumour necrosis factor-alpha (TNF-α), interferon-
gamma (IFN-γ) and interleukin-6 (IL-6) (Domingo-Gonzalez et al., 2016). These cytokines 
recruit other immune cells to the site of infection and facilitate the presentation of pathogen-
specific antigens to T- and B-lymphocytes (T- and B-cells), triggering the adaptive immune 
response. 
The innate immune system clears most infections but can fail to do so when bacterial numbers 
are high, or if the pathogen is extremely virulent. In such cases, the adaptive immune response 




responses in the form of phagocytosis and killing of pathogens by innate immune cells. The 
adaptive immune response is dependent on antigen presentation to appropriate Major 
Histocompatibility Complex (MHC) molecules, dendritic cell migration to the draining lymph 
node and the activation of resting (naïve) T-cells (Wolf et al., 2008). The MHC class II 
molecules are encoded by the human leukocyte antigen (HLA) gene complex, consisting of ten 
variants which are uniquely expressed in different populations around the world.  
TB disease encompasses complex interactions between M. tuberculosis and the host, many of 
which we do not fully understand. This is further complicated by the heterogenous nature of 
M. tuberculosis infections. There is an immense number of M. tuberculosis proteins that 
influence the progression and outcome of TB disease, and more insight into the function of 
understudied protein families, such as the PE/PPEs, can aid in gaining a more complete 
understanding of TB disease. The PE/PPE proteins are speculated to interact with both the 
innate and adaptive immune systems, however their precise role/s have not yet been defined. 
These knowledge gaps make it difficult to develop more effective anti-tuberculosis drugs, 
diagnostic tools and vaccines.  
2.2 The Innate Immune response to Mycobacterium 
tuberculosis infection 
The innate immune cells are typically the first cell types encountered by M. tuberculosis 
following inhalation and include AMs, neutrophils, natural killer (NK) and dendritic cells 
(DCs) (Basset et al., 2003; Gantner et al., 2003; Sia et al., 2015). Once inhaled, M. tuberculosis 
bacilli are phagocytosed by AMs and can exploit mechanisms to prevent phagosome 
maturation by inhibiting the fusion between the phagosome and an active lysosome (Armstrong 
et al., 1971; Indrigo et al., 2003; Vergne et al., 2003; MacGurn et al., 2007; Sun et al., 2010; 
Sullivan et al., 2012; Schnettger et al., 2017). Mycobacterial phagosomes typically lack 
lysosomal associated membrane proteins (LAMPs) and mature lysosomal hydrolases, creating 
a favourable niche for the bacilli to reside in.  
M. tuberculosis-presented PAMPs interacting with PRRs present of the surface of AMs initiate 
specific signalling cascades, which activate the innate immune response. Some phagocytic cells 
have the same PRRs, however many of these cells express unique receptors which are 
dependent on the antigens which bind these receptors (Murphy, 2012). In parallel, a pro-
inflammatory response is triggered, which involves the recruitment of mononuclear cells from 




macrophages become surrounded by an assortment of immune cells resulting in the formation 
of a fibrous cuff which consists of fibroblasts and a surrounding layer of T-lymphocytes and 
foamy macrophages. The constant recruitment of new immune cells to the granuloma, results 
in the activation of the adaptive immune response. When the immune status changes or in the 
case of immunocompromised individuals, more foamy macrophages are recruited to the 
granulomatous structure, the centre undergoes necrosis and becomes hypoxic. Once the 
hypoxic centre bursts M. tuberculosis bacilli are released into the lungs, activating the immune 
response and recruiting antigen-presenting cells (APCs) to the lung in an attempt to control 
dissemination (Amaral et al., 2016; Scriba et al., 2016). 
2.2.1  Mycobacterium tuberculosis interacts with the alveolar 
macrophage  
Surfactant coated AMs are located beneath a monolayer of pulmonary surfactant along with 
surfactant-associated proteins-A to -D (SP-A to -D). SP-A and SP-D interact with different M. 
tuberculosis-specific PAMPs, with each PRR-PAMP interaction resulting in a different 
immune response (Gaynor et al., 1995; Pasula et al., 1997; Ferguson et al., 1999, 2006). For 
example, when SP-A interacts with a 60 kDa cell-surface associated glycoprotein of M. 
tuberculosis, AM-mediated phagocytosis of M. tuberculosis is enhanced (Gaynor et al., 1995; 
Pasula et al., 1997). Simultaneously, SP-D diminishes these interactions when bound to M. 
tuberculosis mannosylated lipoarabinomannan (ManLAM) (Ferguson et al., 1999) 
Even though AMs function to defend the host against M. tuberculosis dissemination, M. 
tuberculosis manipulates the intracellular environment of AMs to provide a favourable niche 
for replication (Malik et al., 2000; Rohde et al., 2007; Via et al., 1997). The exact mechanism 
employed by M. tuberculosis to interfere with phagolysosome maturation remains unclear, 
however, M. tuberculosis is thought to secrete several proteins which prevent phagosome-
lysosome fusion. One such protein is PknG, one of the 11 protein kinases encoded by M. 
tuberculosis. PknG is dispensable for M. bovis BCG growth in 7H9-OADC media, however is 
required for intracellular growth (Walburger et al., 2004). Further, only M. bovis-pknG deletion 
mutants were seen to localise to lysosomal organelles within macrophages (Walburger et al., 
2004).  
There are many classes of PRRs that M. tuberculosis interacts with on the surface of the AM, 
with each receptor playing a different role in the recognition and uptake of M. tuberculosis-




(MR), dectin-1, toll-like receptors (TLRs) and complement receptor 3 (CR3) are the three main 
macrophage receptors that mediate M. tuberculosis entry into the AM and facilitate the 
downstream signalling events in response to infection (Rajaram et al., 2014). The following 
section will focus on the effect M. tuberculosis-specific ligands have on the host immune 
response following interactions with the MR and members of the TLR family. The MR is one 
of the main classes of PRRs on the AM. Some members of the PE/PPE protein family have 
been shown to interact with some members of the TLR family on the AM, however their 
interaction with dectin-1, MR and CR3 require more investigation.  
2.2.1.1 The Mannose Receptor (CD206) 
The mannose receptor (MR) is a 175 kDa transmembrane glycoprotein (Wileman et al., 1986) 
with eight carbohydrate recognition domains located on the surface of macrophages. The MR 
is one of the main PRRs facilitating entry of M. tuberculosis into the AM (Tailleux et al., 2003) 
and can also be referred to as ‘cluster of differentiation 206’ (CD206) (East et al., 2002). The 
MR is not only cell-surface localised, but can also be found within the MHC-II loading 
compartment of the macrophage, where it enhances MHC-II antigen presentation and the 
recruitment of CD4+ T-cells (Koning, 1997; Prigozy et al., 1997). Similar to mannose binding 
lectin, the MR also engages mannose containing M. tuberculosis-specific ligands such as 
lipoarabinomannan (LAM) and its derivatives ManLAM (Reiling et al., 2001). Lipomannans 
and LAMs are multi-glycosylated forms of biosynthetic precursor phosphatidylinositol 
mannoside (PIM), located on the cell wall of M. tuberculosis (Khoo et al., 1995).  
Human monocyte-derived macrophages (HMDMs) stimulated with M. tuberculosis H37Rv 
and ManLAM derived from M. tuberculosis H37Rv displayed enhanced expression of 
macrophage peroxisome proliferator activated receptor gamma (PPARγ) (Rajaram et al., 
2010). This was dependent on the activation of MAPK-p38 mediated by M. tuberculosis or 
ManLAM binding to MR. In contrast, stimulation with M. bovis BCG also resulted in the 
production of IL-8, however lower expression levels of PPARγ were observed. This was 
explained by NFκB-induced production of IL-8 due to M. bovis BCG, rather than via MAPK-
p38 as seen with M. tuberculosis H37Rv or ManLAM (Rajaram et al., 2010). PPARγ is 
required for intracellular growth and to induce the production of IL-8 and cyclooxygenase 2 
(COX2) (Rajaram et al., 2010), which are involved in downregulating inflammatory responses 
by the recruitment of neutrophils and lymphocytes that mediate granuloma formation (Ameixa 




M. tuberculosis ManLAM-MR-mediated entry into the AM also prevents phagosome 
maturation and interferes with phagosome-lysosome fusion (Kang et al., 2005). During 
phagosomal maturation, there is progressive loss-and-gain of cellular markers that identify the 
endosome as ‘early’ or ‘late’. Proteins involved in this process include those from the rab-
family of GTPases and LAMP proteins (Desjardins et al., 1994), as well as lipids such as, 
lysobisphosphatidic acid (LBPA) (Kobayashi et al., 1998). Following phagocytosis of M. 
tuberculosis via MR, the phagosome interacts with early endosomes and acquires the 
expression of Rab-5 on its surface. The presence of M. tuberculosis ManLAM interferes with 
Ca2+ levels, which prevents the recruitment of the Rab-5 effector proteins, early endosomal 
autoantigen-1 (EEA1) and phosphatidylinositol-3-kinase (PI3K), hVPS34 (Malik, et al., 2000; 
Malik et al., 2003).  
The activation product of hVPS34, phosphatidylinositol-3-phosphate (PI3P), is required to 
retain EEA1 to the early endosomal membrane. Without EEA1, the switch between Rab-5 and 
Rab-7, a late endosomal marker, is prevented, thus preventing the delivery of vacuolar ATPase 
(V-ATPase), lysosomal hydrolases and cathepsins from the trans-golgi network to the 
endosome (Via et al., 1997). As a result, the intraluminal pH of the endosome does not 
decrease, and M. tuberculosis is able to create a favourable niche within the phagosome. 
Although ManLAM interferes in host recognition of M. tuberculosis, its precursor PIM 
enhances the fusion of M. tuberculosis phagosomes with early endosomes, and contributes to 
phagosome-lysosome fusion (Fratti et al., 2003). This could be a way in which M. tuberculosis 
is able to manipulate the host through interactions with the MR, while still obtaining nutrients 
from the phagosome and aiding survival. 
2.2.1.2 The Toll Like Receptor (TLR) Family  
The interaction between M. tuberculosis and members of the TLR family occurs early during 
M. tuberculosis infection. TLRs are expressed on various immune cells, including AMs, DCs 
and certain types of T-cells and B-cells (Akira et al., 2006). TLRs are type I integral membrane 
glycoproteins, classified as part of the IL-1 receptor (IL-1R) superfamily due to the similarities 
of the cytoplasmic regions, which are homologous to that of IL-1Rs and contain a Toll-IL-1 
receptor (TIR) domain (Slack et al., 2000) with an extracellular domain comprised of leucine-
rich repeats (Akira and Takeda, 2004). There is a large repertoire of ligands that interact with 
TLRs, with some ligands interacting with more than one TLR to bring about an immune 
response. The complexity of these interactions is highlighted by the antagonist-agonist nature 





Table 2.1: The effect of the immune response during TB infection following interactions between TLRs and M. tuberculosis-specific 
TLR ligands 







Induce macrophage apoptosis THP-1 / MDMs 
 
(Lopez et al., 2003) 





Promotes TNF-α production THP-1  (Pecora et al., 2004) 
 
(Bhat et al., 2012) 
(Qureshi et al., 2019) 
Antagonist 
p19 MHC-II expression repressed THP-1 / BMDMs (Noss et al., 2001; 
Drennan et al., 2004; 










C57BL/6 background mice 
(Gehring et al., 2004) 
(Koh et al., 2009)  
(Brennan et al., 2002)  
(Saini et al., 2016) 
PPE18 Induces anti-inflammatory Th2-skewed immune response  Monocyte-derived 
macrophages 
(Nair et al., 2009) 
ESAT-6  Selectively inhibits LPS-driven activation of p38-MAPK, 
preventing the production of IFN-β and IFN-inducible genes 
RAW264.7 
Murine BMDMs  
(Pathak et al., 2007) 
TLR9 Antagonist CpG motifs Large granuloma formation with increased eosinophils and decrease myeloid DCs 
TLR9-/- mice 
 
(Ito et al., 2007) 
TLR4 
Agonist 
LPS Induces the production of pro-inflammatory cytokines  
Induces autophagy 
RAW264.7 (Xu et al., 2007). 
M. tb PIM4-6 Promotes TLR4-CD14 or TLR4-MD2-dependent production of 
pro-inflammatory cytokines  
C3H/HeJ mice (Abel et al., 2002) 
Antagonist 
M. tb  Exacerbated pulmonary pathology, increased bacterial load, 
decreased IL-17A production 
C3H/HeJ mice (Abel et al., 2002) 
M. bovis BCG 
PIM6 








The importance of TLRs in M. tuberculosis infection has been emphasized with in vivo and 
genetic association studies which demonstrated single nucleotide polymorphisms in TLR2 and 
TLR9 are associated with an increased susceptibility to TB infection (Velez et al., 2010). 
i Toll-Like Receptor-2  
Surface expression of TLR2 has been shown to be required for resistance against M. 
tuberculosis infection, with TLR2-bound ligands stimulating the production of pro-
inflammatory cytokines such as TNF-α and IL-12 (Underhill et al., 1999; Pompei et al., 2007). 
TLR2 is believed to be a regulator of inflammation during infection and studies have suggested 
that this regulatory role is indispensable under chronic or high bacterial load infections (Reiling 
et al., 2002; Drennan et al., 2004). As such, challenge of BMDMs derived from TLR2-deficient 
mice (TLR2-/-) with M. tuberculosis demonstrated that M. tuberculosis-induced apoptosis 
requires TLR2 and the adaptor molecule, MyD88 (Sánchez et al., 2009).  
There are some TLR2 ligands that can act as an agonist or an antagonist when bound to TLR2, 
by ‘activating’ or ‘inhibiting’ the host immune response, respectively (Table 2.1). The purified 
19kDa M. tuberculosis lipoprotein (p19) has also been shown to induce apoptosis (Lopez et 
al., 2003), however, it can also function as an antagonist by transcriptionally repressing the 
expression of MHC-II molecules, thus preventing M. tuberculosis antigen processing (Noss et 
al., 2001; Drennan et al., 2004; Fulton et al., 2004). Even in the presence of IFN-γ (which is 
known to increase the expression of MHC-II molecules), there were few MHC-II-peptide 
complexes formed (Fulton et al., 2004) and ultimately the recruitment of fewer activated CD4+ 
T-cells. However, there is evidence for elevated numbers of CD4+ and CD8+ T-cells in lung 
homogenates of TLR2-/- mice upon M. tuberculosis challenge (Drennan et al., 2004), which 
was thought to be a result of the observed increase in pulmonary IFN-γ levels (Drennan et al., 
2004; Reiling et al., 2002). These results suggest that the recruitment of CD4+ and CD8+ T-
cells is not solely dependent on stimulation of TLR2, and that the simultaneous engagement of 
M. tuberculosis-specific PAMPs to other PRRs could have initiated signalling cascades that 
resulted in the recruitment of CD4+ and CD8+ T-cells to the lung. Other M. tuberculosis 
lipoproteins, LprG and LprA, have also been shown to inhibit MHC-II antigen processing 
through TLR2 (Gehring et al., 2004). Even as monomers, these lipoproteins display their 
agonist-antagonistic nature by inducing the secretion of pro-inflammatory cytokines such as 
TNF-α, while preventing MHC-II antigen processing by THP-1 and primary macrophages 




ii Toll-Like Receptor-9  
Unmethylated CpG dinucleotide motifs found in bacterial DNA have been shown to induce a 
strong T-helper-1 (Th1) inflammatory response (Jakob et al., 1998; Sparwasser et al., 1998), 
and act as ligands for TLR9 (Hemmi et al., 2000). In situ hybridization and 
immunohistochemistry of mouse and human lung tissues demonstrated that TLR9 expression 
was increased in patients with chronic obstructive pulmonary disease (Schneberger et al., 
2013), suggesting that TLR9 plays a role in mediating inflammation. It has been demonstrated 
that TLR9 plays an important role in regulating Th1 immune responses that are induced during 
M. tuberculosis infection. TLR9-deficient (TLR9-/-) mice tolerate low-dose M. tuberculosis 
(50-100 CFU) aerosol infections but succumb to high dose (500 CFU) aerosol infections, as a 
result of reduced pulmonary concentrations of IFN-γ and IL-12p40 and a decrease in 
pulmonary IFN-γ+ CD4+ T-cells (Bafica et al., 2005). 
The role TLR9 plays in maintaining a protective Th1 granulomatous response during TB 
infection was demonstrated using a model of granulomatous lung inflammation using PPD-
coupled beads. Mice were immunized with inactivated M. tuberculosis (complete Freund’s 
adjuvant; CFA) and challenged 14 days later by tail-vein with PPD-coupled beads (Ito et al., 
2007). Larger granulomas formed in the lungs of TLR9-/-mice compared to wild-type control 
mice (Ito et al., 2007; Ito et al., 2009). The increased granulomatous size was accompanied 
with more eosinophils and pulmonary F4/80+ macrophages (Ito et al., 2007), and with fewer 
granuloma-associated myeloid DCs (Ito et al., 2009) and CD3+CD4+ T-cells (Ito et al., 2007). 
Furthermore, the granulomas in TLR9-/- mice produced IL-4, IL-5 and IL-13, typically 
associated with an anti-inflammatory Th2 immune response.  
F4/80+ is a murine macrophage marker highly expressed on macrophages found in T-cell 
independent areas of secondary lymph tissue such as the spleen or peritoneum (Gordon et al., 
1992). The F4/80+ macrophages found in TLR9-deficient mice were phenotypically identified 
as M2 (anti-inflammatory) macrophages due to the significantly low mRNA expression level 
of iNOS (typically abundant in M1 (pro-inflammatory) macrophages), and the increased 
expression levels of Arginase-1 and FIZZ-1, both typical of M2 macrophages (Ito, Schaller, 
Cory M. Hogaboam, et al., 2007). It is important to note that M1/M2 macrophage phenotypes 
change according to the homeostatic needs of the host, allowing M1 macrophages to develop 
into M2 macrophages, and vice versa (Mills, 2015) (Figure 2.1). Interestingly, MyD88-/- mice 
and those doubly deficient for TLR9 and TLR2 (TLR9-/-TLR2-/-) were highly susceptible to 




single knockout mice (Bafica et al., 2005). This suggests that TLR9 interacts with TLR2 to 
mediate the production of pro-inflammatory cytokines, and that this dimerization is necessary 
to produce IFN-γ+ CD4+ and IFN-γ+ CD8+ T-cells during low- and high dose M. tuberculosis 
challenge (Bafica et al., 2005). 
Collectively, these studies suggest TLR9 to play an important role maintaining a Th1 immune 
response during chronic M. tuberculosis infection and works synergistically with TLR2 to 
promote protection during early infection (Bafica et al., 2005; Ito et al., 2007; Ito et al., 2009). 
In its absence, granulomas are enlarged and pro-inflammatory responses from granulomas are 
Figure 2.1: Macrophage activation states. M1 (or “classically activated”) macrophages are 
known to produce a pro-inflammatory Th1 immune response through the secretion of IL-12 
and IL-8. M1 macrophages express CD80 and CD86 on their surface that recruit neutrophils 
and cytotoxic T-cells. M2 (or “alternatively activated”) macrophages are associated with 
inducing an anti-inflammatory Th2 immune response through the production of TGF-β and 
growth factors, VEGF and EGF. M2 macrophages express CD163 and CD206 and mediate 
the production of antibodies to further mediate the Th2 immune response. The red arrow 
indicates the ability of M1/M2 macrophages to modulate immune responses by alterng their 




down-regulated (Ito et al., 2007). The M. tuberculosis ligands containing CpG dinucleotide 
motifs that specifically interact with TLR9, or with dimerized TLR9/TLR2 have not yet been 
identified. It is possible that M. tuberculosis ligands for TLR2 also interact with TLR9, just via 
a different recognition pathway, however more evidence is needed to clarify this.  
iii Toll-Like Receptor-4  
The immunomodulatory effects mediated upon activation through TLR4 need to be further 
examined, however available literature suggests TLR4 plays a bigger role in secondary immune 
responses to M. tuberculosis, rather than primary host defence. Bacterial endotoxin, 
lipopolysaccharide (LPS), has been experimentally demonstrated to signal through TLR4 
(Poltorak et al., 1998; Hoshino et al., 1999) and LPS-induced autophagy through TLR4 is 
achieved in a TIR domain-containing adaptor inducing IFN-β (TRIF)-dependent MyD88-
independent manner (Xu et al., 2007) (Figure 2.2). Furthermore, along with TLR2 and 
MyD88, TLR4 has demonstrated a major role in M. tuberculosis-induced apoptosis (Sánchez 
et al., 2009).  
The LPS-TLR4 interaction activates MAP kinases (MAPK). The M. tuberculosis ESAT-6 
antigen has been shown to interfere with this signal transduction pathway by selectively 
inhibiting the LPS-driven activation of p38-MAPK (Pathak et al., 2007). The inhibition was 
thought to be ‘selective’ due to the unaffected activation states of extracellular signal-regulated 
kinase (Erk) and c-Jun N-terminal kinase (Jnk). The activity of apoptosis signal-regulating 
kinase 1 (ASK1), which is involved in signalling upstream of p38, was also shown to be 
inhibited in the presence of ESAT-6. The ASK1-p38 signalling axis is important for the LPS-
induced activation of IRF3 (Sakaguchi et al., 2003), which following translocation to the 
nucleus, induces transcription of IFN-β and IFN-inducible genes. In the presence of ESAT-6, 
IRF3 failed to translocate to the nucleus, thus inhibiting the production of IFN-β and IFN-






Figure 2.2: Signal transduction through TLRs. Signal transduction through the TLRs is initiated upon binding of specific ligands to their respective TLRs. 
Once bound to the ligand, various signal transduction pathways are activated through binding of adaptor molecules to the TIR domain; these can be classified 
as MyD88-dependent or MyD88-independent. MyD88-dependent signalling involves the binding of MyD88 to the TIR domain of the TLR and results in the 
phosphorylation and activation of the early phase NF-κB complex that leads to the production of pro-inflammatory cytokines (TNF-α/IL-12p40). The initiation 
of MyD88-independent signalling requires two additional adapter molecules, TRIF and TRAM, and involves the phosphorylation and activation of late-phase 




Supporting the role TLR4 plays in the secondary host response, TLR4 has been implicated in 
the production of IL-17A from IL-17A/IFN-γ-positive CD4+ memory T-cells and γδ T-cells 
(Veerdonk et al., 2010). IL-17A has a role in maintaining the inflammatory response, as it has 
been implicated in the maintenance of granuloma formation and the recruitment of Th1 T-cells 
to the site of infection (Umemura et al., 2007). In vivo experiments have also demonstrated the 
importance of TLR4 in mediating a pro-inflammatory response (Poltorak et al., 1998; Abel et 
al., 2002). Compared to wild type mice (C3H/HeN), TLR4 mutant mice (C3H/HeJ) were 
unable to control bacterial burden and all succumbed to infection within 5 months, whereas 
C3H/HeN mice survived the duration of the experiment (6 months) (Abel et al., 2002). This 
could be attributed to the lack of IL-17A that dampens the Th1 immune responses and impairs 
mycobacterial containment within the granuloma. As such, without a functional TLR4, a state 
of chronic inflammation was observed with dissemination into the liver and spleen (Abel et al., 
2002).  
Evidently, without a functional TLR4, necrosis rather than apoptosis is significantly 
upregulated (Sánchez et al., 2009), which could explain the exacerbated inflammation 
observed. Increased inflammation was accompanied by a significantly reduced pro-
inflammatory bronchoalveolar lavage (BAL) cytokine profile, showing the reduction of IL-
12p40 (Abel et al., 2002). In addition to IL-12p40, TLR4-mutant and wild-type mice lungs 
also showed significantly lower TNF-α levels, and only slightly reduced IFN-γ (Abel et al., 
2002). Interestingly, in another study no difference in pulmonary bacterial load between 
C3H/HeJ-, TLR2-/-- and CD14-/- mice compared to the appropriate wild-type controls was 
observed for low dose M. tuberculosis infection (Reiling et al., 2002). Furthermore, no 
significant differences in pro-inflammatory cytokine production was observed between 
C3H/HeJ mice and wild-type mice (Reiling et al., 2002). A defect in the immune response 
similar to that seen by Abel et al was only identified during high-dose M. tuberculosis 
challenge (2000 CFU). The discrepancy between these studies is unclear as the reported 
experimental conditions in which both studies were conducted were identical. 
M. tuberculosis PIM is a ligand for TLR4 and interacts with this receptor as a GPI anchor of 
LAM and lipomannan. M. tuberculosis PIM4-6 have been shown to induce a pro-inflammatory 
immune response in a TLR4/CD14- or TLR4/MD2-dependant manner, by inducing NFκB 
transctivation (Abel et al., 2002). However, M. bovis BCG PIM6, negatively regulates the 
production of MyD88-dependant, TRIF-independent secretion of pro-inflammatory cytokines 




structural differences between PIM from M. tuberculosis and M. bovis BCG that allow M. 
tuberculosis PIM to enhance a pro-inflammatory response.  
2.2.1.3  Interactions between the PE/PPE proteins and receptors on the 
alveolar macrophage 
Some members of the PE/PPE protein family have been shown to interact with TLR2 and 
modulate host immune responses (Basu et al., 2007; Nair et al., 2009; Udgata et al., 2015). 
Due to the similarity of PE_PGRS proteins to the Epstein-Barr virus nuclear antigen, it was 
speculated that these proteins may also interfere with antigen processing and presentation (Cole 
et al., 1998). In support of this, the inhibition of antigen processing was demonstrated for 
PE_PGRS33 (Brennan and Delogu, 2002), PE_PGRS17 (Koh et al., 2009) and PE_PGRS47 
(Saini et al., 2016). PE_PGRS33 has also been implicated with inducing macrophage apoptosis 
in a TLR2-TNF-α-dependant mechanism (Basu et al., 2007) (Table 2.1), and has also been 
shown to trigger macrophage necrosis and enhance the intracellular survival of mycobacteria 
(Dheenadhayalan et al., 2006), however the involvement of TLR2 in the latter remain unclear.  
Localised in the cell wall of M. tuberculosis, PPE18 has been shown to specifically interact 
with TLR2 through its leucine-rich repeat 11 ~ 15 domain and induce a Th2-skewed immune 
response (Nair et al., 2009; Udgata et al., 2015). Recombinant M. tuberculosis PPE18 was 
shown to induce the production of IL-10 by triggering the phosphorylation of p38 MAPK and 
supressing the production of IL-12p40 (Table 2.1) (Nair et al., 2009). It was later demonstrated 
that for PPE18 to inhibit the production of IL-12p40, it upregulates the expression of suppressor 
of cytokine signalling 3 (SOCS3) which physically interacts with IκBα- NFκB complex, 
preventing the translocation to the nucleus and induction of pro-inflammatory cytokines 
(Figure 2.2) (Nair et al., 2011). Furthermore, PPE18 was also shown to interfere with IRAK-
PKCα signalling cascade (Udgata et al., 2015), resulting in the proliferation of Th2 T-cells that 
produce high levels of IL-5 rather than IFN-γ (Nair et al., 2009) (Table 2.2). By skewing the 
immune response towards an anti-inflammatory Th2 response, M. tuberculosis PPE18 down-




CD4+ T-cell effector 
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Role in the immune 





T-helper 1 CD4+ T-
cells (Th1) 
Activate inflammatory 
effector functions in 
alveolar macrophages, 
resulting in effective 




(Prezzemolo et al., 
2014) 
(Lyadova et al., 
2015) 
T-helper 2 CD4+ T-
cells (Th2) 
Associated with 
dampening of the 
immune response 
during TB infection by 
counter-regulating Th1 




(Prezzemolo et al., 
2014) 
 
T-helper 17 CD4+ T-
cells (Th17) 
Recruitment of 
monocytes and Th1 
CD4+ T-cells to the site 
of granuloma formation 
during early TB disease. 






(Prezzemolo et al., 
2014) 
(Lyadova et al., 
2015) 
 
PPE17 and PPE65 have also been shown to interact with TLR2, but unlike PPE18, they interact 
with the 16 ~ 20 leucine-rich repeat domain of TLR2 (Bhat et al., 2012; Qureshi et al., 2019) 
and induce a pro-inflammatory immune response (Bhat et al., 2012; Udgata et al., 2015; 
Qureshi et al., 2019). When bound to TLR2, PPE17 was shown to increase the intracellular 
levels of NFκB, resulting in production of high TNF-α concentrations (Bhat et al., 2012) 
(Table 2.1). Similarly, THP-1 macrophages infected with recombinant M. smegmatis 
expressing PPE65, produced higher levels of TNF-α compared to uninfected cells, however the 
mechanism through which this is achieved remains unclear (Qureshi et al., 2019). 
PPE17 has also been shown to promote dimerization between TLR2 and TLR1 (Udgata et al., 
2015), which may explain the contrasting immune responses observed for PPE18, PPE17 and 
PPE65. There is also evidence to suggest that PPE17 requires the hetero-dimerization of 
TLR1/2 to induce TNF-α, as silencing of TLR1 resulted in the downregulation of TNF-α 
(Udgata et al., 2015). In this study, the production of TNF-α was shown to require 
phosphorylation of ERK1/2, a process dependent on the translocation of nuclear IRAK3 into 
the cytosol (Udgata et al., 2015). Although IRAK3 activated ERK1/2, it was shown to have 
inhibitory effects on p38 MAPK (Udgata et al., 2015). This suggests that PPE17 is able to 
Table 2.2: Major effector CD4+ T-cell populations governing the host immune response 




interact with various components within the cell and that where TLR2 ligands bind determines 
which downstream signalling cascade is triggered, either favouring a Th1- or Th2-type immune 
response. 
PE/PPEs interaction with TLR2 can activate either pro- or anti-inflammatory immune 
responses, which may be dependent on which downstream signalling cascade is triggered. The 
exact mechanisms governing this outcome are not fully understood, however one can speculate 
that interactions of TLR2 ligands with different ligand-specific sites in the LRR domain can 
induce conformational changes of downstream complexes, altering the type of signals induced. 
The section of the LRR engaged could also influence TLR2 dimerization with itself, or other 
TLRs, thus also influencing the type of response initiated. The majority of the interactions 
described between PE/PPEs and TLR2 lead to an anti-inflammatory response. The differential 
expression of the pe/ppe genes during TB infection (Voskuil et al., 2004) could also influence 
which protein-TLR interaction may take place at different stages of infection, regulating the 
internal environment to favour M. tuberculosis. 
The interaction between members of the PE/PPE protein family and the MR have not yet been 
described in literature. We know that PE_PGRS17, -33 and -47 inhibits antigen processing 
from MHC-II molecules when bound to TLR2, and the MR can be found within the MHC-II 
loading compartment of the macrophage. The close proximity within the MHC-II loading 
compartment may allow PE/PPEs to interact with the MR, however this is unlikely as the MR 
generally recognises mannosylated carbohydrates (Reiling et al., 2001). Interactions between 
PE/PPEs and another member of the MR family, M-type phospholipase A2 receptor (PLA2R), 
may be worth investigating as PLA2R has been shown to facilitate protein-protein interactions 
through its C-type lectin-like domain 5 (East et al., 2002), however functional studies will need 
to be performed to confirm this.  
2.2.2 Mycobacterium tuberculosis interacts with dendritic cells 
DCs are critical in linking the innate and adaptive immune systems and have a wide variety of 
functions including antigen processing and presentation, T-cell recruitment and clonal 
expansion and co-stimulatory effects. Transportation to the mediastinal lymph node allows M. 
tuberculosis-infected DCs to interact with naïve T-cells, present them with antigen, resulting 
in the naïve T-cell acquiring an effector T-cell function by differentiating into a Th1, Th2 or 
Th17 T-cell (depending on the stimulus), thus triggering the adaptive immune response (Wolf 




becomes downregulated (Geijtenbeek et al., 2003), and expression for adhesin, antigen-
presenting and co-stimulatory molecules are upregulated, constituting a mature DC phenotype 
(Banchereau et al., 1998). Additionally, chemokine receptors are upregulated on mature DCs, 
which improve the ability of mature DCs to migrate to the lymphoid tissue for antigen 
presentation (Al-Ashmawy, 2018).  
Studies done using DCs generated from human peripheral blood and murine-derived DCs have 
supported early literature by showing the ability of DCs to internalize M. tuberculosis, which 
results in the production of pro-inflammatory cytokines TNF-α, IL-12 and IL-1 (Henderson et 
al., 1997; Bodnar et al., 2001). M. tuberculosis-containing DCs had increased surface 
expression of MHC-I and co-stimulatory CD54, CD40 and CD80 molecules (Henderson et al., 
1997; Bodnar et al., 2001). Culture filtrate protein 10 (CFP-10) has been shown to differentiate 
freshly isolated bone marrow cells to DC-like cells with the upregulation of CD11b and CD11c; 
MHC class I and II molecules and T-cell costimulatory molecules CD80, CD86, CD40 and 
CD54 (Latchumanan et al., 2002). M. tuberculosis lipoprotein LprA has also been shown to 
induce a mature DC phenotype associated with the upregulation of cell-surface CD40, CD80 
and MHC-II molecules and the production of TNF-α, IL-12 and IL-10 (Pecora et al., 2004). 
These studies demonstrate the highly responsive nature DCs have to M. tuberculosis and its 
products and emphasizes the highly heterogenous repertoire of ligands able to interact with 
DCs.  
Although DCs have been shown to internalize a higher percentage of M. tuberculosis compared 
to other immune cells (Wolf et al., 2007), they do not support the intracellular growth of M. 
tuberculosis (Bodnar et al., 2001; Tailleux et al., 2003). This is expected as the DCs need to 
present antigen via MHC molecules to T-cells, which requires the generation of peptides from 
the engulfed M. tuberculosis bacilli. Another possible reason that M. tuberculosis is unable to 
proliferate within DCs could be due to DC-lysosome co-localisation (Geijtenbeek et al., 2003) 
during which, DCs may possibly acquire lysosomal hydrolases which will prevent the 
intracellular growth of M. tuberculosis. DCs have different functions, in terms of antigen 
capture and presentation, depending on which stage of activation and maturation they exist. 
Natarajan et al investigated the ability of CFP-10 to induce the maturation of CD8a+/CD11c+ 
and CD8a-/CD11c+ mouse splenic DCs (Natarajan et al., 2003). CD8a+/CD11c+ induce a pro-
inflammatory Th1 response while CD8a-/CD11c+ typically induce an anti-inflammatory Th2 
response (Reid et al., 2000). CFP-10 stimulation of DC subsets was shown to induce the full 




subsets released high concentrations of IFN-γ, however only the CD8a+/CD11c+ DC subset 
released high concentrations of IL-12p40 (Natarajan et al., 2003). The cytokine profiles of 
CD8a- and CD8a+ DCs suggest that these subsets induce opposing immune responses, but both 
subsets demonstrated the ability to activate CD4+ T-cells in response to CFP-10. This 
emphasizes the complexity of this immune response and highlights that other factors are 
involved that influence the outcome of the T-cell response.  
Although CFP-10-matured DC subsets appear to be fully-capable of processing and presenting 
antigen via MHC-II molecules, they do not respond to secondary antigenic challenge with M. 
tuberculosis whole cell extract T-cells in vivo (Natarajan et al., 2003; Balkhi et al., 2004). The 
significantly reduced levels of IL-2 and, especially IFN-γ, from these DCs is interesting as 
whole cell extract contains various components (proteins, lipids and carbohydrates) of M. 
tuberculosis that may be released from the macrophage during infection. These results suggest 
that DCs that have engulfed CFP-10 secretory antigen become less capable of inducing a 
proliferative and proinflammatory T-cell response. Furthermore, CFP-10-matured DCs 
maintain their phagocytic ability (Natarajan et al., 2003), while modulating the levels of 
reactive oxygen species to promote mycobacterial survival within DCs (Sinha et al., 2006). It 
is possible that M. tuberculosis uses CFP-10 to dampen the proinflammatory response upon 
secondary challenge and manipulate DCs to migrate to secondary lymphoid organs and 
disseminate, thus contributing to the spread of infection. Alternatively, CFP-10 can be used by 
M. tuberculosis to create a favourable niche in which to proliferate.  
2.2.2.1  CD209 – DC-SIGN 
Dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) is a 
calcium-dependant C-type transmembrane lectin with a C-terminal carbohydrate recognition 
domain (Geijtenbeek et al., 2003). Monoclonal antibodies (mAb) specific for DC-SIGN, 
prevented ~90% of M. tuberculosis attachment to monocyte-derived DCs (Tailleux et al., 
2003). This suggests that DC-SIGN is the major receptor on immature DCs that facilitates 
interactions with M. tuberculosis (Geijtenbeek et al., 2003; Tailleux et al., 2003) through the 
recognition of cell wall associated mannose-capped lipoglycans (Maeda et al., 2003) such as 
LAM, ManLAM (Geijtenbeek et al., 2003; Tailleux et al., 2003) and lipomannan.  
Although present in the cell wall of M. tuberculosis and M. bovis BCG, ManLAM can also be 
secreted by M. tuberculosis-infected macrophages, and circulate as a virulence factor, thus 




M. tuberculosis and M. bovis BCG were shown to inhibit the production of IL-12p70 from 
LPS-stimulated human monocyte derived-DCs (Nigou et al., 2001; Geijtenbeek et al., 2003), 
whereas internalization with whole bacilli resulted in the production of IL-12, TNF-α and IL-
1 (Henderson et al., 1997; Bodnar et al., 2001). This suggests that ManLAM dampens the pro-
inflammatory response induced by activated DCs. As such, there is evidence to suggest this to 
be true as ManLAM isolated from M. tuberculosis H37Rv was shown to increase the 
expression of SOCS1 following interaction with DC-SIGNR1 on mouse bone marrow derived 
dendritic cells (Srivastava et al., 2009).  
The interaction between DC-SIGN and ManLAM seems to depend on the presence of the 
mannooligosaccharide caps and lipidic part of the GPI anchor. ManLAMs devoid of these 
mannose caps showed reduced binding to DC-SIGN and the impaired inhibitory ability on the 
production of IL-12p70 from DCs (Nigou et al., 2001). These results suggest that lipoglycans 
lacking mannose caps are not recognised as effectively by DC-SIGN compared to 
mannosylated lipoglycans. Furthermore, these results highlight the varying immune response 
that can be elicited by different mycobacterial strains harbouring structural differences in the 
mannosylated lipoglycans. Evidently, M. smegmatis phosphoinositol-capped LAM (PILAM) 
(Nigou et al., 2001), nor AraLAM (Geijtenbeek et al., 2003) showed inhibitory ability on the 
secretion of IL-12 from DC-SIGN.  
M. tuberculosis and M. bovis BCG have been shown to induce DC maturation, however 
ManLAM-bound DC-SIGN has been implicated in interfering with DC maturation 
(Geijtenbeek et al., 2003). In the presence of ManLAM alone, DC maturation markers CD80, 
CD83, CD86 or MHC-II showed no-upregulation. LPS-bound TLR4 stimulates intracellular 
signalling that induces DC maturation, however in the presence of ManLAM, LPS-activated 
DCs also failed to acquire a mature phenotype. M. bovis BCG-induced DC maturation was 
inhibited in the presence of ManLAM but was seen to be restored following preincubation with 
antibodies specific for DC-SIGN (Geijtenbeek et al., 2003). These results suggest that when 
secreted as a virulence factor from M. tuberculosis-infected macrophages, ManLAM is able to 
interfere with DC maturation through DC-SIGN-dependant pathways and the LPS-TLR4 
induced DC maturation pathway.  
IL-10, an immunosuppressive cytokine involved in dampening immune responses, was seen to 
be induced in the presence of ManLAM (Geijtenbeek et al., 2003). IL-10 has many 
immunosuppressive abilities, including, inhibiting expression of MHC-II and co-stimulatory 




α (Couper et al., 2008). The release of IL-10 could have contributed to the low level of 
activation markers observed in the above studies, thus could also play a role in interfering with 
DC maturation. IL-10 prevents the activity of effector T-cells, therefore preventing an effective 
immune response and control of M. tuberculosis.  
The host cell could have a mechanism of counteracting this clever immune-evasion strategy of 
M. tuberculosis. Following uptake into the DC via DC-SIGN, both whole bacilli and purified 
ManLAM-infected DCs were seen to colocalize with lysosomes, and lose the expression of 
DC-SIGN on their surface (Geijtenbeek et al., 2003). This could explain why DCs do not 
support intracellular growth of M. tuberculosis; once co-localised with lysosomes, there could 
be exchange of lysosomal hydrolases between the lysosome and DCs, which prevents 
intracellular growth. The discrepancies observed in DC maturation following incubation with 
whole bacilli or purified virulence factors suggest that internalization of M. tuberculosis by 
DCs activates the immune system. Interaction between DCs and virulence factors mediated by 
DC-SIGN seem to have an opposing effect on each other and dampen the host immune 
response, giving M. tuberculosis time to establish infection.  
2.2.2.2  Toll-like receptors and dectin-1  
The important role of TLRs in activating cellular immune responses has been well defined. We 
have already mentioned the importance of macrophage TLRs during TB pathogenesis and the 
ability of M. tuberculosis and its derived antigens to dampen or activate immune responses 
using these receptors. M. tuberculosis secreted antigens have also been shown to modulate the 
host immune response by interacting with TLRs expressed on DCs. Although there is no 
evidence for PE/PPE interaction with TLRs on DCs, M. tuberculosis p19 has been shown to 
promote DC maturation and induce the production of pro-inflammatory cytokine, IL-12 from 
DCs in a TLR2-dependent manner (Thoma-Uszynski et al., 2000; Hertz et al., 2001).  
The mycobacterial cell wall constitutes ligands for phagocytic, and proinflammatory receptors, 
both of which share intracellular signalling molecules, thus suggesting that various classes of 
receptors interact with each other to induce an effective immune response (Underhill and 
Ozinsky, 2002). This is also the case for dectin-1 found on DCs. In response to zymosan, LPS 
and Pam3Csk4 (synthetic lipopeptide), the simultaneous engagement of dectin-1 and TLR2 was 
shown to enhance pro-inflammatory cytokine production in murine BMDMs and bone 
marrow-derived DCs, compared to engagement of one receptor alone (Gantner et al., 2003). In 




H37Rv, M. bovis BCG and M. avium), the production of pro-inflammatory cytokine, IL-12p40 
was abrogated in the absence of dectin-1 and TLR2 (Rothfuchs et al., 2007). This suggests that 
dectin-1 is able to function independently of TLR2, however the presence of both receptors 
enhances the pro-inflammatory immune response. 
The synergistic action of dectin-1 and other TLRs has also been demonstrated. Pompei et al. 
demonstrated the ability of TLR9 and TLR2 to remodel the IL-12p40 promoter thus influencing 
the inflammatory response mediated following engagement of dectin-1 with pathogenic 
mycobacterial strains (Pompei et al., 2007). It is interesting to note that TLR9-deficient mice 
produced no IL-12p40 from DCs and those lacking TLR2 were unable to produce IL-12p40 
from macrophages. However, when both TLR9 and TLR2 are absent, DCs and macrophages 
are both unable to produce IL-12p40 (Pompei et al., 2007), suggesting that both receptors 
provide unique functional elements that are needed for initiating a pro-inflammatory response.  
The interaction between dectin-1 and other receptors does not always lead to an inflammatory 
response. A study by Zenaro et al. showed that M. tuberculosis induced the release of TNF-α, 
IL-1β, IL-6 and IL-23 from monocyte derived DCs in a dectin-1 dependent manner (Zenaro et 
al., 2009). In agreement with other studies, these cytokines stimulated the formation of CD4+ 
T-cells with characteristics of Th1 or Th17 and Th1 and Th17 cells (LeibundGut-Landmann et 
al., 2007; Manicassamy et al., 2009; Zenaro et al., 2009). Both these processes were inhibited 
by stimulation of DC-SIGN and MR and was reactivated in the presence of monoclonal 
antibodies blocking DC-SIGN and MR (Zenaro et al., 2009). This suggests that signals initiated 
by the MR and DC-SIGN interfere with pro-inflammatory signals initiated by dectin-1. In TB 
infection, Th1-cells play a protective role by producing IFN-γ, while Th17-cells have been 
implicated in tissue damage and neutrophilic inflammation thus playing a role in the lung 
pathology associated with TB disease. In the studies above, it appears as though M. tuberculosis 
has used dectin-1 to induce a Th17 response to increase the pathological effects of TB disease 
and promote its own survival.  
Murine studies with mice deficient for the Clec4n gene, encoding the dectin-2 receptor, 
demonstrated the critical role for dectin-2 in the host response during mycobacterial infection 
(Yonekawa et al., 2014). Dectin-2-deficient mice had higher bacterial burden and displayed 
increased lung histopathology compared to wild-type mice. It was also demonstrated that M. 
tuberculosis ManLAM is a direct ligand for the dectin-2 receptor, resulting in the release of 
pro- and anti-inflammatory cytokines from bone marrow-derived DCs. Furthermore, dectin-2 




(Yonekawa et al., 2014). The recognition of ManLAM by dectin-2 was shown to be dependent 
on the mannose caps of ManLAM and the mannose-recognition property of dectin-2. The 
production of anti- and pro-inflammatory cytokines following interactions between dectin-2 
and ManLAM on DCs may be beneficial to the host in balancing the immune response to M. 
tuberculosis. ManLAM did not induce an inflammatory response in vivo (Yonekawa et al., 
2014) and could thus be used, in conjunction with dectin-2 as hydrophilic ‘regulatory adjuvant’ 
that promotes the development of the adaptive immune response.  
AMs and DCs are in a constant battle for immune control during TB infection due to the 
differential expression of M. tuberculosis virulence factors during infection (Gupta et al., 
2010). Antigens produced by M. tuberculosis on day 1 (D1) of infection are essential for 
intracellular survival within the AM and enhance the maturation and activation of DCs, 
however, these, and antigens produced after D5 of infection prevented AM activation and 
downregulated the expression of MHC-I and II. Consequently, even if activated T-cells were 
present, no antigen presentation could have occured between the AM and the T-cell. Most 
antigens expressed on D5 also played a major role in promoting latency and dampened DC 
function by downmodulating the surface expression of CD54 and MHC-I and II molecules 
(Gupta et al., 2010).  
These inhibitory effects could be attributed to the increased SOCS1 (suppressor of cytokine 
signalling 1) expression in both DCs and macrophages. SOCS1 is the most characterized 
member of the SOCS protein family primarily involved in regulating cytokine expression and 
cytokine receptor-mediated gene expression of immune cells (Alexander, 2002). In DCs, the 
increase in SOCS1 expression occurred early during infection in a TLR2-dependent manner by 
D1 antigen Rv2463. Furthermore, both antigens repressed the oxidative burst from the DC 
(Gupta et al., 2010). Prevention of ROI in the DC allowed the intracellular survival of M. 
tuberculosis, while interfering with cytokine signalling during early infection, with possible 
negative implications for T-cell priming and Th1 responses from DCs. This study highlights 
how elegantly M. tuberculosis interacts with two of the most important innate immune cells to 
induce the dysregulation of the host immune response and ensure its own survival.  
These studies truly emphasize the heterogenous innate immune response induced, depending 
on what type of immune cell is interacting with M. tuberculosis during infection. Receptors 
behave differently on different innate cells, thus allowing many avenues of immune activation, 
leading to a pro-inflammatory response. However, this heterogeneity also provides M. 




manipulate for immune evasion. The interactions between M. tuberculosis and the innate 
immune cells have implications for the resulting adaptive immune response, within which there 
are new targets for M. tuberculosis manipulation.   
2.3 The Adaptive Immune response to Mycobacterium 
tuberculosis infection 
One extremely important characteristic of the adaptive immune system is its ability to recognise 
known M. tuberculosis antigens and rapidly produce effector CD4+ T-cells and antibodies 
specifically for that antigen, allowing for a quicker and more specialized host defence response 
(Alberts et al., 2002). The adaptive immune response can be classified as a cell-mediated- or 
humoral immune response, both working together to defend the host against M. tuberculosis. 
The cell-mediated response is mainly governed by CD4+ T-cells that attempt to destroy the 
intracellular pathogen and stimulate the release of cytokines that sequester other immune cells 
to the site of infection. The humoral immune response is governed by B-cells that produce 
antibodies which help prevent intracellular pathogens from disseminating (Janeway et al., 
2001). B-cell antigen binding and internalisation results in the activation of helper T-cells 
through peptide presentation. The bound antigen, along with the signals produced by the 
activated helper T-cells, induces the proliferation and differentiation of the B-cell into plasma 
cells, which secrete antibodies specific for the bound antigen. These antibodies function to 
eliminate the pathogen by neutralization, opsonisation or through activating the complement 
pathway (Janeway et al., 2001). 
2.3.1 Initiating the adaptive immune response during TB infection  
The adaptive immune response to TB infection is initiated once M. tuberculosis disseminates 
to the pulmonary lymph node (Chackerian et al., 2002; Wolf et al., 2008), which becomes rich 
in M. tuberculosis-specific T-cells 2-3 days post dissemination  (Chackerian et al., 2002). The 
faster dissemination occurs, the more efficient the adaptive immune response to M. 
tuberculosis will be. DCs are instrumental in this process and differ in functionality depending 
on which part of the lung they originate. DCs found in lung mucosa present antigen more 
efficiently than those in lung parenchyma (von Garnier et al., 2005), which may be due to the 
highly regulated environment of AMs within the mucosa that may prevent these DCs from 




suggest that time is required for the bacterial burden to increase to a level that may activate the 
adaptive immune response.  
 
Activated T-cells can circulate back to the lung and activate resident APCs, a process that takes 
roughly seven days. IFN-γ-producing T-cells can detected in the lung at 14 days post infection 
(p.i), however, inhibition of M. tuberculosis proliferation is only detected at 20 days p.i 
(Cooper, 2009), suggesting that IFN-γ needs to accumulate at the site of infection before 
growth can be restricted. Following antigen presentation, activated T-cells differentiate into 
various effector subsets in response to the pathogenic stimulus. The effector phenotype is also 
influenced by the availability of cytokines and co-stimulatory molecules, and type of APC 
(Luckheeram et al., 2011). Cytokine-derived signals are the major determinants of the resultant 
T-cell lineage of the naïve T-cell. They activate signal transducer and activator of transcription 
(STAT) factors that bind lineage-specifying transcription factors and induce the transcription 
Figure 2.3: The initiation of the adaptive immune response during M tuberculosis 
infection. Aerosol infection mimics the natural route of infection during TB disease. Low 
numbers of M. tuberculosis are deposited in the lungs where they are phagocytosed by 
antigen presenting cells such as alveolar macrophages and dendritic cells. DCs are 
instrumental in transporting M. tuberculosis to the draining lymph node where they present 
M. tuberculosis antigens to naïve T-cells via MHC-I and MHC-II. Once primed, these effector 
T-cells will differentiate into different effector subsets and will migrate back to the lung through 
circulation. The effector T-cells are attracted to the site of infection through inflammatory 
signals. Once in the inflammatory lesion, the T-cells respond to the inflammatory response by 
activating resident APCs. When an appropriate immune response has been initiated by T-
cells and activated macrophages, intracellular growth M. tuberculosis will be inhibited. (Image 




of pro-inflammatory cytokines in the nucleus. This process results in the generation of a 
specific CD4+ T-cell lineage (Lyadova and Panteleev, 2015). Two of the most important 
effector CD4+ T-cell subsets involved in the maintenance and regulation of the adaptive 
immune responses during TB infection are T-helper 1 (Th1) and Th17 CD4+ T-cells (Table 
2.2) (Khader et al., 2009; Zenaro et al., 2009; Ottenhoff, 2012; Lyadova et al., 2015). 
Attempting to better understand the M. tuberculosis-specific adaptive immune response and 
the factors that tip the balance between protection and immunopathology will allow us to 
identify correlates of protection which could possibly lead to advances in the TB vaccine 
development pipeline. 
2.3.2 The Th1-mediated cellular response during TB infection  
M. tuberculosis has been shown to impair Th1 mediated cellular responses (Almeida et al., 
2009). IL-12 and IFN-γ are the major cytokines involved during Th1 cell development. Naïve 
CD4+ T-cells express functional IFN-γ receptors on their surface, however the signalling 
subunit of the IL-12 receptor, IL-12Rβ2 is only induced upon antigen activation of the T-cell 
(Szabo et al., 1997; Afkarian et al., 2002). Following cytokine-receptor interactions on naïve 
T-cells, STAT4 and STAT1 are induced (Kaplan et al., 1996; Lighvani et al., 2002).  
These transcription factors induce the Th1 lineage specific ‘master regulator’ T-bet (Afkarian 
et al., 2002; O’Shea et al., 2011) that is responsible for the activation of Th1 genes, such as 
IFN-γ, and the negative regulation of Th2 and Th17 cells (Hwang et al., 2005; Djuretic et al., 
2007; Lazarevic et al., 2011; Zhu et al., 2012) (Figure 2.4). T-bet induction was significantly 
reduced in IFN-γ-deficient mice, while stimulation of human myeloid antigen-presenting cells 
with IFN-γ alone resulted in T-bet induction (Lighvani et al., 2002). For maximum IFN-γ 
production, it was shown that a second transcription factor, Runx3, was required (Djuretic et 
al., 2007), suggesting that STAT4 and IL-12 play a redundant role to STAT1 and IFN-γ, and 
mainly function to enhance the development of Th1 cells and Th1 mediated immune response 








The importance of IFN-γ and IL-12 during M. tuberculosis infection has been well documented 
using murine knock-out models. IFN-γ-knockout mice were unable to control intracellular M 
tuberculosis growth and showed increased levels of necrosis (Cooper et al., 1993; Flynn et al., 
1993). Macrophages isolated from IFN-γ-knockout mice showed reduced surface expression 
of MHC-II molecules and impaired ability to produce antimicrobial peptides. These IFN-γ-
knockout mice were even susceptible to intravenous M. bovis BCG infection (Dalton et al., 
1993). Mice lacking IL-12 have also shown impaired ability to control the intracellular growth 
of M. tuberculosis, with decreased T-cell activation and accumulation at the site of infection 
(Orme et al., 1997). Genetic studies done on patients with disseminated mycobacterial infection 
identified an important role for the IL-12 receptor subunit, IL-12Rβ1. T-lymphocytes isolated 
from these patients were unable to produce IFN-γ in response to tuberculin. This suggests that 
the ability of CD4+ Th1 cells to produce effective levels IFN-γ depend on the co-stimulation of 
IL-12 and IFN-γ with functional receptors (Altare et al., 1998). Based on the literature covered 
in Section 2.2, it is safe to assume that during chronic infection, circulating M. tuberculosis 
Figure 2.4: Induction of Th1 immune responses during M tuberculosis. The Th1 immune 
response to M. tuberculosis infection is mainly mediated through IFN-γ-induced STAT-1-
dependent production of proinflammatory cytokines. This process is also mediated through IL-
12-induced STAT4-dependent production of proinflammatory cytokines. T-cells in which this 
occurs are classified as Th1 CD4+ T-cells and have a number of mechanisms that aid in 
eliminating or containing M. tuberculosis in antigen-presenting cells in the lung. As discussed 
in Chapter 2.2, M tuberculosis has developed various ways in which to disrupt this pro-




antigens may interfere with Th1 CD4+ T-cell priming and differentiation and could therefore 
contribute to the impaired IFN-γ production by Th1 cells observed in TB positive patients. 
When exposed to M. tuberculosis antigens, T-cells from TB positive patients showed delayed 
phosphorylation, thus activation, of ERK and MAPK-p38 with the lowest levels of IFN-γ 
producing T-cells correlating with greatest reduction in phosphorylation (Pasquinelli et al., 
2013).  
Although members of the PE/PPE family are being considered for vaccine development due to 
suggested immunostimulatory effects, there is evidence implicating certain PE/PPE proteins in 
dampening Th1 mediated cellular responses (Gong et al., 1996; Nair et al., 2009; O’ Leary et 
al., 2011; Khubaib et al., 2016). A study to investigate the effects of co-operonic PE32/PPE65 
proteins on the immune response in RAW 264.7 macrophages showed a dose-dependent 
increase of anti-inflammatory IL-10 and decrease of pro-inflammatory TNF-α (Khubaib et al., 
2016). Additionally, the levels of IFN-γ found in the supernatant of PE32/PPE65 stimulated 
splenocytes were significantly decreased, which correlated with the reduced CD4+ and CD8+ 
T-cells producing IL-2 and IFN-γ (Khubaib et al., 2016). M. tuberculosis infection of 
macrophages has been shown to induce IL-10 production, which has been implicated in 
inhibiting phagosome maturation and IFN-γ production (Gong et al., 1996; O’ Leary et al., 
2011). M. tuberculosis PPE18 may contribute to this effect as it has also been shown to induce 
the production of IL-10 from macrophages (Nair et al., 2009).  
2.3.3 The Th17-mediated cellular response during TB infection  
Th17 T-cells are most commonly known for the role they play in autoimmune diseases 
(Steinman, 2007; Zambrano-Zaragoza et al., 2014), suggesting that these cells induce a 
potentially unfavourable immune response during mycobacterial infection. The development 
of Th17 cells is mediated by the combined stimulatory signal of IL-6, IL-21, IL-23 and IL-1β 
(Torrado and Cooper, 2011) (Figure 2.5). Once engaged on the T-cell, these cytokines induce 






IL-17 is classified as the major Th17 effector cytokine, however IL-22, IL-26 and GM-CSF 
also have important roles in the inflammatory process (Codarri et al., 2011; Torrado and 
Cooper, 2011). IL-17 has been implicated in neutrophil recruitment, granuloma formation and  
delayed-type hypersensitivity (DTH) responses to PPD (Umemura et al., 2007). The reduced 
DTH response in the absence of IL-17 suggests that IL-17 is indispensable for an efficient cell-
mediated immune response. However, impaired granuloma formation is not necessarily a 
negative outcome for the progression of TB disease as the granuloma provides a protected 
niche for M. tuberculosis to reside in and may promote dissemination once it bursts.  
A population of T-cells known as the γδ T-cells are thought to be responsible for IL-17 
production (Umemura et al., 2007). However, this was shown to not be the case in healthy, M. 
tuberculosis-exposed individuals in response to PPD and viable M. bovis BCG (Scriba et al., 
2008). In these individuals, CD4+ T-cells were shown to be the major contributor to IL-17 
production (Scriba et al., 2008). It was suggested that the differences between these two studies 
could be attributed to the presence of non-protein components in PPD and M. bovis BCG that 
induced cytokines from γδ T-cells. Furthermore, γδ T-cells have mainly been implicated during 
early immunity whereas CD4+ T-cells are mainly involved during memory responses.  
Figure 2.5: Th17 T-cell development and their role in TB disease. M. tuberculosis induced 
Th17 immune responses are initiated following the differentiation of naïve CD4+ T-cells into 
Th17 CD4+ T-cells. This process is mediated by the presence of various cytokines and their 
respective interactions with their receptors. Th17 immune responses are mainly mediated 
through the STAT3-mediated activation of RORγt that induces that transcription of pro-
inflammatory cytokines. Alternatively, Th17 differentiation can be mediated by TRAF6-Act1-
mediated activation of NFκB and JNF which induces the transcription of pro-inflammatory 




It has been suggested that IL-17 producing CD4+ T-cells are absent during active TB disease 
(Perreau et al., 2013). However, whole blood from baseline active TB patients (no TB 
treatment) was shown to have reduced quantities of PPD-specific and BCG-specific IL-17+ IL-
22+ CD4+ T-cells compared to exposed healthy controls. Consequently, the levels of IL-17 and 
IL-22 in whole blood of baseline active TB patients was also reduced. Interestingly, the 
bronchoalveolar lavage (BAL) fluid from baseline active TB patients showed reduced IL-17 
and elevated IL-22 levels, which was attributed to Th1-mediated downregulation of Th17 
development and IL-17 production during TB (Scriba et al., 2008). Associated with elevated 
IL-22 in the BAL fluid was the increase of BAL neutrophils and alveolar lymphocytes and a 
reduction in AMs.  
Investigation into Th17-mediated responses following vaccination to an ESAT-6-adjuvanted 
vaccine demonstrated that IL-17+ CD4+ T-cells accumulated more rapidly in vaccinated mouse 
lungs compared to IFN-γ+ CD4+ T-cells (Khader et al., 2007). The accumulation of Th17 cells 
in the lung correlated with the induction of CXCR3 (CD183) chemokines, CXCL9, CXCL10 
and CXCL11, which was prevented in the absence of IL-17 and IL-23. IFN-γ recall responses 
were also inhibited in the absence of IL-17 and IL-23, while the absence of IL-23 alone 
prevented the production of IL-17 from vaccinated mice (Khader et al., 2007). Similarly, IL-
17 production in M. bovis BCG vaccinated mice challenged with M. tuberculosis was also 
shown to be dependent on IL-23 (Umemura et al., 2007), however human PBMCs stimulated 
with M. tuberculosis H37Rv demonstrated IL-17 production to be dependent on signalling 
through the IL-1 receptor (Veerdonk et al., 2010). 
From the results above, it is speculated that Th17 cells play a role in monitoring the peripheral 
environment, responding rapidly to antigen stimulation and recruiting other effector cells to 
control M tuberculosis growth. The production of IL-23 seems to play an indispensable role 
during Th17-mediated protection in vaccinated mice challenged with M. tuberculosis, due to 
its role in the formation of a large mononuclear granulomatous structure and establishing a 
Th17 memory population following vaccination (Khader et al., 2007).  
2.3.4 The PE/PPE-induced cellular response during TB infection 
PE/PPE protein interactions with cells of the innate immune system have been shown to have 
an influence on the pathophysiological outcomes of TB disease (Sampson, 2011). In addition, 
there are numerous reports of cell-mediated and humoral immune responses to various PE/PPE 




immunogenicity of 36 PE/PPE proteins, from 4 phylogenetic sub-groups, in M. bovis-infected 
cattle and M. tuberculosis-infected humans elegantly demonstrated the immunogenic potential 
of numerous (1043) PE/PPE-derived peptides. Interestingly, there were very similar 
immunodominant peptides in bovine and human hosts, and between patients with active and 
latent TB disease. Numerous PE/PPE peptides induced an immune response that was sustained 
throughout disease progression, which suggests that these peptides may have an important 
functional role during pathogenesis (Vordermeier et al., 2012). 
The study by Vordermeier et al. is the most comprehensive analysis of PE/PPE 
immunogenicity to date, however, insight into the effect these proteins have on cytokines (other 
than IFN-γ) and the immunophenotype of responding cell populations was not in the scope of 
the study. Immunization with PPE39 (Rv2353c) from the hypervirulent M. tuberculosis strain 
Beijing/K was shown to induce a combined Th1/Th17 immune response as measured by the 
increased levels of IFN-γ, IL-2, IL-6 and IL-17 in the lungs and spleen, 4 and 9 weeks post 
challenge (Kim et al., 2017). PPE39-immunized mice also had fewer inflammatory lesions and 
reduced bacterial burden in the lung compared to unimmunized mice (Kim et al., 2017). 
Interestingly, IFN-γ levels continued to increase between 4 and 9 weeks, whereas the levels of 
the other cytokines did not. This gives us some insight into the cell populations governing the 
PPE39-mediated immune response and suggests that Th17 T-cells enhance early protection 
against challenge, and as the infection becomes more chronic, Th1 T-cells become the major 
role players in protection (Kim et al., 2017).  
The expression of PPE34 (Rv1917c) has been shown to be selectively enhanced in M. 
tuberculosis infected murine macrophages (Schnappinger et al., 2003). PPE34-matured human 
DCs demonstrated the ability to activate naïve CD4+ T-cells, however their polarization was 
skewed to an anti-inflammatory Th2-mediated cellular response, as characterised by the 
production of IL-4, IL-5 and IL-10 (Bansal et al., 2010). CD4+ T-cells isolated from pulmonary 
TB patients secreted no IFN-γ and significantly higher levels of IL-5 compared to healthy 
controls following PPE34 stimulation. Furthermore, the Th2-mediated immune response 
elicited by PPE34 was seen to be critically dependant on the expression of PGE2 and COX-2 
(Bansal et al., 2010). PGE2 is a biosynthetic product of COX-2 mediated inflammatory 
enzymatic reactions and has been shown to be a potent inflammatory mediator that favours a 
Th2 response (Meyer et al., 2003). Th2-mediated responses inhibited Th1 responses as 
demonstrated by the lack of IFN-γ released by CD4+ T-cells. It would be interesting to 




in producing granulocytic granulomas during TB infection as opposed to mononuclear ones 
(Domingo-Gonzalez et al., 2016) 
The effect PE/PPE proteins have on the immune response was further exemplified in a study 
in which the all ESX-5 pe/ppe-associated genes (ppe25-pe19) from M. tuberculosis H37Rv 
were deleted (Sayes et al., 2012). Mice infected with the deletion mutant (∆ppe25-pe19) 
produced significantly higher levels of IFN-γ in response to ESAT-6 and CFP-10 when 
compared to IFN-γ produced by mice infected with M. tuberculosis H37Rv (Sayes et al., 2012). 
The protective responses elicited by the mutant strain ∆ppe25-pe19 were also shown to be 
higher than those produced in response to the recombinant RD1 BCG vaccine (Pym et al., 
2003; Sayes et al., 2012). When challenged with M. tuberculosis, ∆ppe25-pe19-vaccinated 
mice demonstrated a reduced bacterial burden in the lungs and spleen with an evident decrease 
in lung lesions, when compared to BCG-vaccinated mice (Sayes et al., 2012). Furthermore, the 
∆ppe25-pe19 strain proved safe to use in severely immunocompromised mice while inducing 
IFN-γ in response to CFP-10 and ESAT-6. These results provide compelling evidence that 
warrants the further investigation of M. tuberculosis::∆ppe25-pe19 as a vaccine candidate. 
As such, several epitopes from PPE25 and PE19 have demonstrated substantial cross-reactivity 
with CD4+ T-cells (Sayes et al., 2012). It has been speculated that multiple PE/PPE proteins 
could be recognised by the same T-cell population due the significant T-cell response elicited 
by PE/PPE peptides from the conserved N-terminal (Vordermeier et al., 2012). This was 
confirmed when short-term bovine T cell lines, raised by primary stimulation with a particular 
PE or PPE peptide were shown to release IFN-γ in response to stimulation with a different PE 
or PPE peptide (Vordermeier et al., 2012). These results suggest that the differentially 
expressed pe/ppe genes (with variations in their amino acid sequences) may still be recognised 
by cross-reactive T-cells, making these proteins promising candidates for the development of 
new TB vaccines.  
The studies highlighted above have provided some insight into the immune response elicited 
to selected members of the PE/PPE protein family. However, information regarding the 
immune response elicited by the PE_PGRS and PPE_MPTR subgroups is desperately required 
to gain a better understanding of the functional and immunological consequences of their 
highly variable C-terminal region. A member of the PPE_MPTR subfamily, PPE_MPTR42 
(Rv2608), has been identified as a promising T-cell antigen for the development of new TB 
vaccines (Bertholet et al., 2008; Baldwin et al., 2009) and has been evaluated among 68 other 




2008). Following challenge with M. tuberculosis H37Rv and Erdman, PPE_MPTR42 
adjuvanted with low dose CpG (PPE_MPTR42/CpG) displayed the highest protective efficacy 
as demonstrated by the greatest decrease in mean pulmonary CFU counts, which were 
comparable to CFUs in the lungs of recombinant-BCG-vaccinated mice. Furthermore, 
PPE_MPTR42 elicited strong CD4+ and CD8+ T-cell responses to a variety of HLA types and 
immune responses were predominately Th1-skewed (Bertholet et al., 2008). 
Due to the protective efficacy and strong immunogenicity elicited by PPE_MPTR42, it was 
included with Rv1813c (conserved hypothetical protein), Rv3620 (esxW) and Rv3619 (esxV) 
in the ID93 vaccine candidate, adjuvanted with GLA-SE (Bertholet et al., 2010). ID93/GLA-
SE was shown to be highly immunogenic in mice, guinea pigs and cynomolgus monkeys and 
induced the formation of polyfunctional CD4+ Th1 T-cells that produced antigen specific IFN-
γ, TNF-α and IL-2. Following immunization with ID93 and challenge with virulent or multi-
drug resistant M. tuberculosis, there was a significant reduction in pulmonary bacterial burden 
in ID93-immunized mice versus the control mice. Furthermore, boosting BCG-vaccinated 
guinea pigs with ID93/GLA-SE prevented death following challenge with M. tuberculosis 
H37Rv and resulted in reduced pulmonary pathology and bacterial burden (Bertholet et al., 
2010).  
PPE_MPTR42 has also been included in a recombinant BCG (rBCG) vaccine with Ag85A and 
ESAT-6 (Lu et al., 2012). Mice immunized with rBCG elicited a more effective humoral 
response and an improved Th1 immune response compared to mice immunized with M. bovis 
BCG. The immune response to rBCG was primarily governed by cytotoxic CD8+ T-cells as 
seen by the significantly higher proliferation of CD8+ T-cells in rBCG-vaccinated compared to 
M. bovis BCG-vaccinated mice. The improved cell-mediated immune response was 
characterized by the production of Th1 cytokines, higher antibody titres, and more CD8+ T-
cells. Th1 cytokines induced Th1 mediated immune responses which were necessary for 
protection against mycobacteria, furthermore CD8+ T-cells eliminated mycobacterial infection 
by lysing infected cells. 
2.4 Conclusion 
In this review we have highlighted the heterogenous immune response to TB infection, a 
complex reaction that is not fully understood. The large number of innate immune receptors 
and innate mechanisms M. tuberculosis can interact with and modulate, make characterising 




investigating the effect of understudied M. tuberculosis protein families, such as the PE/PPE 
proteins. Although tremendous advances have been made in our knowledge about M. 
tuberculosis and its modulatory abilities on the host immune system, it is clear that there are 
still many areas of uncertainty and speculation. Continued investigation into the cellular 
responses to M. tuberculosis will aid in identifying potential mechanisms and antigens that can 
be targeted for immunodiagnostics and vaccine development. As highlighted in this review, 
members of the PE/PPE protein family have shown potential as possible vaccine candidates, 
however more investigation needs to be done concerning their role in the immune response 
(See Chapter 4). 
An effective immune response is achieved when both the innate and adaptive immune systems 
work synergistically to overcome an infection, therefore, in this review chapter, we attempted 
to unravel the effect PE/PPE, and other M. tuberculosis proteins have on the innate and adaptive 
immune response during TB disease. In the remaining chapters of this thesis, we will explore 
how the adaptive immune response is activated in response to PPE_MPTR proteins and 
characterise the type of cell-mediated immune response induced by these peptides in an African 
context. Furthermore, their potential as a correlate of active TB disease will also be evaluated.  
Properly understanding how M. tuberculosis exploits and manipulates both arms of the host 
immune system may help to decipher the highly heterogeneous immune response observed 
during infection with M. tuberculosis. With this knowledge, new approaches can be developed 
that prevent M. tuberculosis from manipulating the host immune response and may succeed in 






Chapter 3  
Methods and Materials 
3.1 Ethics Statement  
Ethical approval for this study was obtained from the Committee for Human Research of the 
University of Stellenbosch with ethics number N16/05/070 (Section 7.1). All the study 
participants gave written informed consent for participation in the study (Section 7.2). 
3.2 Peptide reconstitution  
PPE_MPTR, ESAT-6 (EsxA) and CFP-10 (EsxB) peptides (Table 3.1) used in this study were 
synthesised by GL Biochem Ltd (Shanghai) and subjected to HPLC/MS to confirm purity. 
Lyophilized peptides were centrifuged at 18 928 rcf for 2 minutes prior to reconstitution to 4 
mg/ml in 800 µl Phosphate Buffered Saline (PBS; Thermo Fisher). Peptides were stored as 200 
µl and 10 µl aliquoted volumes at -80°C until use. Two positive controls were selected for 
whole blood assays (WBAs); Phaseolus vulgaris phytohaemagglutinin (PHA) (10 µg/ml) 
(Sigma-Aldrich) as a non-specific positive control to confirm that the stimulation assay is 
working, and M. tuberculosis purified protein derivative (PPD) (10 µg/ml) (Sigma-Aldrich) as 
a M. tuberculosis-specific control. Phosphate-buffered saline (PBS) was used as a negative, 





3.3 Peptide concentration optimization experiments  
For optimization of PPE_MPTR peptide concentrations, two participants were recruited from 
The Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health 
Science, Stellenbosch University. One participant had previously tested positive for the 
interferon-gamma (IFN-γ) release assay (IGRA) and one participant tested negative. Nine 
millilitres (9 mL) of undiluted, heparinized whole blood was obtained from both study 
participants with informed signed consent.  
To determine the optimal concentration for peptide reactivity, a range of peptide concentrations 
was used to stimulate whole blood in a whole blood assay (WBA) experiment. Peptides were 
diluted into a final volume of 20 μl in a 96-well U bottom plate prior to the addition of 180 µl 
undiluted, heparinized whole blood. Peptide concentrations ranged from 20, 10, 5 or 1 µg/ml 
for the peptides P1-P19 and controls peptides ESAT-6 and CFP-10, in a final volume of 200 
µl. The 96-well U bottom plates were incubated for 24 hours in a humidified, 5% CO2, 37°C 
Table 3.1: ESAT-6 and CFP-10 peptides used in this study (Vordermeier et al., 2001) 
















ESAT-6 p46 AGIEAAASAIQGNVTS 
ESAT-6 p47 AIQGNVTSIHSLLDEG 
ESAT-6 p48 IHSLLDEGKQSLTKLA 
ESAT-6 p49 KQSLTKLAAAWGGSGS 
ESAT-6 p50 AAWGGSGSEAYQGVQQ 
ESAT-6 p51 EAYQGVQQKWDATATE 
ESAT-6 p52 KWDATATELNNALQNL 
ESAT-6 p53 LNNALQNLARTISEAG 
ESAT-6 p54 ARTISEAGQAMASTEG 




incubator, after which plates were centrifuged at 500 rcf for 10 minutes. Approximately 100 µl 
of supernatant was harvested from each well and stored at -80°C until Luminex analysis.  
The concentration (pg/ml) of six host markers [interferon-gamma (IFN-γ); interleukin-6 (IL-
6); IL-10; IL-17A; IL-13 and tumour necrosis factor-alpha (TNF-α)] were measured from 
supernatants using a customized Human Magnetic Luminex Screening Assay (R&D Systems, 
Whitehead Scientific) on the Bio Plex platform (Bio Plex™, Bio Rad Laboratories), according 
to the manufacturer’s instructions. Culture supernatants were thawed at room temperature (RT) 
prior to a 2-fold dilution with calibrator diluent RD6-52. One Luminex kit was used to 
determine the analyte concentrations from 100 µl of sample in two 96-well flat bottom plates. 
The standard curve range between analytes varied and can be seen in Table 3.2. Bio-Plex 
Manager Software, version 4.1.1 was used to analyse the bead median fluorescence intensity 
and to plot fluorescent intensity values to corresponding analyte concentrations on a standard 
curve. The upper and lower limit of detection for each analyte on the standard curve was 






Before data analyses was performed on the raw data generated from the Bio-Plex Manager 
Software, the controls were scrutinized to ensure they were within their specified ranges of the 
kit. Following this, the out-of-range (OOR) values for each analyte per plate were removed 
from the raw data (Microsoft Excel, Windows 10 Pro, version 1803). If the observed analyte 
concentration for a sample was below the limit of detection (<OOR), one was subtracted from 
the lowest observed concentration of that specific analyte on that plate (<OOR-1). If the 
observed analyte concentration for a sample was above the limit of detection (>OOR), one was 
added to the highest observed analyte concentration for the specific plate (>OOR+1). Microsoft 
Excel was used to analyse cytokine concentration data. The data generated in this experiment 
was used to select peptide concentrations for the experiments performed in Section 3.4 and 
3.5.  
Table 3.2: Standard curve range of analytes during peptide concentration optimization 
experiments 
 Standard Curve Concentration Range (pg/ml) 
IFN-γ 50 – 15 000 
IL-13 300 – 91 000 
IL-6 0 – 1 200 
IL-10 0 – 1 200 
IL-17A 10 – 4 000 




3.4 Validating the immunogenicity of population-tailored 
PPE_MPTR peptides  
To determine if computationally-identified PPE_MPTR epitopes elicit an immune response in 
a subset of the African population, eleven study participants from South Africa, Zimbabwe, 
Congo and Ethiopia (Table 3.3) were recruited from the Faculty of Medicine and Health 
Science, Stellenbosch University.  
 
 
Nine millilitres (9 mL) of undiluted, heparinized whole blood was obtained from all study 
participants with informed signed consent. Previous exposure to Mycobacterium tuberculosis 
was assessed using the QuantiFERON®-TB Gold Test. Participants with previous exposure to 
M. tuberculosis tested positive for the IFN-γ-ELISA (QuantiFeron® +; QFN+), and those 
without previous exposure to M. tuberculosis tested negative for the IFN-γ ELISA (QFN-). All 
participants were HIV-negative, Hepatitis-B-negative and without signs or symptoms of any 
illness at the time of sample collection. On the day of the WBA experiment, 20 µl of the 
peptides were aliquoted into 96-well U-bottom plates and 180 µl of undiluted, heparinized 
whole blood was added to the peptide and control wells, to achieve the optimized final peptide 
Table 3.3: Study participants used to assess the immunogenicity of the chosen 
PPE_MPTR peptides. 
Population Heritage No. of participants (n) No. of QFN+ participants (n) 
South Africans 6 2 
Zimbabwean 2 0 
Congolese 1 1 
Ethiopian 2 2 
Total 11 5 
Table 3.4: The chosen concentration for whole blood stimulation with PPE_MPTR 
peptides and control peptides, ESAT-6 and CFP-10. The concentrations of PPE_MPTR 
peptides were determined by comparing the cytokine responses to a gradiant of PPE_MPTR 
peptide concentrations. The concentration at which the most cytokines were produced at the 
highest concentrations were chosen.  
Peptide Final [peptide] in 200 µl 
P1 and P19 5 µg/ml 
P2 to P17 10 µg/ml 
P18 1 µg/ml 
ESAT-6 peptide pool* 10 µg/ml 
CFP-10 peptide pool* 10 µg/ml 




concentration (Table 3.4). The plates were incubated for 24 hours in a humidified, 5% CO2, 
37°C incubator, after which, plates were centrifuged at 500 rcf for 10 minutes. Approximately 
100 µl of supernatant was harvested from each of the peptide and control wells and stored at -
80°C until Luminex analysis. 
A customized Human Magnetic Luminex Screening Assay (R&D Systems, WhiteSci) was 
used to measure the concentration of seven host markers [IFN-γ; IL-1β; IL-4; IL-6; IL-10; IL-
17A; TNF-α] on the Bio Plex platform (Bio Plex™, Bio Rad Laboratories), according to the 
manufacturer’s instructions. The customized Human Magnetic Luminex Screening Assay was 
performed as previously described in Section 3.3. The standard curve range for the different 
analytes is provided in Table 3.5. 
 Standard curve concentration range (pg/ml) 
IL-1β 10 - 5 000 
IL-10 4 000 - 12 000 
IL-4 10 - 4 000 
TNF-α 10 - 3 000 
IFN-γ 50 – 15 000 
IL-6 1 – 1 500 
IL-17A 10 – 4 000 
 
The raw data generated from the Bio-Plex Manager Software was manually filtered as 
previously described in Section 3.3. In addition to this, the percentage of <OOR values was 
calculated, and analytes containing more than 70% <OOR values were omitted from further 
analysis. This data was imported into GraphPad Prism version 8.3.0 where the PPE_MPTR-
specific cytokine responses to the 19 PPE_MPTR peptides were evaluated. Box-and-whisker 
plots depicting the median cytokine response between QFN+ and QFN- participants of this 
cohort were plotted using the Log cytokine concentration values (pg/ml) in response to 
peptides. The peptides which induced the production of the four or more cytokines (above 
unstimulated levels) were selected for flow cytometric analysis. R-Studio version 3.5.3 was 
used to do statistical analyses on these data and can be seen in Section 3.6.  




3.5 Assessing the diagnostic potential of population-tailored 
PPE_MPTR peptide  
To assess the diagnostic potential of the computationally predicted PPE_MPTR epitopes, 
twenty-one study participants (n=21) were recruited from high incident TB communities 
surrounding Tygerberg Hospital, namely Ravensmead and Uitsig, Cape Town, South Africa 
(Table 3.6). Participants with baseline active TB were newly diagnosed cases, showing TB 
symptoms, with a positive M. tuberculosis culture and a positive GeneXpert result. Participants 
with latent TB infection (LTBI) were all asymptomatic with a positive IFN-γ-ELISA result and 
a negative M. tuberculosis culture and GeneXpert result. Healthy controls were negative for 
the IFN-γ-ELISA, GeneXpert and M. tuberculosis culture. All participants were HIV- and 
Hepatitis-B-negative. To increase the sample size of this cohort for post-hoc statistical 
analyses, the South African study participants from Section 3.4 (Table 3.3) were also included.  
Only South African study participants from Section 3.4 were included in the statistical analyses 
as the individuals recruited from high incident TB communities included only South African 
participants. Study participants were split into 2 groups; ‘cases’ and ‘controls’ and can be seen 
in Table 3.6. 
 
Nine millilitres (9 mL) of undiluted, heparinized whole blood was obtained from all study 
participants as mentioned in Section 3.4, to measure the cytokine response to the candidate 
epitopes. WBA experiments were performed as described in Section 3.4. and approximately 
100 µl supernatant from each well was stored at -80°C until Luminex analysis. A customized 
Groups Study participants Sample size (n) Total sample size in analysis (N) 
Cases TB* 5 5 














Total number of samples in statistical analysis 27 
* Study participants recruited from high incident TB communities surrounding Tygerberg Hospital 
TB = active TB individuals; LTBI = latently infected individuals; HC = healthy controls 
Table 3.6: Study participants used to investigate the diagnostic potential of PPE_MPTR 
peptides. Twenty-one study participants were recruited from high incident TB communities 
surrounding Tygerberg Hospital. To increase the sample size of the cohort for pos-hoc 




Human Magnetic Luminex Screening Assay (R&D Systems, Whitehead Scientific, South 
Africa); was used to measure the concentration of seven host markers [IFN-γ; IL-1β; IL-4; IL-
6; IL-10; IL-17A; TNF-α] in the supernatants of TB, LTBI and healthy control samples on the 
Bio Plex platform (Bio Plex™, Bio Rad Laboratories), according to the manufacturer’s 
instructions (Whitehead Scientific, South Africa). The Luminex Multiplex Immunoassay was 
performed as stated in Section 3.4. The standard curve range between analytes varied and can 
be seen in Table 3.5. The raw data generated from the Bio-Plex Manager Software was 
manually filtered as stated in Section 3.3 and analysed as described in Section 3.4. Statistical 
analyses were performed on these data using R-Studio version 3.5.3 as described in Section 
3.6.  
3.6 Luminex Multiplex Immunoassay Data Analysis  
The data generated from Luminex Multiplex Immunoassay experiments in Sections 3.4 and 
3.5 underwent statistical analyses using R-Studio version 3.5.3. Briefly, the data for thirty-two 
individuals, seven analytes and 24 stimulations underwent quality assessment and missing 
concentration-values removed using the ‘Base-R’ (R Core Team, 3.5.3) and ‘TidyVerse’ 
(Wickam, 2017) packages on R-Studio. These data were transformed by winsorizing, to limit 
the effect of outlier data points on the statistical analyses. The winsorized mean of data was 
obtained by replacing the smallest and the largest values in the dataset by the data values closest 
to them. Using the winsorized data, the stimulation-specific cytokine concentrations were 
determined by subtracting the unstimulated conditions from the stimulated conditions. PBS-
stimulated cytokine responses were classified as ‘unstimulated/blank’ and ESAT-6 and CFP-
10 cytokine responses were used as positive controls. 
The winsorized data generated from the Luminex experiments in Section 3.5 were statistically 
analysed. This data, ‘All-Groups Dataset’ included cytokine responses from 27 participants of 
South African origin, namely, the 21 individuals recruited from high-incident TB communities 
surrounding Tygerberg hospital, and the six South African individuals from Table 3.3. The 
Wilcoxon-signed-rank-test was used to compare cytokine responses to PPE_MPTR peptides. 
The comparisons included: Controls vs Cases, LTBI vs TB and LTBI vs HC. Bonferroni-Test-
Correction, with a false discover rate (FDR) = 0.05, was used to adjust for multiple testing. 
Due to the small sample size of this study, the raw significant p-values were used to generate 




3.7 Red Blood Cell Lysis and Peripheral Blood Cell Isolation  
To determine the proportions of immune cell subsets and their levels of activation in response 
to PPE_MPTR peptides, the remaining whole blood pellet from the WBA was lysed and 
cryopreserved for subsequent flow cytometric analyses. The red cell pellet was incubated with 
2 mM ethylenediaminetetraacetic acid (EDTA) for 15 minutes at RT. Following incubation, 
the red pellet was added to 1X FACS Lysing Solution (Becton-Dickinson Biosciences; BD 
Biosciences), in the dark. The cells were vortexed on maximum speed for 10 seconds and 
incubated in the dark for 10 minutes, followed by centrifugation at 500 rcf for 10 minutes. Cells 
were immediately placed on ice before discarding the supernatant. The remaining cell pellet 
was resuspended in 500 µl ice-cold fetal bovine serum (FBS), to which 500 µl cryosolution 
(2% DMSO; 8% FBS) was added (drop-wise). Cells (1 mL) were placed in a MrFrosty freezing 
container (Thermo Scientific) filled with 250 mL 100% isopropanol for 24-hours at -80°C, and 
subsequently stored at -80°C. 
3.8 Flow cytometry  
Flow cytometry was performed on selected peripheral blood cell samples from the 21 
individuals recruited from high-incident TB communities surrounding Tygerberg hospital 
(Section 3.5). Samples were chosen based on the number of cytokines produced in response to 
individual PPE_MPTR peptides as measured in Luminex assays and only samples stimulated 
with peptides inducing the production of more than four cytokines were chosen for flow 
cytometric analysis. The distribution of immune cells, memory and activation states were 
identified using a panel of ten fluorophore-conjugated monoclonal antibodies (mAbs) (BD 













CD8+ T-cells  CD8 FITC SK1 Mouse IgG1, κ 1:10 
BD 
BioSciences 
CD3+ T-cells  CD3 BV421 UCHT1 Mouse IgG1, κ 1:40 
BD 
BioSciences 
CD4+ T-cells CD4 APC-H7 SK4 Mouse IgG1, κ 1:40 
BD 
BioSciences 
B-cells  CD19 BB700 HIB19 Mouse IgG1, κ 1:40 
BD 
BioSciences 
Th1 cells  CD183 PE G025H7 Mouse IgG1, κ 1:10 BioLegend 
Th2 cells CD193 BV605 5E8 Mouse IgG2b, κ 1:10 BioLegend 
Th17 cells  CD196 APC G034E3 Mouse IgG2b, κ 1:20 BioLegend 
Memory 
cells 
CD45RA BV510 HI100 Mouse IgG2b, κ 1:40 BioLegend 
CD28 PE-Cy7 CD28.2 Mouse IgG1, κ 1:160 BioLegend 
Activated 
cells CD25 PE-Cy5 BC96 
Mouse 
IgG1, κ 1:80 BioLegend 
3.8.1 Antibody Staining  
Cryopreserved peripheral blood cell samples (1 mL) were thawed at RT before the cells were 
added to 10 mL staining buffer (2% FBS in PBS) and centrifuged at 400 rcf for 5 minutes to 
retain the cell pellet. The staining buffer was discarded, and the cell pellet was transferred to a 
96-well U-bottom plate before centrifugation at 400 rcf for 5 minutes. The remaining staining 
buffer was discarded from the plate, and the cell pellet resuspended in 20 µl mAb master mix. 
The antibody master mix consisted of PBS with all ten mAbs at the optimal concentrations as 
decided from titration experiments (Section 3.8.2). The cells were incubated with the mAb 
mastermix in the dark for 60 minutes at 4°C, resuspending mid-way through the incubation. 
Cells were subsequently resuspended in 200 µl staining buffer and centrifuged at 400 rcf for 5 
minutes. The staining buffer was discarded and the cells were washed again with 200 µl 
staining buffer (without resuspending). Following centrifugation at 400 rcf for 5 minutes, the 
cell pellet was resuspended in 200 µl staining buffer and placed in the dark at 4°C until 
acquisition on the BD LSR II™ using the BD FACSDiva 8.0.1 software. 




3.8.2 Antibody titration and voltration experiments 
Antibody titration and voltration optimization experiments were performed for each mAb in 
this study. Antibody titration experiments were performed to determine which mAb 
concentration was most optimal in identifying the cell population of interest. PHA-stimulated 
whole blood was used for CD45RA-BV510, CD28-PE-Cy7 and CD25-PE-Cy5 mAb titrations. 
These mAbs are specific for activation and memory receptors, therefore PHA-stimulated blood 
was used to activate the whole blood cells, allowing the identification of these activated 
populations (Table 3.7). Unstimulated whole blood was used for CD8-FITC, CD3-BV421, 
CD4-APC-H7, CD19-BB700, CD183-PE, CD193-BV605 and CD196-APC mAb titrations. 
These receptors are expressed on lymphocyte populations regardless of activation, and 
therefore unstimulated whole blood could be used. All whole blood samples were prepared 
using the same experimental conditions as study samples. All samples stained for antibody and 
voltration experiments were done using the protocol in Section 3.8.1.  
The starting serial dilution for each mAb titration was twice that of the concentration 
recommended in the antibody datasheet. Six serial dilutions (1:10, 1:20, 1:40, 1:80, 1:160) 
were prepared for all mAbs except for CD8-FITC, which also included a 1:5 dilution. An 
unstained control was included for each mAb to identify the negative population. The serial 
dilutions were prepared in 0.5 mL Eppendorf tubes® in a final volume of 60 µl. For a starting 
serial dilution of 1:10, 6 µl of undiluted mAb was added to 54 µl staining buffer and mixed 
well, after which 30 µl was serially transferred until all appropriate dilutions were made. The 
peripheral blood cell samples used for antibody titration experiments were stained according 
to the protocol in Section 3.8.1, however samples were incubated in BD polystyrene flow tubes 
instead of a 96-well U bottom plate. Data was acquired on the BD LSR II™ using the BD 
FACSDiva 8.0.1 software. The data was analysed using the FlowJo™ 10.6.1 software to obtain 
the median fluorescent intensity (MFI) of the negative and positive populations for each mAb. 
This data was exported to Microsoft Excel and converted to a ratio (MFIpos/MFIneg) which was 
used to generate line graphs. The optimal mAb concentration was determined by the highest 
MFIpos/MFIneg ratio as seen on the line graph.  
Following the identification of optimal mAb concentration, voltration optimisation 
experiments were performed to identify which voltage setting best separates the negative and 
positive cell populations. PHA-stimulated whole blood samples were stained according to the 
protocol in Section 3.8.1, however samples were incubated in BD polystyrene flow tubes 




and 800V in 50V increments and the acquired data was further analysed using FlowJo™ 10.6.1 
software to identify which voltage provided the best separation of positive and negative 
populations per antibody.  
3.8.3 Compensation and FMO controls  
Compensation was performed to limit fluorescent spill-over of excited fluorophores into other 
detectors on the flow cytometer. Fluorescent Minus One (FMO) experiments were used to 
evaluate the effect of spill-over of fluorochromes into the channel of interest and to ensure that 
the compensation set-up had no errors. FMO are samples that include all mAbs except the one 
of interest, allowing the true positive population to be identified. FMO controls were acquired 
each time study sample acquisition occurred to aid in identifying the true positive populations 
during data analysis and to account for the variable detector settings between runs as mentioned 
in Section 3.8.4. PHA-stimulated peripheral blood cell samples were used for FMO 
experiments and stained according to the protocol in Section 3.8.1. 
Compensation controls were prepared for each acquisition and mAb using the BD Anti-mouse 
Compensation Particle set (LOT: 552846; BD BioSciences). An unstained control was also 
included to identify the negative population. Briefly, one drop of each compensation particle 
(negative comp bead and comp bead anti-mouse) was added to 100 µl staining buffer 
containing the appropriate mAb concentration. This was vortexed and incubated in the dark for 
1 hour at 4°C after which 2 mL staining buffer was added to the beads, which were centrifuged 
at 200 rcf for 10 minutes. The pellet was resuspended in 500 µl staining buffer and kept in the 
dark at 4°C until acquisition. Compensation was calculated using MFI values by the BD 
FACSDiva 8.0.1 software before sample acquisition on the BD LSR II™ (Table 3.8). 
Compensation was also performed during data analyses on FlowJo™ 10.6.1 and applied to all 





Detector Target MFI ± 10% Target MFI Range 
FITC 2210± 221 1989 – 2431 
PE 47328 ± 4732 42 596 – 52 060 
PE-Cy5 60 490 ± 6049 54 441 – 66 539 
BB700 25 763 ± 2576 23 183 – 28 339 
PE-Cy7 10 271 ± 1027 9244 – 11 278 
BV421 18 030 ± 1803 16 227 – 19 833 
BV510 17 946 ± 1794 16 152 – 19 740 
BV605 16 769 ± 1676 15 093 – 18 445 
APC 52 138 ± 5313 46 825 – 57 451 
APC-H7 1218 ± 121 1096 – 1339 
 
3.8.4 Sample Acquisition  
Samples were acquired on the BD LSR II™ flow cytometer at the Central Analytical Facility 
(CAF) at The Faculty of Medicine and Health Sciences, Tygerberg Campus and at the IDM 
Flow Core Facility, University of Cape Town. The FACSDiva 8.0.1 software was used to 
create data from the flow cytometers as FCS files.  
Before acquiring samples on the BD LSR II™, BD FACSDiva CS&T Research Beads (LOT: 
82158; BD BioSciences) were used to ensure the cytometer was properly calibrated before use. 
The detector settings (voltage) used for each parameter, except forward scatter (FSC), 
fluctuated between runs (Table 3.9). As a consequence, populations shift during acquisition 
and the appropriate controls (Section 3.8.3) needed to be included during each sample 
acquisition. Compensation controls were acquired until 5000 events were recorded and FMO 
controls were recorded until 10 000 events were recorded. FMO controls can be used to adjust 
the gates between positive and negative populations during data analysis on FlowJo™ 10.6.1. 
Fully stained samples were acquired until 1 000 000 events were recorded or once the available 
volume of sample was depleted.  





3.8.5 Data Analysis for Flow Cytometric Data  
Sample acquisition on the BD LSR II™ generated FCS files that were exported from the 
FACSDiva software. The FCS files were imported and analysed using FlowJo™ 10.6.1. 
Compensation was calculated on FlowJo™ 10.6.1 and the compensation matrix analysed to 
determine if any parameters needed adjusting to get clear separation between populations. 
Compensation was applied to all sample and FMO controls run together on the same day. FMO 
samples were used to set up the gating strategy template (Figure 3.1 and Figure 3.2) on the 
FlowJo™ workspace that was applied each time samples were analysed. When analysing the 
data files, a plot of the cytometer time run (SSC-A vs Time) was analysed to access the stability 
of the cytometer during each run. Stable time gates were further analysed using FSC-H vs FSC-
A to identify the single cells detected by the lasers. The single cells were separated based on 
size (SSC-A vs FSC-A) to identify the lymphocyte fraction within which, the T- and B-cells 
were distinguished and immunophenotyped (Figure 3.1 and Figure 3.2).  
The relative frequencies of T-helper cell populations (Th1, 2 and 17) were calculated as a 
percentage of the CD3+CD4+ T-cell population (CD4+ T-cells). The frequency of T-helper cell 
populations in different memory states (TN, TEM, TCM and TTEMRA) was calculated as a 
percentage of the grandparent T-helper cell population. The frequency of activated memory 
populations was calculated as a percentage of the T-helper population. All statistical analyses 
were done using FlowJo™ 10.6.1.   
Table 3.9: LSR II Configuration and detectors used to acquire samples during this 
study.  
Laser Wavelength Detector 
array 
Detector Parameter Voltage range 
(V) 
Blue 488nm Octagon FSC FSC 505 
A PE-Cy7 502-504 
B BB700 503-507 
C PE-Cy5 604-613 
E PE 545-554 
F FITC 500-505 
G SSC 352-355 
Violet 405nm Trigon A BV605 497-508 
B BV510 501-517 
C BV421 500-525 
Red 633nm Trigon A APC-H7 690-695 





Figure 3.1: Flow cytometry gating strategy applied to identify the relative numbers and 
activation states of CD3+CD4+ and CD3+CD8+ T-lymphocytes. Firstly, the T-helper 
differentiation state was identified (Th1, Th2, Th17), followed by the relavant proportion of 







Figure 3.2: Flow cytometry gating strategy applied to the identify the percentage of B-
cells in response to PPE_MPTR-stimulation, and their subsequent level of activation. 





Chapter 4  
Results  
4.1 Introduction  
The PPE_MPTR proteins of Mycobacterium tuberculosis are hypothesized to contribute to M. 
tuberculosis pathogenesis and disease progression. The cell-membrane localisation of 
PPE_MPTR proteins is thought to facilitate interactions with host immune cells, however these 
interactions at the host-pathogen interface are not well characterised. Several PE/PPE proteins 
have demonstrated immunogenic potential (Vordermeier et al., 2012), however the 
immunogenicity of PPE_MPTR proteins is under explored.  
A previous study identified some promising PPE_MPTR epitopes as subunit vaccine 
candidates for M. tuberculosis (Colic et al., Manuscript in progress) (Table 4.1). Thirty-five 
computationally identified epitopes were predicted to elicit a strong immune response in high 
burden TB African countries (Colic et al., Manuscript in progress). Human populations from 
different geographical regions have different human leukocyte antigen (HLA) allele 
frequencies (Longmate et al., 2001) and based on the differential distribution of HLA alleles 
across geographical regions, nineteen of the identified thirty-five epitopes were selected for 
this study (Table 4.1). These were also representatives of six different PPE_MPTR proteins. 
Nineteen peptides representing these epitopes were commercially synthesized by GL Biochem 
Ltd (Shanghai) for use in this study. These peptides were predicted to have a high likelihood 
of binding to HLA alleles frequently found in South African, Zimbabwean, Congolese and 
Ethiopian populations (González-Galarza et al., 2015). Based on this, we predicted that these 
would be more likely to elicit an M. tuberculosis-specific immune response.  
In this study we sought to provide functional evidence for the immunogenicity of the nineteen 
epitopes computationally identified and predicted to elicit an immune response in individuals 
from the four geographical regions, in Africa, stated above. The immune responses to these 
peptides were also investigated and compared in newly diagnosed TB patients with active 
disease, latently infected individuals and healthy controls. Lastly, to gain insight into the 
immune cell populations governing the immune response against the computationally 
identified PPE_MPTR epitopes, flow cytometric analysis was conducted on the isolated whole 




Specific fluorophore-conjugated monoclonal antibodies were selected to assess the relative 
percentages and activation states of the immune cells in response to stimulation with 
PPE_MPTR-derived peptides. 





TNSLRMYLGAGSRPL 48.73% 23.96% 62.88% 47.71% P1 
NSLRMYLGAGSRPLL 48.73% 23.96% 62.88% 47.71%  
SLRMYLGAGSRPLLA 53.90% 24.66% 66.19% 51.61%  
LRMYLGAGSRPLLAA 53.90% 24.66% 66.19% 51.61% P2 
Rv0878c 
TARECSIRVIISRVS 62.67% 23.96% 36.48% 53.31% P3 
ARECSIRVIISRVSS 63.52% 23.96% 36.48% 53.31%  
RECSIRVIISRVSST 72.44% 45.98% 53.90% 64.41% P4 
ECSIRVIISRVSSTG 71.48% 45.98% 50.11% 60.84% P5 
CSIRVIISRVSSTGA 72.44% 45.98% 53.90% 64.41% P6 
SIRVIISRVSSTGAP 70.73% 45.98% 50.11% 60.84%  
IRVIISRVSSTGAPP 70.73% 45.98% 50.11% 60.84% P7 
Rv1800 
TMTQYYIIRTENLPL 29.10% 5.91% 77.58% 44.29% P8 
MTQYYIIRTENLPLL 35.20% 6.68% 80.14% 48.32% P9 
TQYYIIRTENLPLLE 35.20% 6.68% 80.14% 48.32% P10 
QYYIIRTENLPLLEP 29.10% 5.91% 76.00% 42.63%  
PEVSPVVIADALVAG 53.08% 45.98% 46.91% 49.76%  
EVSPVVIADALVAGT 53.08% 45.98% 46.91% 49.76%  
VSPVVIADALVAGTQ 53.08% 45.98% 46.91% 49.76%  
SPVVIADALVAGTQQ 53.08% 45.98% 46.91% 49.76%  
GGLQLLIIISAGRTI 53.62% 0.00% 36.50% 42.16%  
GLQLLIIISAGRTIA 72.12% 0.00% 50.18% 42.16%  
LQLLIIISAGRTIAN 72.12% 0.00% 50.18% 42.16%  
Rv2356c RSAFVQLVLSNVFGQ 57.75% 23.96% 29.94% 50.04% 
P11 
SAFVQLVLSNVFGQN 57.75% 23.96% 29.94% 50.04%  
Rv2608 
GNEVVVFGTSQSATI 40.71% 23.96% 50.76% 45.89% P12 
TIATFEMRYLQSLPA 62.67% 23.96% 42.85% 53.31% P13 
IATFEMRYLQSLPAH 67.05% 24.66% 46.97% 56.99% P14 
ATFEMRYLQSLPAHL 91.99% 26.21% 90.95% 77.47%  
TFEMRYLQSLPAHLR 95.29% 40.86% 90.95% 80.62% P15 
FEMRYLQSLPAHLRP 95.29% 40.86% 90.95% 80.62%  
EMRYLQSLPAHLRPG 94.29% 40.86% 86.33% 78.64% P16 
MRYLQSLPAHLRPGL 78.47% 40.86% 46.97% 67.48% P17 
Rv3533c 
HPLLVAANRNAFAQL 40.71% 58.40% 26.01% 32.83% P18 
PPELNSLRMFTGAGS 64.48% 25.52% 36.48% 56.40% P19 
PELNSLRMFTGAGSA 64.48% 25.52% 36.48% 56.40%  
 
Table 4.1: Population coverage of computationally identified PPE_MPTR epitopes in 
four high burden TB African countries. Epitopes that provided a population coverage of 
more than 50% is highlighted in orange. Nineteen of these peptides were included in this 




4.1.1 Peptide concentration optimization  
To determine the optimal concentration for peptide reactivity, a range of peptide concentrations 
(20, 10, 5, 1 μg/ml) was used to stimulate whole blood from two participants from The Division 
of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, 
Stellenbosch University. Microsoft Excel (Windows 10 ProfessionalPlus, 2016) was used to 
ensure the controls included with the kit fell within their specified concentration ranges through 
the removal of the out-of-range values as described in Section 3.3.  
Optimal peptide reactivity concentrations were determined by identifying the peptide 
concentration that induced the most cytokines and the concentration at which the highest 
cytokine responses were measured. PPE_MPTR peptides 2 to 18 (P2 to P18) met these criterion 
at a concentration of 10 μg/ml. Interestingly, P1 and P19 stimulated cytokine production at 
concentrations of 5 μg/ml and 1 μg/ml, respectively (Figure 4.1). The peptides that elicited the 
lowest cytokine concentrations overall were P1, P15 and P18. The controls included ESAT-6, 
CFP-10, PHA and PPD and were all used at 10 µg/ml as described in literature (Vordermeier 


















   




   
 
Figure 4.1: Clustered Bar Graphs used to assess the optimal peptide reactivity by comparing the cytokine responses to a gradiant of 
peptide concentrations. The x-axis represents the cytokine concentrations of TNF-α (green), IL-17A (dark blue), IL-10 (yellow), IL-6 (grey), IL-
13 (orange) and IFN-γ (light blue) in pg/ml. The y-axis represents the peptide concentrations (20, 10, 5, 1 μg/ml) in QFN+ (indicated with +) and 




4.1.2 The Immunogenicity of population-tailored PPE_MPTR 
peptides 
To functionally validate the immunogenicity of the computationally-identified PPE_MPTR 
peptides in an African cohort (Table 3.3), the concentration of seven cytokines in response to 
these peptides were measured using a customized Human Magnetic Luminex Screening Assay 
as a screening tool (Whitehead Scientific, South Africa). These peptides were predicted to elicit 
an immune response in M. tuberculosis-exposed individuals based on their predicted binding 
to the HLA alleles commonly encoded by individuals from this African cohort. We stimulated 
peripheral blood with peptide candidates and assessed the immunogenicity thereof in QFN+ 
individuals (Essone et al., 2019). 
Luminex Data Quality Assessment 
Before Luminex data analyses was performed, the observed absolute concentrations of the kit 
standards were analysed to ensure they fell within their specified concentration ranges. To 
assess the quality of these data, the percentage of OOR values for each analyte was determined, 
and analytes with more than 70% below-OOR (<OOR) values were excluded from data 
analysis (IFN-γ, IL-1β and IL-4) (Table 4.2). The percentage <OOR values was calculated 
from a total number of 768 data points which included data from 32 study participants in 
response to 24 stimulations.  
 
To perform statistical analyses on the concentration data for TNF-α, IL-6, IL-17A and IL-10, 
the OOR values were arbitrarily assigned values; if a data point was <OOR, one was subtracted 
from the lowest observed analyte concentration on that specific plate, and if the data point was 
>OOR, one was added to the highest observed analyte concentration for that specific plate.  
Table 4.2: Percentage of below Out-Of-Range (<OOR) values observed during Luminex 
Data Quality Assessment. The number of <OOR values for 32 study participants in response 
to 24 stimulations were caluclated as a percentage of the total number of data points (n=768). 
Analytes included in further analysis are highlighted in grey.  
Analyte Number <OOR values % < OOR  
IL-1β 558/768 72% 
IL-4 560/768 73% 
IL-6 130/768 17% 
IL-10 381/768 50% 
IL-17A 476/768 62% 
IFN-γ 561/768 73% 




Luminex Data are not normally distributed 
To determine if the remaining data followed a normal distribution, GraphPad Prism 8.3.0 was 
used to run normality tests. Three tests were performed to evaluate the normal distribution of 
Luminex data, namely the D’Agostino & Pearson, Shapiro-Wilk and Kolmogorov-Smirnov 
test. Each normality test computed a significant p-value of <0.0001 for each analyte, which 
indicated that the data were significantly different from the normal distribution. The non-
normal distribution of these data is represented in Quantile-quantile (QQ)-plots and can be seen 
in Figure 4.2. The QQ-plots compare the quantiles in which datapoints are predicted to be 
found (if they are from a normal distribution) and the actual quantiles observed for the data. If 
data originate from a normal distribution, there should be no deviations from the straight dotted 
line (red) seen on the QQ-plot in Figure 4.2. The quantiles in which our study data are found 
do not align with the predicted quantiles of a normal distribution, therefore they deviate from 
the straight line seen in the QQ-plots (Figure 4.2). 
Figure 4.2: QQ-plots demonstrating the non-normal distribution of data generated from 
Human Multiplex Luminex Assay from individuals in an African cohort. The x-axis 
represents the quantiles into which the study data fall (actual) and the y-axis represents the 
quantiles of a normal distribution (predicted). QFN+ (n=5) individuals are represented in red 
and QFN- (n=6) individuals are represented in green. *Data points for QFN- individuals lie 
directly behind data points for QFN+ individuals for TNF-α and IL-6 cytokines. **Data points 




Analyte concentrations in response to control stimulations 
The analyte responses of QFN+ and QFN- individuals towards control stimulations were 
assessed prior to investigating the influence of PPE_MPTR peptides on cytokine concentration. 
The responses to control stimulations provide information regarding the (i) baseline immune 
response of an individual (unstimulated) and (ii) immune response to known M. tuberculosis 
antigens (ESAT-6 and CFP-10). These results provide the backdrop for analysis of the cytokine 
responses following PPE_MPTR peptide stimulation.  
The median control-stimulated and unstimulated cytokine responses were compared between 
QFN+ and QFN- participants (Figure 4.3 and Figure 4.4). Low background levels of all 
analytes were observed for the unstimulated controls (Figure 4.3 and Figure 4.4). The 
measured concentration of TNF-α in the unstimulated control was comparable between QFN+ 
and QFN- individuals (Figure 4.4a). Unstimulated controls for IL-6 (Figure 4.3b) and IL-10 
(Figure 4.4b) demonstrated a lower concentration of these cytokines in QFN- individuals. In 
the case of IL-17A, higher concentrations were produced by QFN- individuals in unstimulated 
conditions compared to QFN+ individuals (Figure 4.3a). 
In response to PHA, all individuals produced higher concentrations of IL-17A, IL-6, TNF-a 
and IL-10 than measured in the unstimulated control, as expected (Figure 4.3 and Figure 4.4). 
QFN+ individuals produced higher concentrations of IL-6 in response to PHA compared to 
QFN- individuals (Figure 4.3b). However, the concentrations of IL-17A (Figure 4.3a), TNF-
α and IL-10 (Figure 4.4a, b) in response to PHA were higher in QFN- individuals compared 
to QFN+ individuals. PPD-stimulation induced higher concentrations of IL-17A, IL-6, TNF-α 
and IL-10 in QFN+ and QFN- individuals than observed in unstimulated controls (Figure 4.3 
and Figure 4.4). As expected, in response to PPD, QFN+ individuals produced higher 
concentrations of IL-6 (Figure 4.3b), TNF-α and IL-10 (Figure 4.4) when compared to QFN- 
individuals, whereas comparable IL-17A concentrations were observed between QFN+ and 
QFN- individuals. 
In response to ESAT-6, only IL-10 was produced in higher concentrations compared to 
unstimulated levels, and unexpectedly, this was observed for QFN- individuals (Figure 4.4b). 
In response to CFP-10, QFN- individuals produced higher concentrations of IL-6 (Figure 
4.3b), TNF-α and IL-10 (Figure 4.4) above unstimulated levels. QFN+ individuals only 
produced higher concentrations of IL-6 and TNF-α above unstimulated levels (Figure 4.3b 




unstimulated control in QFN+ individuals (Figure 4.4b). The concentrations of IL-6 and TNF-
α measured in response to CFP-10 and ESAT-6 were higher in QFN+ individuals than QFN- 
individuals (Figure 4.3b and Figure 4.4a), however the concentrations of IL-17A and IL-10 




Figure 4.3: The concentration of a) IL-17A and b) IL-6 observed in QFN+ and QFN- 
individuals from an African cohort in response to PPE_MPTR peptides. The floating bars 
represent the minimum-to-maximum log transformed concentration values, with the median 
concentration represented by the horizontal line. Values below zero indicate low absolute 
concentration values were obtained in response to stimulation condition before data was log 
transformed. The controls used in this study can be seen within the dotted box and include US 
= Unstimulated; PHA= Phaseolus vulgaris phytohaemagglutinin; PPD= Purified protein 
derivative; ESAT-6 = Early Secreted Antigen -6 and CFP-10 = Culture Filtrate Protein-10. 
QNF+ individuals = red and QFN-ve individuals = green. P1-P19 = candidate PPE_MPTR 








Figure 4.4: The concentration of a) TNF-α and b) IL-10 observed in QFN+ and QFN- 
individuals from an African cohort in response to PPE_MPTR peptides. The floating bars 
represent the minimum-to-maximum log transformed concentration values, with the median 
concentration represented by the horizontal line. Values below zero indicate low absolute 
concentration values were obtained in response to stimulation condition before data was log 
transformed. The controls used in this study can be seen within the dotted box and include 
US = Unstimulated; PHA= Phaseolus vulgaris phytohaemagglutinin; PPD= Purified protein 
derivative; ESAT-6 = Early Secreted Antigen -6 and CFP-10 = Culture Filtrate Protein-10. 
QNF+ individuals = red and QFN-ve individuals = green. P1-P19 = candidate PPE_MPTR 




Analyte concentrations induced in response to candidate PPE_MPTR peptides 
The median PPE_MPTR-specific cytokine concentration was used to evaluate which 
PPE_MPTR peptides induced the production of the most cytokines in African individuals. 
Overall, the PPE_MPTR peptides elicited higher cytokine responses in QFN+ individuals 
compared to QFN- individuals (Figure 4.3 and Figure 4.4), however the measured absolute 
cytokine concentrations detected by the Luminex screening assay were low for all analytes 
investigated.  
IL-17A 
In QFN+ individuals, the concentration of IL-17A in response to P2, P3, P6 and P7 was higher 
than observed for QFN- individuals (Figure 4.3a). These PPE_MPTR-induced IL-17A 
concentrations in QFN+ individuals were greater than what was seen in response to ESAT-6 
and CFP-10. In response to P4, P5, P10, P11, P16, P17, P18, P19, all QFN- individuals induced 
higher concentrations of IL-17A compared to QFN+ individuals, however these peptides were 
all at similar levels observed for the unstimulated control (Figure 4.3a), suggesting that these 
are background responses.  
IL-6 
In response to P2, P3, P4, P5, P6, P8, P9, P11, P12, P14 and P16, QFN+ individuals produced 
higher concentrations of IL-6 compared to QFN- individuals (Figure 4.3b). The remaining 
peptides also produced more IL-6 in QFN+ individuals, however these peptides induced lower 
IL-6 concentrations than observed for the unstimulated.  
TNF-α 
There were only three PPE_MPTR peptides that produced higher concentrations of TNF-α in 
QFN+ individuals compared to QFN- individuals. These included P11, P12 and P14 (Figure 
4.4a).  
IL-10 
QFN+ and QFN- individuals produced very low median absolute concentrations of IL-10 in 
response to PPE_MPTR peptides (Figure 4.4b). All peptides induced lower IL-10 
concentrations from QFN+ individuals than QFN- individuals.  
In summary, selected PPE_MPTR peptides induced higher cytokine responses from QFN+ 
individuals than QFN- individuals in our study. This suggests that previous sensitization to M. 




thereby suggesting QFN+ individuals elicit a M. tuberculosis-specific response. In response to 
PPE_MPTR peptides, the Luminex platform detected very low concentrations of pro-
inflammatory cytokines IL-6, IL-17A and TNF-α. On the basis of detected cytokine 
production, PPE_MPTR peptides P4, P5, P11, P12, P14 and P16 were considered the most 




4.1.3 Assessing the diagnostic potential of population-tailored 
PPE_MPTR peptides  
The diagnostic potential of the computationally identified PPE_MPTR peptides was 
investigated by comparing PPE_MPTR-specific cytokine responses in individuals (i) cases vs 
controls; (ii) LTBI vs TB and (iii) LTBI vs healthy controls. This was done to assess if the 
candidate PPE_MPTR peptides elicited notably different immune responses between 
individuals (i) with or without active TB infection; (ii) latently infected or diagnosed with 
active TB and (iii) latently infected or healthy individuals. Study participants included in cases 
(n=5) included the five baseline active TB individuals recruited from high incident TB 
communities around Tygerberg Hospital. The study participants included as controls (n=22) 
included ‘healthy controls’(n=11) and ‘LTBI’ individuals (n=5) recruited from high incident 
TB communities around Tygerberg Hospital. Four QFN- (n=4) and two QFN+ (n=2) South 
African participants (Table 3.3) were also included in these analyses and were added to the 
group of eleven ‘healthy controls’ and five ‘LTBI’ individuals, respectively (Table 3.6). 
The PPE_MPTR peptide-specific cytokine concentration was calculated as the difference in 
cytokine concentration between unstimulated and PPE_MPTR peptide-stimulated responses 
(delta cytokine concentration). Non-parametric data analysis was done using the Wilcoxon-
Signed Rank Test, which identified 11 significant differences (raw p-values < 0.05) between 
groups. Given that this is a pilot study that is aimed at identifying trends in PPE_MPTR 
cytokine responses, these 11 differences were further assessed. However, it should be noted 
that before data was corrected for multiple testing (621 tests) using Bonferroni Test Correction 
(FDR of 0.05), no significant p-value remained (corrected p-value) suggesting that the 11 
significant raw p-values observed prior to Bonferroni Test Correction may have occurred by 
chance.  
The computationally-identified PPE_MPTR peptides that induced significant differences in 
cytokine concentration between ‘cases and controls’ or ‘LTBI and TB’ or ‘LTBI and HCs’ can 





Cases vs Controls  
The cytokine responses to candidate PPE_MPTR peptides was compared between individuals 
diagnosed with baseline active TB disease and those without active TB disease. These results 
may indicate whether candidate PPE_MPTR peptides are able to distinguish between 
individuals with and without active TB disease.  
PPE_MPTR peptides that induced the most significant differences in cytokine production, as 
measured by the raw p-value, between cases (n=5) and controls (n=22) were P17 (IL-6) and 
P11 (IL-17A) (Figure 4.5). In response to P17, cases produced a median IL-6 concentration of 
4 pg/ml (controls 0 pg/ml). Of the 22 controls, 40% (9/22) did not produce detectable IL-6 in 
response to P17, compared to 20% (1/5) observed for the cases (Figure 4.5b).  
The median IL-17A concentration detected in response to P11 was also significantly higher in 
cases compared to controls (Figure 4.5b), with cases producing a median IL-17A 
concentration of 10 pg/ml (Controls: 0 pg/ml). There were 60% (3/5) of cases that produced 
no IL-17A in response to P11, with 40% (2/5) producing >100 pg/ml IL-17A in response to 
Table 4.3: PPE_MPTR peptides inducing differences in cytokine production. The 
Wilcoxon-Signed Rank Test identified 11 differences in cytokine production between groups 
in response to PPE_MPTR peptides that had a p-value below 0.05. The smallest p-value was 
observed between cases and controls for the production of IL-6 in response to P17 
(highlighted in grey). Following Bonferroni Test Correction (FDR = 0.05), no significant p-
values remained. The raw p-values were used for further analyses. 
Peptide Cytokine Groups Raw p-value < 0.05 
Corrected p-
value < 0.05 
P4 IL-6 LTBI vs TB  0,0303030 18,8181818 
P8 IL-6 LTBI vs TB 0,0419966 26,0799328 
P11 IL-17A Cases vs Controls 0,0346458 21,5150462 
P12 IL-6 LTBI vs TB 0,0479797 29,7954545 
P17 IL-6 Cases vs Controls 0,0088417 5,4907561 LTBI vs TB 0,0479797 29,7954545 
P19 TNF-α LTBI vs HC 0,0262806 16,3202816 
CFP-10* IL-6 Cases vs Controls 0,0051410 3,19261020 TNF-α Cases vs Controls 0,0295002 18,3196479 
PPD* TNF-α LTBI vs HC 0,0200034 12,4221362 
PHA* IL-17A LTBI vs HC 0,0250226 15,5390349 




P11. Of the controls, 90% (20/22) produced no IL-17A in response to P11, with 10% (2/22) 
participants producing IL-17A concentrations comparable with cases (Figure 4.5b).  
TB vs LTBI individuals  
The cytokine responses to candidate PPE_MPTR peptides was compared between individuals 
living with latent TB infection and those diagnosed with baseline active TB disease. Individuals 
with active TB disease are expected to elicit higher cytokine responses to PPE_MPTR peptides 
compared to individuals with LTBI.  
Significant differences in cytokine production were observed for IL-6 in response to P12 and 
P17 (Figure 4.6) as well as against P4 and P8 (Figure 4.7). Overall, TB individuals produced 
higher concentrations of IL-6 in response to P12 compared to LTBI individuals with a median 
of 175 pg/ml (LTBI: 30 pg/ml) (Figure 4.6a). In response to P17, the median IL-6 
concentration produced by TB individuals was 4 pg/ml compared to 1 pg/ml observed in LTBI 
individuals (Figure 4.6b). Only one TB participant (20%) produced no IL-6 in response to 
P17, compared to 28% (2/7) observed for LTBI individuals (Figure 4.6b). Similarly to what 
was observed between cases and controls in Figure 4.5a, the IL-6 produced by the remaining 
72% (5/7) LTBI individuals was less compared to the IL-6 produced by TB participants 
(Figure 4.6b). The median IL-6 concentration observed by LTBI individuals in response to 
Figure 4.5: Box plot demonstrating significant differences in a) IL-6 and b) IL-17A 
concentration between cases and controls in response to P17 and P11, respectively. 
The winsorized delta cytokine concentration is plotted on the graph with the significance bar 
depicting the raw p-value. The box plots represent the minimum to maximum cytokine 
concentration, with the horizontal line showing the median cytokine concentration. Delta 
cytokine concentration = PPE_MPTR-specific conc. - Unstimulated cytokine conc. Cases 




P17 is comparable to the median IL-6 concentration observed for controls in response to P17 
(Figure 4.5a). Interestingly, the range of IL-6 produced by controls in response to P17 (Figure 
4.5a) was greater than observed for LTBI individuals alone (Figure 4.6b), with some healthy 
controls releasing more IL-6 than LTBI individuals.  
The median IL-6 concentration produced in response to P4 by TB and LTBI individuals was 
18 pg/ml and 6 pg/ml, respectively (Figure 4.7a, b). There was one LTBI individual who 
produced concentrations of IL-6 in response to P4 comparable with TB individuals (Figure 
4.7a), with the remaining LTBI individuals producing lower IL-6 concentrations than TB 
individuals. The median IL-6 concentration produced in response to P8 by TB and LTBI 
individuals was 4 pg/ml and 0 pg/ml, respectively (Figure 4.7b).  
Figure 4.6: Box plot demonstrating significant differences in IL-6 concentration 
released from baseline active TB and LTBI individuals in response to a) P12 and b) P17. 
The winsorized delta cytokine concentration is plotted on the graph with the significance bar 
depicting the raw p-value. The box plots represent the minimum to maximum cytokine 
concentration, with the horizontal line showing the median cytokine concentration. Delta 
cytokine concentration = PPE_MPTR-specific conc. - Unstimulated cytokine conc. TB: 
baseline active TB participants (n=5) are represented in red. LTBI = latently infected 




LTBI vs Healthy Controls 
The PPE_MPTR-specific cytokine responses between latently infected and healthy individuals 
was compared to determine if the candidate peptides can identify individuals with LTBI. The 
PPE_MPTR-specific cytokine response is expected to be higher in LTBI individuals compared 
to healthy individuals. 
PPE_MPTR peptide, P19, induced a significantly higher median concentration of TNF-α in 
LTBI individuals (0.75 pg/ml) compared to healthy individuals (0 pg/ml) (Figure 4.8). A single 
healthy control produced TNF-α in response to P19, and interestingly at a higher concentration 
(2.5 pg/ml) than observed for all LTBI individuals (Figure 4.8).  
Figure 4.7: Box plot demonstrating significant differences in IL-6 concentration released 
from baseline active TB and LTBI individuals in response to a) P4 and b) P8. The 
winsorized delta cytokine concentration is plotted on the graph with the significance bar 
depicting the raw p-value. The box plots represent the minimum to maximum cytokine 
concentration, with the horizontal line showing the median cytokine concentration. Delta 
cytokine concentration = PPE_MPTR-specific conc. - Unstimulated cytokine conc. TB: 
baseline active TB participants (n=5) are represented in red. LTBI = latently infected individuals 





Figure 4.8: Box plot demonstrating significant differences in TNF-α concentrations in 
LTBI individuals and healthy controls in response to P19. The winsorized delta cytokine 
concentration is plotted on the graph with the significance bar depicting the raw p-value. The 
box plots represent the minimum to maximum cytokine concentration, with the horizontal line 
showing the median cytokine concentration. Delta cytokine concentration = PPE_MPTR-
specific conc. - Unstimulated cytokine conc. LTBI = latently infected individuals (n=7) in blue. 




4.1.4  PPE_MPTR-specific functional marker frequencies of 
lymphocyte populations in the peripheral blood of TB, LTBI and 
healthy individuals 
Little is currently known about the cellular populations that are responsible for the 
PPE_MPTR-specific immune response. Flow cytometry was therefore used to assess the 
distribution of functional markers and activation states of CD4+ and CD8+ T-lymphocytes and 
B-lymphocytes in the peripheral blood of TB, LTBI and healthy individuals. PPE_MPTR 
peptides were selected for flow cytometry experiments based on results of multiplex cytokine 
assays performed on individuals from South Africa, Zimbabwe, Congo and Ethiopia (See 
Section 4.1.1). Six peptides that induced the production of more than three cytokines were 
selected, namely P4, P5, P11, P12, P14 and P16. These were representative of four PPE_MPTR 
proteins. Although it was not a selection criterion, it is interesting to note that P4, P11 and P12 
elicited significantly different cytokine responses between individuals of different health 
statuses (unexposed, uninfected healthy individuals / baseline (untreated) active TB individuals 
/ latently infected individuals) (Section 4.1.3). 
Positive controls included peripheral blood cells stimulated with ESAT-6 and CFP-10 peptide 
cocktails, and PBS-stimulated blood was included as the negative control. Stimulated 
peripheral blood cells from the 21 study participants recruited from high-incident TB 
communities surrounding Tygerberg Hospital (Table 3.6) were analysed as stated in Section 
3.8. Ten-fluorophore-conjugated monoclonal antibodies were used to define the 
immunophenotypes of T- and B-cells in response to the selected PPE_MPTR peptides (Table 
4.4 and Figure 3.1 and Figure 3.2). Before acquiring samples on the BD LSR II™, BD 







4.1.4.1 Distribution of CD4+ and CD8+ T-cells in PPE_MPTR-stimulated 
peripheral blood  
T-lymphocyte populations in the peripheral blood of TB, LTBI and healthy individuals were 
defined based on the expression of CD3 (CD3+). Subsequently, CD4+ and CD8+ cells were 
identified by the expression of CD4 and CD8, respectively (Table 4.4). Immunity to M. 
tuberculosis is critically dependent on CD4+ T-cells and the production of a pro-inflammatory 
response (Ancelet and Kirman, 2012). The role of CD8+ T-cells in TB disease is less clear, 
however they have been shown to be required for an optimal immune response against M. 
tuberculosis (Prezzemolo et al., 2014).  
To better understand the adaptive immune response to the candidate PPE_MPTR peptides, two 
of the most important T-helper (Th) subsets involved in maintaining the adaptive immune 
response during TB infection were investigated, namely the Th1 (CD183+ ) and Th17 (CD196+) 
CD4+ cells (Khader et al., 2009; Ottenhoff, 2012). Due to the antagonizing effects Th2-derived 
cytokines have on Th1-mediated control of M. tuberculosis (Rook, 2007) and the important 
role of Th2 T-cells in promoting antibody-mediated (humoral) immunity (Walker and 
McKenzie, 2018), the PPE_MPTR-specific distribution of Th2 CD4+ T-cells was also 
investigated. Because little is known regarding the frequency distribution of both CD4+ and 
Table 4.4: Markers used to assess the phenotype and activation status of different 
memory subsets of T- and B- cells.  




Memory State  
Effector memory (TEM) CD45RA-CD28- 
Central memory (TCM) CD45RA-CD28+ 
Naïve (TN) CD45RA+CD28+ 
Effector memory cells re-expressing CD45RA 
(TTEMRA) 
CD45RA+CD28- 





CD3- B-cell populations CD3- 
B-cell population CD3-CD19+ 




CD8+ T-cells in response to PPE_MPTR proteins, the corresponding CD8+ T-cell populations 
were also investigated.  
Lymphocytes found in peripheral whole blood of individuals are typically comprised of 
approximately 60% CD4+ T-cells and 40% CD8+ T-cells (McBride and Striker, 2017). As such, 
the proportion of observed CD4+ and CD8+ T-cells in response to ESAT-6, CFP-10 and PBS 
(unstimulated) was as expected, with 60% CD4+ T-cells and 40% CD8+ T-cells (Figure 4.9). 
Likewise, following stimulation with PPE_MPTR peptides, a similar distribution of CD4+ T-
cells and CD8+ T-cells was observed in peripheral blood of TB, LTBI and healthy individuals 
with the expected proportions of CD4+ T-cells (60%) and CD8+ T-cells (40%) (Figure 4.10). 
These results indicate that the proportions of CD4+ and CD8+ T-cell subsets are not 
fundamentally different between TB, LTBI and healthy individuals, suggesting that any 







Figure 4.9: Circulating CD4+- and CD8+ T-cells in the peripheral blood of healthy, LTBI 
and active TB individuals in (a) unstimulated conditions or in response to (b) ESAT-6 
(c) CFP-10. The proportion (%) of CD4+ and CD8+ T-cells are represented as a mean 
percentage of the total circulating CD3+ population in the peripheral blood of TB (n=5), LTBI 
(n=5) and healthy individuals (n=11) recruited from high incident TB areas surrounding 
Tygerberg Hostpital. LTBI = latent tuberculosis infection. HC = healthy control. ESAT-6 = Early 












4.1.4.2 Distribution of CD4+ T-cell subsets in PPE_MPTR-stimulated 
peripheral blood  
Naïve T-cells (TN) are released from the thymus with the ability to recognise specific M. 
tuberculosis antigens through interactions with MHC-I (CD8+) or MHC-II (CD4+) molecules 
(Murphy, 2013). As a result, TN cells become activated, proliferate and differentiate into 
different effecter cell subtypes. Differentiation of T-helper (Th) subset is cytokine dependant 
and each Th subset (Th1, Th2, Th17) releases a specific subset of cytokines that are associated 
with different effector functions (TN, TCM TEM TTEMRA), contributing to the immunophenotype 
of the cell. Intracellular cytokine staining was not in the scope of this project, however the 
functional marker frequencies and activation states of Th1, Th2 and Th17 TN, TCM TEM TTEMRA 
CD4+ cells were investigated.   
The proportions of total CD4+ TN, TCM TEM TTEMRA (Th1, Th2, Th17) in the peripheral blood 
of TB, LTBI and healthy controls in response to ESAT-6 and CFP-10 did not differ from those 
observed in unstimulated conditions (Figure 4.11, Figure 4.12 and Figure 4.13). Despite the 
similar distribution of cells between stimulated and unstimulated conditions, the TN and TCM 
CD4+ cells in the peripheral blood of LTBI individuals had a higher expression of surface 
markers CD183+(Th1) (Figure 4.11), CD193+ (Th2) (Figure 4.12) and CD196+ (Th17) 
(Figure 4.13) compared to TB and healthy individuals. The percentage CD4+ EM T-cell subset 
was the lowest in all individuals in response to ESAT-6 and CFP-10, comparable with 
measured populations in unstimulated conditions (Figure 4.11, Figure 4.12 and Figure 4.13). 
Noticeable differences in the levels of activated CD4+ cells were measured in the peripheral 
blood of TB, LTBI and healthy controls in response to ESAT-6 and CFP-10, when compared 
to unstimulated controls (Appendix 7.3; Figure 7.1 - Figure 7.4). As expected, no activated 
CD4+ T-cells were observed in healthy individuals in response to controls. In response to CFP-
10, LTBI and active TB individuals exhibited activated CD183+ (Th1) and CD193+ (Th2) CD4+ 
TCM cells, with higher levels of activation observed in LTBI individuals (Appendix 7.3; Figure 
Figure 4.10 (previous page): Circulating CD4+- and CD8+ T-cells in the peripheral blood 
of healthy, LTBI and active TB individuals in unstimulated conditions or in response to 
PPE_MPTR peptides. (a) unstimulated (b) P4 (c) P5 (d) P11 (e) P12 (f) P14 and (g) P16. 
The proportion (%) of CD4+ and CD8+ T-cells are represented as a mean percentage of the 
total circulating CD3+ population in the peripheral blood of TB (n=5), LTBI (n=5) and healthy 
individuals (n=11) recruited from high incident TB areas surrounding Tygerberg Hostpital. P4 
= Rv0878c_c. P5 = Rv0878c_d. P11 = Rv2356c_a. P12 = Rv2608_a. P14 = Rv2608_c and 




7.2). In response to ESAT-6, only LTBI individuals exhibited activated CD196+ (Th17) CD4+ 




Figure 4.11: Circulating CD183+ (Th1) CD4+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in (a) unstimulated conditions or in response to 
(b) ESAT-6 and (c) CFP-10. The pie charts represent the proportions of Th1 TN, TCM TEM TTEMRA 
as a mean percentage of the total circulating CD4+ population in the peripheral blood of TB (n=5), 
LTBI (n=5) and healthy individuals (n=11) recruited from high incident TB areas surrounding 
Tygerberg Hostpital. Naïve T-cells = TN = blue; Central memory T-cells = TCM = green; Effector 
memory T-cells = TEM = pink; Terminally differentiated T-cells = TTEMRA = yellow. P4 = Rv0878c_a. 








Figure 4.12: Circulating CD193+ (Th2) CD4+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in (a) unstimulated conditions or in response 
to (b) ESAT-6 and (c) CFP-10. The pie charts represent the proportions of Th1 TN, TCM TEM 
TTEMRA as a mean percentage of the total circulating CD4+ population in the peripheral blood 
of TB (n=5), LTBI (n=5) and healthy individuals (n=11) recruited from high incident TB areas 
surrounding Tygerberg Hostpital. Naïve T-cells = TN = blue; Central memory T-cells = TCM = 
green; Effector memory T-cells = TEM = pink; Terminally differentiated T-cells = TTEMRA = 








Figure 4.13: Circulating CD196+ (Th17) CD4+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in (a) unstimulated conditions or in response 
to (b) ESAT-6 and (c) CFP-10. The pie charts represent the proportions of Th1 TN, TCM TEM 
TTEMRA as a mean percentage of the total circulating CD4+ population in the peripheral blood 
of TB (n=5), LTBI (n=5) and healthy individuals (n=11) recruited from high incident TB areas 
surrounding Tygerberg Hostpital. Naïve T-cells = TN = blue; Central memory T-cells = TCM = 
green; Effector memory T-cells = TEM = pink; Terminally differentiated T-cells = TTEMRA = yellow. 




In response to stimulation with PPE_MPTR peptides, the CD4+ TN and TCM cells were also the 
predominant circulating CD4+ memory subtype in healthy, LTBI and TB individuals, with the 
CD4+ TEM subset comprising the lowest mean proportion of CD4+ memory cells (Figure 4.14 
- Figure 4.16). The PPE_MPTR peptides induced activated CD4+ TN, TCM, and TEM T-cells in 
healthy, LTBI and active TB individuals (Appendix 7.3; Figure 7.1 - Figure 7.3), with only 
marginal levels of activation observed for the CD4+ TTEMRA subset in LTBI individuals 
(Appendix 7.3; Figure 7.4). 
CD3+CD4+ Naïve T-cells 
A primary cell mediated immune response is established by the activation of circulating naïve 
CD4+ T-cells, their proliferation and subsequent differentiation into CD4+ effecter cells. The 
CD183+ (Th1), CD193+ (Th2) and CD196+ (Th17) naïve T-cell (TN) subsets were defined as 
CD45RA+CD28+ and were the dominant circulating CD4+ memory subset in response to 
PPE_MPTR-stimulation. The proportion of CD4+ TN cells was calculated as a percentage of 
the grandparent Th1, Th2 or Th17 CD3+CD4+ populations (Table 4.4). 
Stimulation with P11, P12, P14 and P16 induced more CD183+ (Th1), CD193+ (Th2) and 
CD196+ (Th17) expressing TN CD4+ T-cells in TB and healthy controls than observed in 
unstimulated conditions (Figure 4.14, Figure 4.15 and Figure 4.16 d, e, f, g). Similar 
expression levels were also observed in LTBI individuals, however the expression of CD183+ 
(Th1) TN CD4+ T-cells was not influenced by stimulation with P14 and P16 as observed in TB 
and healthy individuals (Figure 4.14 f, g). In healthy controls, the highest proportion of CD4+ 
TN cells was observed for CD193+ (Th2) and CD196+ (Th17) TN CD4+ cells in response to P14 
(75%) (Figure 4.15 f and Figure 4.16 f). In active TB individuals, equally high CD193+ (Th2) 
and CD196+ (Th17) proportions of TN CD4+ cells were produced in response to P11 and P14 
(Figure 4.15 d,f and Figure 4.16 d,f) (70%). The highest proportion of CD4+ TN produced in 
LTBI individuals were TN CD4+ cells expressing CD193+ (Th2) in response to P11 and P14 

















Figure 4.14: Circulating CD183+ (Th1) CD4+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in unstimulated conditions or in response to 
PPE_MPTR peptides. (a) unstimulated (b) P4 (c) P5 (d) P11 (e) P12 (f) P14 and (g) P16. 
The pie charts represent the proportions of Th1 TN, TCM TEM TTEMRA as a mean percentage of 
the total circulating CD4+ population in the peripheral blood of TB (n=5), LTBI (n=5) and 
healthy individuals (n=11) recruited from high incident TB areas surrounding Tygerberg 
Hostpital. Naïve T-cells = TN = blue; Central memory T-cells = TCM = green; Effector memory 
T-cells = TEM = pink; Terminally differentiated T-cells = TTEMRA = yellow. P4 = Rv0878c_a. P5 














Figure 4.15: Circulating CD193+ (Th2) CD4+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in unstimulated conditions or in response to 
PPE_MPTR peptides. (a) unstimulated (b) P4 (c) P5 (d) P11 (e) P12 (f) P14 and (g) P16. 
The pie charts represent the proportions of Th2 TN, TCM TEM TTEMRA as a mean percentage of 
the total circulating CD4+ population in the peripheral blood of TB (n=5), LTBI (n=5) and 
healthy individuals (n=11) recruited from high incident TB areas surrounding Tygerberg 
Hostpital. Naïve T-cells = TN = blue; Central memory T-cells = TCM = green; Effector memory 
T-cells = TEM = pink; Terminally differentiated T-cells = TTEMRA = yellow. P4 = Rv0878c_a. P5 












In response to stimulation with each PPE_MPTR candidate, CD183+ (Th1), CD193+ (Th2) and 
CD196+ (Th17) TN CD4+ T-cells were activated in active TB, LTBI and healthy individuals 
(Appendix 7.3; Figure 7.1). PPE_MPTR peptide, P4, induced the highest level of activated 
TN CD4+ T-cells compared to the other peptides and was seen in the CD183+ (Th1) TN CD4+ 
T-cell subset of LTBI individuals. Interestingly, the distribution of activated TN CD4+ T-cells 
was similar in healthy and active TB individuals. In response to P16, higher levels of activated 
CD183+ (Th1), CD193+ (Th2) and CD196+ (Th17) CD4+ TN T-cells were observed in healthy 
and active TB individuals compared to LTBI individuals. The level of activation in response 
to P12 in healthy and active TB individuals was similar to what was observed for P16, however, 
no activated CD193+ (Th2) CD4+ TN T-cells were observed (Appendix 7.3; Figure 7.1). 
CD3+CD4+ Central Memory T-cells  
We went on to assess the proportions of different CD4+ memory subsets. Both central- and 
effector memory cells recognise previously encountered antigens and respond rapidly to 
secondary infection (Mahnke et al., 2013). Central memory CD4+ T-cells (TCM) migrate 
through lymph nodes and like TEM, can secrete effector cytokines. TCM T-cells are known to 
have a substantially higher proliferative capability than TEM T-cells which is vital during 
secondary antigen encounter (Farber et al., 2014). Effector memory CD4+ T-cells migrate 
though peripheral tissues and exert rapid effector functions at the site of infection in an attempt 
to eradicate the pathogen.  
In response to stimulation with PPE_MPTR peptides, higher proportions of CD4+ TCM cells 
were observed in the peripheral blood of active TB, LTBI and healthy individuals compared to 
CD4+ TEM cells and were defined as CD45RA- CD28+ (Figure 3.1). The proportion of TCM was 
calculated as a percentage of the grandparent CD183+ (Th1), CD193+ (Th2) and CD196+ 
(Th17) CD3+CD4+ populations.  
In response to stimulation with P12, P14 and P16, similar proportions of CD183+ expressing 
(Th1) TCM CD4+ cells were observed in TB, LTBI and healthy individuals as seen in 
Figure 4.16: Circulating CD196+ (Th17) CD4+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in unstimulated conditions or in response to 
PPE_MPTR peptides. (a) unstimulated (b) P4 (c) P5 (d) P11 (e) P12 (f) P14 and (g) P16. 
The pie charts represent the proportions of Th17 TN, TCM TEM TTEMRA as a mean percentage of 
the total circulating CD4+ population in the peripheral blood of TB (n=5), LTBI (n=5) and 
healthy individuals (n=11) recruited from high incident TB areas surrounding Tygerberg 
Hostpital. Naïve T-cells = TN = blue; Central memory T-cells = TCM = green; Effector memory 
T-cells = TEM = pink; Terminally differentiated T-cells = TTEMRA = yellow. P4 = Rv0878c_a. P5 




unstimulated conditions (Figure 4.14 e, f, g). In response to P4, P5 and P11, active TB, LTBI 
and healthy individuals all exhibited increased expression of CD183+ on TCM CD4+ cells (Th1) 
(Figure 4.14 b, c, d) compared to unstimulated levels. One exception to this result was 
observed in LTBI, where only marginal PPE_MPTR-specific differences in the expression of 
CD183 was observed on TCM CD4+ cells. The greatest proportion of PPE_MPTR-specific TCM 
CD4+ cells in LTBI individuals expressed CD196 (Figure 4.16). In response to P4 and P5, the 
proportion of CD196+CD4+cells increased by 30% and 27%, respectively (Figure 4.16 b, c). 
Only in response to P5, did the proportions of CD196+ TCM CD4+ cells (Th17) increase in 
active TB (20%) and healthy individuals (15%) (Figure 4.16 c).  
Similarly to the proportions of activated TN CD4+ T-cells observed in response to PPE_MPTR 
peptides, all TCM CD4+ cell subtypes were activated in healthy, LTBI and active TB individuals 
during stimulation (Appendix 7.3; Figure 7.2). PPE_MPTR peptide P4 induced the highest 
levels of activated CD183+ (Th1), CD193+ (Th2) and CD196+ (Th17) TCM CD4+ T-cells 
compared to the other peptides, the distribution of which was similar between healthy, active 
TB and LTBI individuals. In response to P11 and P14, LTBI individuals exhibited higher levels 
of activated CD183+ (Th1), CD193+ (Th2) and CD196+ (Th17) TCM CD4+ T-cells compared to 
healthy and active TB individuals. The activated TCM CD4+ T-cell subsets between healthy 
individuals displayed a large amount of variation, especially in response to P11, P12 and P14 
(Appendix 7.3; Figure 7.2).  
CD3+CD4+ Effector memory T-cells  
Effector memory CD4+ T-cells (TEM) mediate rapid protective responses during M. 
tuberculosis infection by travelling through peripheral tissues to the lung, where they secrete 
pro-inflammatory cytokines that aid in pathogen clearance (Murphy, 2013). From the four 
memory subsets investigated, the CD4+ TEM subset comprised the lowest mean proportion of 
circulating memory cells in response to controls and PPE_MPTR peptides. The TEM cells were 
defined as CD45RA-CD28- and the proportion of TEM in the peripheral blood cells of TB, LTBI 
and healthy individuals was calculated as a percentage of the grandparent CD183+ (Th1), 
CD193+ (Th2) and CD196+ (Th17) CD3+CD4+ populations (Table 4.4).  
There was no difference in the PPE_MPTR-specific proportions of CD4+ TEM cells expressing 
CD183 (Th1), CD193 (Th2) or CD196 (Th17) compared to those observed in unstimulated 
conditions (Figure 4.14, Figure 4.15 and Figure 4.16). There were marginal increases, above 




CD193+ (Th2) observed in response to P4 and P5 (Figure 4.14 and Figure 4.15 b, c). This 
occurred in equal distributions between active TB, LTBI and healthy individuals.  
Activated TEM CD4+ cells were observed in response to all PPE_MPTR peptides, with higher 
proportions of CD183+ (Th1) and CD193+ (Th2) expressing TEM CD4+ T-cells than CD196+ 
(Th17) expressing TEM CD4+ T-cells (Appendix 7.3; Figure 7.3). The levels of activated TEM 
CD4+ T-cells were highest in LTBI and active TB individuals compared to healthy controls. In 
response to P4, TB individuals produced higher proportions of activated CD183+ (Th1) and 
CD193+ (Th2) expressing TEM CD4+ T-cells than LTBI individuals, however P4 and P5 
activated more CD196+ (Th17) TEM CD4+ T-cells in LTBI individuals compared to active TB 
individuals (Appendix 7.3; Figure 7.3).  
CD3+ CD4+ TEMRA T-cells 
Highly differentiated effector memory CD4+ cells have been identified in individuals with 
active TB disease (Arrigucci et al., 2018). These cells can be referred to as terminally 
differentiated effector memory T-cells re-expressing CD45RA (TTEMRA) and are characterised 
by low functional and proliferative abilities. The TTEMRA subset was defined as 
CD45RA+CD28- and the proportion of TTEMRA was calculated as a percentage of the 
grandparent CD183+ (Th1), CD193+ (Th2) and CD196+ (Th17) CD3+CD4+ populations (Table 
4.4). 
In response to P4, P5 and P12, higher proportions of CD183+ (Th1) and CD193+ (Th2) 
expressing TTEMRA CD4+ cells were measured in the peripheral blood of active TB, LTBI and 
healthy individuals and the distribution of these subsets was comparable between the different 
study groups as compared to unstimulated conditions (Figure 4.14 and Figure 4.15 c, d, e). 
Only P12 induced higher proportions of CD196+ (Th17) expressing TTEMRA CD4+ cells (Figure 
4.16 e) above unstimulated conditions in LTBI and healthy individuals.  
In response to all PPE_MPTR peptides, activated CD193+ (Th1) TTEMRA CD4+ T-cells were 
observed in healthy, LTBI and active TB individuals, with the highest level of activated 
CD193+ TTEMRA’s observed in LTBI individuals in response to P4 (Appendix 7.3; Figure 7.4). 
Overall, CD196+ (Th17) TTEMRA CD4+ T-cell subset in LTBI individuals exhibited the highest 
level of activation (P4) compared to CD183+ (Th1) and CD193+ (Th2) subsets. Healthy controls 
exhibited no activated CD193+ (Th2) or CD196+ (Th17) TTEMRA CD4+ T-cell subsets in 




CD196+ (Th17) TTEMRA CD4+ T-cells were observed in response to P5 and P12 respectively 
(Appendix 7.3; Figure 7.4).  
4.1.4.3 CD8+ T-cells subsets found in PPE_MPTR-stimulated peripheral 
blood  
The precise function of CD8+ T-cells during TB disease is less well characterised than those of 
CD4+ T-cells, however it has been shown that optimal CD4+ T-cell function requires the 
presence of CD8+ T-cells (Ling Lin and Flynn, 2005). CD8+ T-cells are also able to secrete 
pro-inflammatory cytokines such as IFN-γ and TNF-α, but unlike CD4+ T-cells, CD8+ T-cells 
also release cytotoxic molecules (perforin, granzymes or granulysin) that result in the apoptosis 
of heavily burdened M. tuberculosis cells (Prezzemolo et al., 2014). We included CD8+ T-cells 
in the analyses of functional marker frequencies to PPE_MPTR peptides to determine if the 
candidate peptides induce any PPE_MPTR-specific changes.  
In response to ESAT-6 and CFP-10, the proportions of CD183+ (Th1) and CD193+ (Th2) TN 
CD8+ T-cells in healthy controls was higher compared to what was observed for the 
unstimulated control (Figure 4.17 and Figure 4.18). No changes in the proportions of CD183+ 
(Th1) TN, TCM TEM TTEMRA CD8+ cells were observed in response to ESAT-6 or CFP-10 in 
LTBI or active TB individuals (Figure 4.17). In response to CFP-10, LTBI, active TB and 
healthy individuals exhibited higher proportions of CD196+ (Th17) TN CD8+ T-cells compared 
to the unstimulated control (Figure 4.19). This was also observed for CD193+ (Th2) TN CD8+ 
T-cells, but only in LTBI and TB individuals (Figure 4.18). Only stimulation with ESAT-6 
resulted in activation of CD183+, CD193+ and CD196+ TN CD8+ T-cells in healthy controls. 
The proportions of activated CD183+, CD193+ and CD196+ TN CD8+ T-cells observed in 
healthy controls was greater than seen in TB and LTBI individuals. In response to ESAT-6, 
active TB and LTBI individuals did not exhibit activated CD183+, CD193+ and CD196+ CD8+ 
T-cells in proportions greater than observed for unstimulated conditions (Figure 4.17 and 
Figure 4.18 and Figure 4.19). No activated CD183+, CD193+ and CD196+ CD8+ T-cells (TN, 
TCM, TEM, TTEMRA) were observed in response to ESAT-6 or CFP-10 in healthy controls, LTBI 
or active TB individuals (Appendix 7.4; Figure 7.5 - Figure 7.8).  
The functional marker frequencies of the CD3+CD8+ T-cells in response to stimulation with 
PPE_MPTR peptides were comparable to unstimulated levels. PPE_MPTR peptides induced 







Figure 4.17: Circulating CD183+ (Th1) CD8+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in (a) unstimulated conditions or in response 
to stimulation with (b) ESAT-6 and (c) CFP-10. The pie charts represent the proportions 
of Th1 TN, TCM TEM TTEMRA as a mean percentage of the total CD8+ population. HC = healthy 
controls (n=11). LTBI = latent TB infection (n=5). TB = active TB (n=5). ESAT-6 = Early 
Secreted Antigen-6. CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). 
Naïve T-cells = TN = pink; Central memory T-cells = TCM = red; Effector memory T-cells = TEM 







Figure 4.18: Circulating CD193+ (Th2) CD8+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in (a) unstimulated conditions or in response to 
stimulation with (b) ESAT-6 and (c) CFP-10. The pie charts represent the proportions of Th2 
TN, TCM TEM TTEMRA as a mean percentage of the total CD8+ population. HC = healthy controls 
(n=11). LTBI = latent TB infection (n=5). TB = active TB (n=5). ESAT-6 = Early Secreted 
Antigen-6. CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). Naïve T-cells 
= TN = pink; Central memory T-cells = TCM = red; Effector memory T-cells = TEM = green; 






Figure 4.19: Circulating CD196+ (Th17) CD8+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in (a) unstimulated conditions or in response 
to stimulation with (b) ESAT-6 and (c) CFP-10. The pie charts represent the proportions of 
Th17 TN, TCM TEM TTEMRA as a mean percentage of the total CD8+ population. HC = healthy 
controls (n=11). LTBI = latent TB infection (n=5). TB = active TB (n=5). ESAT-6 = Early 
Secreted Antigen-6. CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). 
Naïve T-cells = TN = pink; Central memory T-cells = TCM = red; Effector memory T-cells = TEM 




CD3+CD8+ Naïve T-cells  
Naïve CD8+ T-cells circulate in the peripheral blood and become activated in lymphoid tissues 
following recognition of antigen. Naïve CD8+ undergo expansion and are able to differentiate 
in various subpopulations, namely central memory (TCM), effector memory (TEM) and 
terminally differentiated effector (TTEMRA) cells (Geginat et al., 2003). The CD183+ (Th1) 
CD193+ (Th2), and CD196+ (Th17) naïve CD8+T-cell (TN) subsets were defined as 
CD45RA+CD28+ and the proportion of CD8+ TN cells was calculated as a percentage of the 
grandparent Th1, Th2 or Th17 CD3+CD4+ populations (Table 4.4). 
Overall, candidate PPE_MPTR peptides caused marginal differences in the proportions of 
CD8+ TN cells compared to those observed for unstimulated conditions. No changes in the 
proportions of TN CD8+ cells expressing CD183+ (Th1) or CD193+ (Th2) were measured in 
active TB, LTBI or healthy individuals in response to stimulation with PPE_MPTR peptides 
(Figure 4.20 and Figure 4.21). In response to stimulation with P4 and P5, active TB, LTBI 
and healthy individuals all exhibited increased proportions of CD196+ (Th17) TN CD8+ cells 
compared to unstimulated conditions (Figure 4.22 b, c). The mean highest proportions of 
CD196+ (Th17) TN CD8+ cells in response to P4 and P5 was observed in active TB and healthy 
controls (~58%) compared to LTBI individuals (~43%) (Figure 4.22 b, c).  
In response to stimulation with PPE_MPTR peptides, no activation of CD183+ TN CD8+ cells 
(Th1) were detected in healthy, LTBI or active TB individuals in response to P5 (Appendix 
7.4; Figure 7.5). The highest proportion of activated TN CD8+ T-cells was observed for the 
CD183+ (Th1) subset in TB individuals in response to P14. In response to P11, P12, P14 and 
P16 similar proportions of activated CD193+ (Th2) and CD196+ (Th17) TN CD8+ T-cells were 















Figure 4.20: Circulating CD183+ (Th1) CD8+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in unstimulated conditions or in response to 
PPE_MPTR peptides. (a) unstimulated (b) P4 (c) P5 (d) P11 (e) P12 (f) P14 and (g) P16. 
The pie charts represent the proportions of Th1 TN, TCM TEM TTEMRA as a mean percentage of 
the total circulating CD8+ population in the peripheral blood of TB (n=5), LTBI (n=5) and 
healthy individuals (n=11) recruited from high incident TB areas surrounding Tygerberg 
Hostpital. Naïve T-cells = TN = pink; Central memory T-cells = TCM = red; Effector memory T-
cells = TEM = green; Terminally differentiated T-cells = TTEMRA = orange. P4 = Rv0878c_a. P5 













Figure 4.21: Circulating CD193+ (Th2) CD8+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in unstimulated conditions or in response to 
PPE_MPTR peptides. (a) unstimulated (b) P4 (c) P5 (d) P11 (e) P12 (f) P14 and (g) P16. 
The pie charts represent the proportions of Th2 TN, TCM TEM TTEMRA as a mean percentage of 
the total circulating CD8+ population in the peripheral blood of TB (n=5), LTBI (n=5) and 
healthy individuals (n=11) recruited from high incident TB areas surrounding Tygerberg 
Hostpital. Naïve T-cells = TN = pink; Central memory T-cells = TCM = red; Effector memory T-
cells = TEM = green; Terminally differentiated T-cells = TTEMRA = orange. P4 = Rv0878c_a. P5 














CD3+CD8+ Central memory T-cells  
The subpopulations of circulating memory CD8+ T-cells in response to PPE_MPTR 
stimulation were also investigated. Like CD4+ memory cells, CD8+ memory T-cell populations 
are defined as antigen-specific, long-lived lymphocyte populations that provide a more 
effective immune response following secondary encounter with an antigen (Samji and Khanna, 
2017). The CD183+ (Th1), CD193+ (Th2), and CD196+ (Th17) TCM subsets were defined as 
CD45RA-CD28+ and the distribution of these populations was calculated as a mean percentage 
of the CD3+CD8+ T-cell population.  
Akin to what was observed for TN CD8+ cells in response to PPE_MPTR stimulation, no 
differences in the proportions of CD183+ (Th1) and CD193+ (Th2) TCM CD8+ cells were 
observed in active TB, LTBI or healthy controls (Figure 4.20 and Figure 4.21). In response to 
P4 and P5, the peripheral blood of LTBI individuals exhibited higher proportions of CD196+ 
(Th17) TCM CD8+ cells compared to what was observed in unstimulated conditions (Figure 
4.22 b, c). Active TB individuals also exhibited higher proportions of CD196+ (Th17) TCM 
CD8+ cells above unstimulated conditions, but only in response to P5 (Figure 4.22 c).  
All PPE_MPTR peptides induced the activation of CD183+ (Th1) and CD196+ (Th17) TCM 
CD8+ T-cells in healthy, LTBI and active TB individuals (Appendix 7.4; Figure 7.6). For both 
CD183+ (Th1) and CD196+ (Th17) subsets, P11 and P14 induced the highest proportions of 
activated CD8+ T-cells and was observed in active TB individuals. The CD193+ (Th2) TCM 
CD8+ subset of healthy, LTBI and active TB individuals exhibited activation in response to 
P11, P12, P14 and P16, with the highest levels observed in response to P14 in active TB 
individuals. Interestingly, in response to P12, healthy individuals had more activated CD183+ 
(Th1) TCM CD8+ T-cells than LTBI or active TB individuals (Appendix 7.4; Figure 7.6).  
Figure 4.22: Circulating CD196+ (Th17) CD8+ memory subsets in the peripheral blood of 
healthy, LTBI and active TB individuals in unstimulated conditions or in response to 
PPE_MPTR peptides. (a) unstimulated (b) P4 (c) P5 (d) P11 (e) P12 (f) P14 and (g) P16. 
The pie charts represent the proportions of Th1 TN, TCM TEM TTEMRA as a mean percentage of 
the total circulating CD8+ population in the peripheral blood of TB (n=5), LTBI (n=5) and 
healthy individuals (n=11) recruited from high incident TB areas surrounding Tygerberg 
Hostpital. Naïve T-cells = TN = pink; Central memory T-cells = TCM = red; Effector memory T-
cells = TEM = green; Terminally differentiated T-cells = TTEMRA = orange. P4 = Rv0878c_a. P5 





CD3+CD8+ Effector memory T-cells  
Effector memory CD8+ T-cells are responsible for exerting cytotoxic effector functions on M. 
tuberculosis-burdened host cells, ultimately resulting in apoptosis of the target cell (Geginat et 
al., 2003). The CD183+ (Th1), CD193+ (Th2), and CD196+ (Th17) TEM subsets were defined 
as CD45RA-CD28- (Figure 3.1) and the distribution of these subsets was calculated as a mean 
percentage of the CD3+CD8+ T-cell population. The distributions of the CD183+ (Th1), 
CD193+ (Th2), and CD196+ (Th17) TEM CD8+ subsets were comparable between unstimulated 
conditions and in response to stimulation with PPE_MPTR peptides (Figure 4.20, Figure 4.21 
and Figure 4.22).  
In response to P11, P12 and P14, marginal levels of activation were observed for CD193+ (Th2) 
TEM CD8+ T-cell subsets in healthy, LTBI and active TB individuals (Appendix 7.4; Figure 
7.7). None of the PPE_MPTR peptides activated CD183+ (Th1) or CD196+ (Th17) TEM CD8+ 
T-cells (Appendix 7.4; Figure 7.7). 
CD3+CD8+ TEMRA T-cells  
Terminally differentiated memory CD8+ T-cells are characterised by the highest effector 
functionality but are known to lack the ability to recognise antigen on secondary encounter 
(Larbi and Fulop, 2014). The CD183+ (Th1), CD193+ (Th2), and CD196+ (Th17) TTEMRA 
subsets were defined as CD45RA+CD28- (Figure 3.1) and the distribution of these CD8+ 
subsets was calculated as a mean percentage of the CD3+CD8+ T-cell population.  
Out of the four CD8+ cell subsets, the proportions of the TTEMRA CD8+ cells were the most 
influenced by stimulation with PPE_MPTR peptides. The proportions of CD183+ (Th1) TTEMRA 
CD8+ cells in TB individuals increased by 10% following stimulation with P14 (Figure 4.20 
f). In response to P5, P12, P14 and P16, active TB individuals exhibited increased proportions 
of CD193+ (Th2) TTEMRA CD8+ cells (Figure 4.21 c, e, f, g). Healthy controls showed 
comparably elevated proportions of CD193+ (Th2) TTEMRA CD8+ cells, however only in 
response P12 (Figure 4.21 e). The proportions of CD196+ (Th17) TTEMRA CD8+ cells in 
healthy, LTBI and active TB individuals were higher in response to P16 than unstimulated 
conditions (Figure 4.22 g). Only LTBI and active TB individuals exhibited increased 
proportions of CD196+ (Th17) TTEMRA CD8+ cells in response to P12 (Figure 4.22 e), while 
active TB individuals also showed increased proportions of CD196+ (Th17) TTEMRA CD8+ cells 




In healthy, LTBI and active TB individuals, similar levels of activated CD183+ (Th1), CD193+ 
(Th2), and CD196+ (Th17) TTEMRA CD8+ were observed (Appendix 7.4; Figure 7.8). 
PPE_MPTR peptides, P4 and P5, did not induce activation of CD183+ (Th1) TTEMRA CD8+ T-
cells in healthy, LTBI or TB individuals (Appendix 7.4; Figure 7.8).  
4.1.4.4 B-cells found in PPE_MPTR-stimulated peripheral blood  
The role that B-cells play in protection against M. tuberculosis requires deeper characterization, 
however it is known that B-cells contribute to protective immune responses during TB disease 
(Chan et al., 2014). When activated by M. tuberculosis antigens, B-cells produce M. 
tuberculosis-specific antibodies that regulate effector functions that contribute to M. 
tuberculosis clearance. B-cell populations were identified from the CD3- lymphocyte 
population and defined by the expression of CD19 (CD19+). The CD3-CD19+ B-cell population 
was subsequently assessed for the distribution of activated B-cells that express CD25 (CD3-
CD19+CD25+) (Figure 3.2). The distribution of B-cell subsets was calculated as a percentage 
of the parent B-cell population (Table 4.4).  
CD3-CD19+CD25+ B-cell subsets 
Fewer B-cells were detected in response to PPE_MPTR peptides in active TB individuals 
compared to LTBI and healthy individuals, which produced comparable proportions of B-cells 
(~20% vs ~10% for TB). The only PPE_MPR peptides that caused activation (CD25+) of B-
cells were P11, P12, P14 and P16, all of which produced comparable proportions of activated 




Figure 4.23: Circulating B-cell subsets in the peripheral blood of TB, LTBI and healthy 
individuals in response to stimulation PPE_MPTR peptides. The box-and-whisker plots 
represent the distribution of CD3- cells as a mean percentage of the parent population. The 
whiskers represent the minimum-to-maximum percentages. The box represents interquartile 
range with the horizontal line at the median. The CD3- population is represented as a 
percentage of total lympocyte population. The B-cells (CD3-CD19+) are represented a 
percentage of the CD3- population. The activated B-cells (aB-cells; CD3-CD19+CD25+) are 
represented a percentage of the B-cell population. HC = healthy controls (n=11) = blue. LTBI 
= latent TB infection (n=5) = orange. TB = active TB (n=5) = red. ESAT-6 = Early Secreted 
Antigen-6. CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). P4 = 
Rv0878c_a. P5 = Rv0878c_d. P11 = Rv2356c. P12 = Rv2608_a. P14 = Rv2608_c and P16 




Chapter 5  
Discussion  
Tuberculosis (TB) is one of the most concerning global public health issues and desperately 
requires the development of new vaccines and improved diagnostic tools for the prevention 
and detection of disease. For decades the Mycobacterium bovis Bacille Calmette Guèrin (BCG) 
vaccine has been the most widely administered vaccine, worldwide (WHO, 2018). Vaccination 
during early childhood with M. bovis BCG has proven effective, however efficacy has been 
shown to wane with age (Rodrigues et al., 1993; Colditz et al., 1994; Abubakar et al., 2013), 
rendering the adolescent and adult populations vulnerable to TB infection and active disease 
(Sterne et al., 1998; Ozeki et al., 2011). Current TB vaccine development focuses on replacing 
or boosting the BCG vaccine in an attempt to prevent active TB disease in the adult population 
(Harris et al., 2016) Alternatively, a decrease in the incidence of developing active TB disease 
may be achieved through the development of improved diagnostic tools that enable the 
detection of early TB infections (Abu-Raddad et al., 2009). The development of such 
diagnostic tools has been hindered by our incomplete understanding of the heterogeneous host 
response to TB infection as well as our ability to detect and genotype low disease burdens 
without bacterial culture.  
The protective efficacy of a vaccine candidate is influenced both by pathogen diversity and the 
immense variety of Human Leukocyte Antigen (HLA) alleles found in populations of different 
geographical regions (González-Galarza et al., 2015). In silico analyses have proven useful in 
identifying promising vaccine candidates, by predicting population coverage through 
evaluating the binding affinity of M. tuberculosis epitopes to different HLA alleles (McNamara 
et al., 2010; Davila et al., 2012), however these predictions still require laboratory 
characterization to be functionally validated.  
In this study, we aimed to validate the immunogenicity of nineteen computationally identified 
PPE_MPTR epitopes that were predicted to bind to HLA alleles frequently found in South 
African, Zimbabwean, Congolese and Ethiopian populations (Colic, 2016). We predicted that 
peptides representing these epitopes would elicit a M. tuberculosis-specific immune response, 
therefore we assessed the cytokine responses to these peptides in QFN+ and QFN- individuals. 
Further, we went on to investigate the diagnostic potential of these epitopes by comparing the 




was complemented by investigating the distribution of functional marker frequencies, memory 
and activation states of T- and B- lymphocytes in PPE_MPTR-stimulated peripheral blood of 
active TB, LTBI and healthy individuals.  
The functional assays performed in this study successfully validated the immunogenicity of the 
nineteen computationally identified PPE_MPTR epitopes in individuals from the four African 
countries stated above. We found that in response to P4, P5, P11, P12, P14 and P16, measurable 
concentrations of IL-17A, TNF-α and IL-6 were detected in South African, Zimbabwean, 
Congolese and Ethiopian individuals. In a South African cohort of healthy, LTBI and active 
TB individuals, P17 and P11 induced significantly more IL-6 and IL-17A, respectively, in 
active TB individuals than those without active disease. Furthermore, P4, P8, P12 and P17 
induced significantly higher concentrations of IL-6 in active TB than LTBI individuals. Only 
one peptide (P19) induced significantly higher TNF-α in LTBI individuals compared to healthy 
controls.  
The distribution of functional marker frequencies suggest that Th17 CD4+ and CD8+ T-cells 
are the major circulating cellular populations that govern the PPE_MPTR-induced immune 
responses in active TB and LTBI individuals, whereas more variability was observed in healthy 
controls who displayed a combined Th1/Th17 cell-mediated immune response. Activated TN, 
TCM, TEM and TTEMRA CD4+ and CD8+ T-cell populations were mainly observed in response to 
PPE_MPTR peptides P4, P11, P12 and P16, with CD8+ T-cells exhibiting marginal differences 
in functional marker frequencies compared to CD4+ T-cells. Overall, this pilot study has 
identified promising PPE_MPTR candidates that are worthy of further immunological 
investigation and characterization to fully characterize their potential as vaccine candidates for 
TB disease.  
5.1 The immunogenicity of population-tailored PPE_MPTR 
epitopes  
A multiplex cytokine screening assay detected an increase in the production of pro-
inflammatory cytokines, IL-6, TNF-α and IL-17A, in peripheral blood of healthy QFN+ 
individuals in response to positive control (ESAT-6 and CFP-10) and PPE_MPTR candidate 
peptides. None of the PPE_MPTR peptides induced detectable concentrations of anti-





Overall, QFN+ individuals exhibited higher cytokine responses to PPE_MPTR peptides than 
QFN- individuals. Since QFN+ individuals have been previously sensitized to M. tuberculosis 
antigens, this observation confirms that the identified PPE_MPTR peptides elicit an M. 
tuberculosis-specific response as hypothesized (Section 4.1). In QFN+ individuals, the cell-
mediated immune response was characterized by the production of IL-6 and TNF-α, which is 
suggestive of a pro-inflammatory Th1 immune response (Mootoo et al., 2009). The precise 
inflammatory role of IL-6 is unclear as this cytokine has been shown to promote Th2 responses 
through the induction of IL-4 (Diehl and Rincón, 2002), but has also been shown to potentiate 
protective Th1 inflammatory responses following BCG vaccination (Leal et al., 1999). 
Interestingly, there was differential IL-6 production in response to peptides representing 
different regions of the same PPE_MPTR protein. Of the six peptides (P12, P13, P14, P15, P16 
and P17) representing epitopes of PPE_MPTR42, P16 (Rv2608_g) elicited a greater immune 
response from QFN- individuals than QFN+ individuals, whereas QFN+ individuals responded 
better to P12, P13, P14 and P15. The greater immune response elicited by peptides from 
PPE_MPTR42 in QFN+ individuals supports the immunogenicity of PPE_MPTR42, as 
demonstrated in the recombinant BCG (Bertholet et al., 2010) and ID93 vaccine candidates 
(Baldwin et al., 2009). 
There was a substantial amount of inter-individual variation observed in the detected cytokine 
responses, particularly for IL-17A, towards stimulation conditions. IL-17A is most well-known 
for its role during autoimmune and chronic inflammatory disorders where its dysregulation 
causes extensive pro-inflammatory responses that result in the production of numerous 
cytokines and tissue damage. (Domingo-Gonzalez et al., 2016). During participant recruitment, 
information regarding chronic inflammatory disorders (for example, asthma, irritable bowel 
syndrome or coeliac disease) were not accounted for. From the high IL-17A concentrations 
observed during unstimulated conditions and the comparable concentrations of IL-17A in 
response to PPD (QFN+ and QFN-), it seems possible that some individuals included in this 
study had an underlying source of inflammation, which was exacerbated following stimulation.  
The PPE_MPTR peptides that induced the production of three or more cytokines from QFN+ 
individuals were identified as having the greatest immunogenic potential. From these analyses 
P4, P5, P11, P12, P14 and P16 were identified as the most promising candidates and induced 
a pro-inflammatory immune response. PPE_MPTR peptides, P4 and P5 represent epitopes of 
PPE_MPTR13, P11 of PPE_MPTR40 and P12, P14 and P16 of PPE_MPTR42. The 




mediated and humoral responses (Choudhary et al., 2003; Bertholet et al., 2008). The cell-
mediated immune response observed in response to PPE_MPTR42 was observed in healthy 
PPD+ individuals with various HLA types and was characterized by multifunctional CD4+ and 
CD8+ T-cells, releasing TNF-α and IFN-γ (Bertholet et al., 2008). These findings have 
supported its inclusion in a leading TB vaccine candidate (Baldwin et al., 2009; Bertholet et 
al., 2010). We report here for the first time the immunogenicity of PPE_MPTR13 and 
PPE_MPTR40. The results from our functional assays suggest that, like PPE_MPTR42, 
PPE_MPTR13 and PPE_MPTR40 also elicit a Th1 immune response from QFN+ individuals 
as measured by detectable concentrations of IL-6 and TNF-α. Previous vaccine studies have 
demonstrated that combining multiple M. tuberculosis antigens increases vaccine efficacy (Lu 
et al., 2012), thus it would be interesting to assess the immunogenicity of a PPE_MPTR fusion 
protein consisting of PPE_MPTR13, PPE_MPTR40 and PPE_MPTR42.  
5.2 The diagnostic potential of population-tailored PPE_MPTR 
epitopes 
In collaboration with the Stop TB Partnership and the Global Fund to Fight AIDS, Tuberculosis 
and Malaria, the World Health Organisation launched the Find. Treat. All. initiative (WHO, 
2018). This initiative aims at diagnosing and treating 40 million people with TB between 2018 
and 2022, however an improved understanding regarding the interactions between M. 
tuberculosis and the host immune response is desperately needed to accomplish this goal. 
Research on the correlates of disease and host biomarkers of active and latent TB infection 
(Walzl et al., 2011; Chegou et al., 2012; Loxton et al., 2012) have highlighted the heterogeneity 
of immune responses elicited during M. tuberculosis infection, a concept which is further 
complicated when considering understudied M. tuberculosis antigens, such as those from the 
PE/PPE protein family.  
In support of our observations made during the immunogenicity assessment, significant 
differences in Th1 cytokine production were observed between individuals with latent and 
active TB disease. This was characterized by significantly more IL-6 produced from active TB 
individuals in response to P4, P8, P12 and P17. These peptides represent epitopes of 
PPE_MPTR13 (P4), PPE_MPTR28 (P8) and PPE_MPTR42 (P12 and P17). Peptides P12 and 
P17 showed the most promise as diagnostic antigens but further research is needed to fully 
characterize their cell-mediated immune response. IL-6 is a pluripotent cytokine that has been 




(Ladel et al., 1997) and also enhances the Th1 immune responses during BCG vaccination 
(Leal et al., 1999). In our study, the most significant difference in IL-6 production was observed 
between cases and controls in response to P17 (p-value = 0.0088). However, the data suggests 
that P12 (from the same protein, PPE_MPTR42) may elicit a broader immune response 
compared to P17, as little to no IL-6 was produced by any LTBI individuals in response to P17. 
In the case of P12, one LTBI individual produced concentrations of IL-6 comparable to active 
TB individuals. The ability of this individual to release a comparable concentration of IL-6 in 
response to P12 could indicate that this individual may be currently living with undiagnosed 
active TB. 
Unlike the Th1 cytokine mediated response to P11 (PPE_MPTR40) observed during the 
immunogenicity assessment, P11 was shown to induce significant production of IL-17A by 
active TB individuals compared to healthy controls (p=0.0346). The ability of P11 to induce 
IL-6, TNF-α and IL-17A suggests P11 could induce a more robust Th1/Th17 immune response. 
A significant difference in the immune response between LTBI and healthy individuals was 
also observed and characterized by significantly higher TNF-α production by LTBI individuals. 
TNF-α is major pro-inflammatory mediator that has been implicated in establishing and 
maintaining the granuloma during M. tuberculosis infection (Mohan et al., 2001; Roach et al., 
2002; Mootoo et al., 2009). The higher concentrations of TNF-α observed in LTBI individuals 
could indicate the successful maintenance of undetected granulomatous structures in LTBI 
individuals, which is maintaining their latent state of disease.  
It should be noted that the observed absolute cytokine concentrations in response to 
PPE_MPTR peptides produced by active TB, LTBI and healthy individuals were low. This 
does not necessarily mean the PPE_MPTR peptides investigated are not immunogenic, but 
rather that these peptides do not induce the production of the analytes investigated. An 
alternative explanation may be that a 24-hour whole blood assay was not a sufficient 
stimulation time to see a change in cytokine production.  
5.3 The distribution of PPE_MPTR-specific functional marker 
frequencies and activation states  
An effective immune response to M. tuberculosis infection has been shown to depend on the 
production of pro-inflammatory cytokines such as IL-6, IFN-γ and TNF-α from CD4+ and 
CD8+ Th1 T-cells (Flynn and Chan, 2001). There is also evidence for the crucial role of Th17 




been shown to enhance Th1 immune responses and contribute to adequate granuloma 
formation (Jin and Dong, 2013). Interestingly, the proportion of Th1/Th17 T-cells has been 
shown to correlate with severity of active TB disease, with active TB individuals producing 
higher IL-17A concentrations in response to M. tuberculosis whole cell lysate than LTBI 
individuals (Jurado et al., 2012).  
In our study, the distribution of functional marker frequencies was assessed in response to 
PPE_MPTR peptides that have previously been computationally identified as CD4+ T-cell 
epitopes having high binding affinity to HLA alleles in individuals from four African 
populations (Colic, 2016). The distribution of CD4+ T-cell functional marker frequencies 
showed more variation in response to PPE_MPTR candidates than those of CD8+ T-cells. CD4+ 
T-cells also displayed higher levels of activation compared to CD8+ T-cells, suggesting that 
candidate PPE_MPTR peptides are presented to the MHC-II binding groove characteristic of 
CD4+ T-cells, as hypothesized. To functionally confirm this, MHC-II tetramers specific for the 
nineteen PPE_MPTR epitopes represented in this study can be used in future studies to assess 
the specific CD4+ T-cell responses (Nepom, 2012).  
Due to persistent exposure to M. tuberculosis-antigens during infection, the distribution of 
functional, memory and activation states observed in active TB individuals has been shown to 
differ from those observed in healthy or latently infected individuals (Marín et al., 2012). In 
partial agreement with this, higher proportions of activated (CD25+) CD4+ and CD8+ T-cells 
were detected in LTBI and active TB individuals compared to healthy individuals, however no 
noticeable differences were observed between LTBI and TB individuals. All PPE_MPTR 
peptides were capable of inducing activation of CD4+ T-cell populations in healthy controls. 
This may be due to environmental sensitization to M. tuberculosis antigens as a result of 
residing in high incident TB communities. The similar functional marker frequencies observed 
between healthy individuals and active TB individuals only provide information regarding the 
expression of surface markers on various cell types. To properly assess if the memory states 
between healthy and active TB individuals differ functionally, future studies could include 
intracellular cytokine staining to identify the associated cytokine profile of memory 
populations. 
In our study, TN T-cells were characterised as CD45RA+ and CD28+ (CD45RA+ CD28+) which 
indicate a high level of functional and proliferative capabilities, respectively. In response to 
PPE_MPTR peptides, similar distributions of expanded and activated CD183+ (Th1), CD193+ 




individuals. The expansion of naïve T-cell populations observed in LTBI and active TB 
individuals may be a consequence of the persistent pro-inflammatory state within these 
individuals which encourages the proliferation of circulating naïve T-cells. As such, in 
response to ESAT-6 and CFP-10, active TB individuals have been shown to have expanded 
naïve T-cell populations that secreted IFN-γ (Orlando et al., 2018). The expanded TN CD4+ T-
cells observed in healthy individuals suggests that there are other sources of inflammation 
which may be inducing the proliferation of these cells (Orlando et al., 2018). To confirm 
whether TN CD4+ T-cells are indeed proliferating, future cytometric analyses could include a 
proliferative marker, such as Ki67 (Soares et al., 2010).  
Immunosurveillance is performed by circulating central memory cells that rapidly proliferate 
and expand upon antigen encounter (Murphy, 2013). Central memory cells were characterized 
as CD45RA-CD28+ which indicated their highly differentiated state (CD45RA-), however still 
maintaining proliferative capabilities (Shipkova and Wieland, 2012; Larbi and Fulop, 2014). 
Proliferative capabilities allow expansion of this long-lived cellular population for optimal 
immunosurveillance to be maintained (Murphy, 2013). The central memory response to 
stimulation with PPE_MPTR peptides was governed by expanding CD196+ (Th17) TCM CD4+ 
T-cells in healthy, LTBI and active TB individuals. In response to P4, active TB individuals 
displayed increased proportions of CD196+ (Th17) CD4+ TCM cells, whereas in healthy and 
LTBI individuals expanded CD196+ (Th17) CD4+ TCM cell populations were observed in 
response to both P4 and P5. There were significant differences in the concentrations of IL-17A 
observed between healthy, TB and LTBI individuals (Section 5.2; Figure 4.5), which could 
suggest that these Th17 T-cell populations contribute to the IL-17A production observed. This 
is in agreement with reports that demonstrated circulating Th17 TCM CD4+ T-cells to be the 
main source of IL-17A in response to BCG stimulation in active TB individuals (Scriba et al., 
2008). Furthermore, the induction, differentiation and maintenance of CD196+ (Th17) T-cell 
populations in active TB individuals could, in part, be maintained by the high levels of IL-6 
observed (Section 5.2; Figure 4.5). Other cytokines such as IL-21, IL-23 and TGF-1β have 
also been implicated in influencing differentiation of Th17 cells, however, were not 
investigated in this study. In future studies, the production of these cytokines in response to 
PPE_MPTRs in peripheral blood could be investigated and complemented with intracellular 
cytokine staining in order to fully assess immunophenotypes of induced T-cell populations, 
and identify the source of secreted cytokines (Torrado and Cooper, 2011; Lyadova and 




Overall, the effector memory cells showed the lowest amount of expansion in response to 
PPE_MPTR peptides, however due to their highly differentiated state they are still able to 
secrete cytokines in response to antigen (MacLeod et al., 2009; Mahnke et al., 2013).This is 
consistent with reports which describe the TCM cells as the predominant memory population in 
peripheral blood (Sallusto et al., 2004). Although comparable expansion of CD183+ (Th1) and 
CD193+ (Th2) memory subsets (TCM and TEM) was observed in healthy and TB individuals, 
only healthy individuals exhibited expansion of CD196+ (Th17) CD4+ TEM cells. Interestingly, 
the expansion of CD196+ (Th17) CD4+ TEM T-cells was also absent in LTBI individuals which 
could suggest that the expansion of this TEM subset is protective against developing TB disease 
(latent or active). 
Terminally differentiated effector memory cells (TTEMRA) have lost their ability to proliferate 
but have maintained their effector phenotype by re-expressing CD45RA. This allows TTEMRA 
cells to play a functional role during M. tuberculosis infection. Expanded CD183+ (Th1), 
CD193+ (Th2) and CD196+ (Th17) CD4+ TTEMRA cells were comparable among healthy, LTBI 
and active TB individuals, except expanded CD196+ (Th17) CD4+ TTEMRA cells were absent 
from active TB individuals. PPE_MPTR peptides induced the activation of CD183+ (Th1), 
CD193+ (Th2) and CD196+ (Th17) CD4+ TTEMRA cells in LTBI and active TB individuals, 
whereas only activated CD183+ (Th1) CD4+ TTEMRA cells were detected in healthy individuals. 
These results suggest that in response to PPE_MPTR peptides, healthy controls can exhibit a 
pro-inflammatory Th1/Th17 response characterized by expanded CD196+ (Th17) TEM and 
activated CD183+ (Th1) TTEMRA CD4+ T-cells. In LTBI and active TB individuals, the cell-
mediated immune response is evidently more complex due to the activation of CD193+ (Th2) 
TTEMRA CD4+ T-cells. Th2-associated cytokines, such as IL-4 and IL-10, have been shown to 
have a dampening effect on the host immune response during M. tuberculosis infection and 
have been shown to diminish protective Th1 responses (Rook, 2007). Conversely, Th2-
associated cytokines have also been shown to facilitate activation of B-cells and antibody 
production (Diehl and Rincón, 2002). The lack of activated CD193+ (Th2) TTEMRA CD4+ T-
cells in healthy individuals may suggest that healthy individuals fail to produce antibodies in 
response to M. tuberculosis antigens. Alternatively, the lack of CD193+ (Th2) TTEMRA CD4+ T-
cells in these individuals may be a correlate of protection against TB disease, which facilitates 
the induction of a more effective Th1 immune response against stimulation with M. 




The exact role of B-cells during M. tuberculosis infection requires more investigation, however 
it is known that B-cells aid in controlling the host immune response to M. tuberculosis infection 
through the production of cytokines and M. tuberculosis-specific antibodies (Mauri and 
Bosma, 2012; Loxton, 2019). The importance of B-cells in the immune response during M. 
tuberculosis infection was demonstrated in B-cell deficient mice, which showed increased 
immunopathology and susceptibility to M. tuberculosis Erdman challenge (Vordermeier et al., 
1996; Maglione et al., 2007). Furthermore, a reduction in the number and frequency of 
circulating B-cells has been observed in individuals with active TB disease and was shown to 
be restored following successful anti-TB treatment (Joosten et al., 2016; Van Rensburg et al., 
2017). PPE_MPTR42 has been shown to induce a predominately humoral response in relapsed 
TB individuals (Chakhaiyar et al., 2004) and has also been identified as a possible 
serodiagnostic candidate for active TB due to the significantly higher concentrations of 
PPE_MPTR42 antibodies observed in the sera of active TB individuals compared to healthy 
controls (Choudhary et al., 2003).  
In response to stimulation with PPE_MPTR peptides, active TB individuals had the lowest 
proportion of circulating B-cells compared to healthy and LTBI individuals. This finding is in 
support of some literature (Corominas et al., 2004; van Rensburg and Loxton, 2018), however 
others have also observed an increased frequency of B-cells during active TB (Wu et al., 2009). 
The distribution of CD25+ B-cells (activated B-cells) in response to selected PPE_MPTR 
candidates in this study was comparable between healthy, LTBI and active TB individuals. It 
is important to note that the distribution of B-cells and subsequent activation states were not 
extensively characterized in this study. Future work should include a broader panel of 
fluorophore-conjugated monoclonal antibodies to adequately characterize B-cell populations 
in response to PPE_MPTR stimulation. 
5.4 Limitations 
This pilot study was not large enough to provide enough power to draw conclusions regarding 
the populations from which the samples were taken. During participant recruitment, the status 
of chronic inflammatory disorders was not noted, the presence of which may have caused 
unexpected pro-inflammatory responses, resulting in misleading cytokine responses. 
Furthermore, the cohort recruited to assess the immunogenicity of candidate peptides included 
mostly South African individuals, therefore the results observed do not provide an accurate 




peptides. The candidate peptides were predicted to elicit strong immune responses based on 
their potential to bind the HLA alleles common in individuals of South Africa, Congo, Ethiopia 
and Zimbabwe (Colic, 2016). However, HLA-typing was not in the scope of this pilot study 
and could be done in future studies to confirm the HLA subtype of individuals.  
The Luminex multiplex screening assays were not sensitive enough to detect very low 
concentrations of cytokines. Furthermore, inconsistencies were observed between the internal 
control on different plates of the same kit, suggesting large inter-plate variation. Furthermore, 
Luminex data analysis would greatly benefit from standardization within the scientific 
community due to the effects data analysis can have on the interpretation of results (Van 
Meijgaarden et al., 2018). 
In order to properly characterize the immunophenotype of lymphocyte populations, 
intracellular cytokine staining is usually performed, however was not in the scope of this pilot 
study. This hampered our ability to provide a PPE_MPTR-specific immunophenotype of 
circulating T-and B-lymphocytes. In future, candidate PPE-MPTR epitopes identified in this 
study (P11 and P17) will be investigated using a larger cohort of individuals from African 
origin. In these follow-up studies, intracellular cytokine staining will be used to assess the 
ability of PPE_MPTR proteins to induce the production of polyfunctional T-cells, which have 
been shown to correlate with vaccine-induced protection following M. tuberculosis challenge 
(Lindenstrøm et al., 2009; Derrick et al., 2011).  
5.5 Conclusion 
The World Health Organisation have deemed the development of new TB vaccines as essential 
in achieving the goals set out by the ‘End TB Strategy’ (WHO, 2018). Currently, the TB vaccine 
development pipeline includes promising candidates that are already in Phase IIb clinical trials 
(Table 1.1). However due to the lack of immunological correlates of protection against TB 
disease, identifying promising vaccine candidates has proven challenging. This is further 
complicated by HLA allele diversity among individuals of different populations that influence 
the recognition of M. tuberculosis-specific antigens. The use of in silico methods has provided 
researchers with a cost-effective way of identifying promising vaccine candidates that are well 
recognised by individuals from different geographical locations. Members of the PE/PPE 
protein family have demonstrated immunogenic potential (Vordermeier et al., 2012); however, 
little is known regarding the immunogenicity of the PPE_MPTR proteins. The results of this 




epitopes in individuals in South Africa, Zimbabwe, Congo and Ethiopia. Furthermore, these 
PPE_MPTR epitopes also showed potential in differentiating between individuals with and 
without active TB disease by inducing significantly different cytokine responses. Selected 
candidate PPE_MPTR peptides were shown to elicit a pro-inflammatory cell-mediated immune 
response characterized by the production of TNF-α, IL-6 and IL-17A. Functional marker 
frequencies of CD4+ and CD8+ T-cells also suggest that selected PPE_MPTR peptides could 
induce the production of memory populations.  
Vaccine-induced protection is known to rely on immunological memory that maintains 
immunity to pathogens (Seder et al., 2008). A balanced, well-orchestrated Th1/Th17 immune 
response has been shown to be more effective at providing protection against active TB disease, 
compared with a Th1 response alone. This has been demonstrated by the expanded Th1/Th17 
T-cell populations observed in LTBI individuals in response to M. tuberculosis-derived 
antigenic stimulation (Lindestam Arlehamn et al., 2013). The production of IL-17A, IL-6 and 
TNF-α in response to PPE_MPTR peptides, coupled with PPE_MPTR-induced activation of 
CD183+ (Th1), CD193+ (Th2) and CD196+ (Th17) TCM and TEM CD4+ and CD8+ T-cells 
indicates protective potential of these peptides. The presence of complex T-cell profiles, 
however, does not necessarily correlate with protection (Kagina et al., 2010). As such, we 
observed significantly higher concentrations of IL-6 and IL-17A in response to PPE_MPTR 
peptides in active TB individuals, however these cytokines were also detected in LTBI and 
healthy individuals, albeit in low concentrations. To properly assess the protective capabilities 
of PPE_MPTR-induced activation TCM and TEM CD4+ and CD8+ T-cells, intracellular cytokine 
staining should be included in future studies. This should also incorporate proliferation and 
cytolytic markers so that the kinetics of PPE_MPTR-induced responses can be further 
understood and any cytolytic functions imposed by PPE_MPTRs can be identified.  
The results of this study emphasize the heterogeneity of the host immune response to M. 
tuberculosis-specific antigens in both previously sensitized (active TB or LTBI individuals) 
and uninfected healthy individuals. In future studies, the existence of pro-inflammatory 
disorders should be accounted for during participant recruitment and individuals with 
underlying sources of inflammation should not be included. The combination of M. 
tuberculosis-derived antigens in new TB vaccine candidates have demonstrated improved 
immunogenicity and protective efficacy (Bertholet et al., 2010; Lu et al., 2012). In support of 
this, future studies could investigate the combined cell-mediated responses of PPE_MPTR 




The pro-inflammatory response induced by combining PPE_MPTR peptides may be stronger 
than that induced by natural immunity, which is an important consideration in TB vaccine 
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Chapter 7  
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Figure 7.1: Distribution of activated naïve CD4+ T-cells (CD25+) in the peripheral blood 
of TB, LTBI and healthy individuals. The box-and-whisker plots represent the proportions 
of activated Th1, Th2 and Th17 TN CD4+ T-cell subsets as a mean percentage of the total Th1, 
Th2 or Th17 TN CD4+ T-cell populations. Blue = HC = healthy controls (n=11). Yellow = LTBI 
= latent TB infection (n=5). Red = TB = active TB (n=5). ESAT-6 = Early Secreted Antigen-6. 
CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). P4 = Rv0878c_c. P5 = 










Figure 7.2: Distribution of activated central memory CD4+ T-cells (CD25+) in the 
peripheral blood of TB, LTBI and healthy individuals. The box-and-whisker plots represent 
the proportions of activated Th1, Th2 and Th17 TCM CD4+ T-cell subsets as a mean percentage 
of the total Th1, Th2 or Th17 TCM CD4+ T-cell populations. Blue = HC = healthy controls (n=11). 
Yellow = LTBI = latent TB infection (n=5). Red = TB = active TB (n=5). ESAT-6 = Early 
Secreted Antigen-6. CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). P4 = 










Figure 7.3: Distribution of activated effector memory CD4+ T-cells (CD25+) in the 
peripheral blood of TB, LTBI and healthy individuals. The box-and-whisker plots represent 
the proportions of activated Th1, Th2 and Th17 TEM CD4+ T-cell subsets as a mean percentage 
of the total Th1, Th2 or Th17 TEM CD4+ T-cell populations. Blue = HC = healthy controls (n=11). 
Yellow = LTBI = latent TB infection (n=5). Red = TB = active TB (n=5). ESAT-6 = Early 
Secreted Antigen-6. CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). P4 = 











Figure 7.4: Distribution of activated terminally differentiated effector memory CD4+ T-
cells (CD25+) in the peripheral blood of TB, LTBI and healthy individuals. The box-and-
whisker plots represent the proportions of activated Th1, Th2 and Th17 TTEMRA CD4+ T-cell 
subsets as a mean percentage of the total Th1, Th2 or Th17 TTEMRA CD4+ T-cell populations. 
Blue = HC = healthy controls (n=11). Yellow = LTBI = latent TB infection (n=5). Red = TB = 
active TB (n=5). ESAT-6 = Early Secreted Antigen-6. CFP-10 = Culture Filtrate Protein 10. 
Unstim = Unstimulated (PBS). P4 = Rv0878c_c. P5 = Rv0878c_d. P11 =Rv2356c_a. P12 = 













Figure 7.5: Distribution of activated naïve CD8+ T-cells (CD25+) in the peripheral blood 
of TB, LTBI and healthy individuals. The box-and-whisker plots represent the proportions 
of activated Th1, Th2 and Th17 TN CD8+ T-cell subsets as a mean percentage of the total Th1, 
Th2 or Th17 TN CD8+ T-cell populations. Blue = HC = healthy controls (n=11). Yellow = LTBI 
= latent TB infection (n=5). Red = TB = active TB (n=5). ESAT-6 = Early Secreted Antigen-6. 
CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). P4 = Rv0878c_c. P5 = 










Figure 7.6: Distribution of activated central memory CD8+ T-cells (CD25+) in the 
peripheral blood of TB, LTBI and healthy individuals. The box-and-whisker plots represent 
the proportions of activated Th1, Th2 and Th17 TCM CD8+ T-cell subsets as a mean percentage 
of the total Th1, Th2 or Th17 TCM CD8+ T-cell populations. Blue = HC = healthy controls (n=11). 
Yellow = LTBI = latent TB infection (n=5). Red = TB = active TB (n=5). ESAT-6 = Early 
Secreted Antigen-6. CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). P4 = 











Figure 7.7: Distribution of activated effector memory CD8+ T-cells (CD25+) in the 
peripheral blood of TB, LTBI and healthy individuals. The box-and-whisker plots represent 
the proportions of activated Th1, Th2 and Th17 TEM CD8+ T-cell subsets as a mean percentage 
of the total Th1, Th2 or Th17 TEM CD8+ T-cell populations. Blue = HC = healthy controls (n=11). 
Yellow = LTBI = latent TB infection (n=5). Red = TB = active TB (n=5). ESAT-6 = Early 
Secreted Antigen-6. CFP-10 = Culture Filtrate Protein 10. Unstim = Unstimulated (PBS). P4 = 










Figure 7.8: Distribution of activated terminally differentiated effector memory CD8+ T-
cells (CD25+) in the peripheral blood of TB, LTBI and healthy individuals. The box-and-
whisker plots represent the proportions of activated Th1, Th2 and Th17 TTEMRA CD8+ T-cell 
subsets as a mean percentage of the total Th1, Th2 or Th17 TTEMRA CD8+ T-cell populations. 
Blue = HC = healthy controls (n=11). Yellow = LTBI = latent TB infection (n=5). Red = TB = 
active TB (n=5). ESAT-6 = Early Secreted Antigen-6. CFP-10 = Culture Filtrate Protein 10. 
Unstim = Unstimulated (PBS). P4 = Rv0878c_c. P5 = Rv0878c_d. P11 =Rv2356c_a. P12 = 
Rv2608_a. P14 = Rv2608_c. P16 =Rv2608_g. 
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